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Abstract
About 50% of all cancer patients receive radiotherapy in the course of their disease. Hadron ther-
apy uses protons or ions and shows a more advantageous depth-dose characteristic compared to
photons. The superior dose distribution of particles enables to deliver a high dose to the tumour
whilst sparing normal tissue. Although hadron therapy is believed to be superior to advanced photon
therapies for certain types of cancers it has yet not been possible to draw definite conclusions from
current clinical studies.
To support the necessary extensive documentation of tumour, treatment and side effects data
a database model for hadron therapy was established. It was implemented in a prototype hadron
therapy information sharing platform.
The assessment of a new treatment modality is based on the evaluation of treatment outcome
and treatment related side effects. For this a generic Markov model for the evaluation of side effects
was developed. Data from the database can automatically be used to refine the model and convert it
into a tumour or treatment specific prediction model.
Treatment models are a very powerful tool to investigate therapy options within silico clinical tri-
als. A novel analytical model is introduced which describes the response of solid tumours to radiation
therapy in a simple yet effective way. The introduction of proliferating and quiescent tumour cells en-
ables to simulate important characteristics of tumour behaviour like sigmoid growth, cell quiescence,
cell death and response to radiation therapy with different beam qualities. Main basic principles of
fractionation like repair, redistribution, repopulation, reoxygenation and radiosensitivity are natur-
ally contained within the model. The model involves the patient, tumour growth and fractionated ra-
diotherapy to predict tumour recurrence. It is successfully applied to clinical data of patients treated
with photons, protons and carbon ions for skull base chordoma and investigated for indications for
hadron therapy.
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1 Introduction
1.1 Cancer
Cancer is a complex class of diseases which share the characteristics of uncontrolled cell growth and
the ability to metastasise through the body to different organs. It is the second largest cause of death
in Europe and also responsible for the biggest fraction of deaths in people aged 45-64 [1]. In the
future, these rates will increase due to the ageing populations as age is the most significant risk for
developing cancer [2].
Rare Cancers Incidence
per 100,000/yr.
Epithelial tumours of nasal cavity
and sinus
0.44
Epithelial tumours of oropharynx 2.75
Epithelial tumours of gallbladder and
extrahepatic biliary tract
4.37
Epithelial tumours of middle ear 0.03
Bone sarcoma 0.8
Soft tissue sarcoma 4.74
Adnexal carcinoma of skin 0.28
Neuroendocrine tumours 2.53
Table 1: Estimates of incidence per 100,000
per year of rare cancers in Europe [3].
Patients diagnosed with cancer mainly
undergo treatment with surgery, chemo-
therapy and radiotherapy as sole therapy
or combined modalities. About 50% of all
patients can be cured, 40% of those cures
are related to radiotherapy. Furthermore,
about 50% of all patients receive radiother-
apy in the course of their disease making it
an important tool in the fight against can-
cer [4].
20% of all cancer cases are rare can-
cers [5]. A cancer is defined as rare when
fewer than 6 in 100.000 people are dia-
gnosed each year, examples can be found
in tab. 1. Their treatment experience is of-
ten limited which makes it difficult to form
evidence-based treatment guidelines. In particular this applies to the increasing number of patients
with rare tumours which will be treated in the emerging European hadron therapy centers.
1.2 Radiotherapy
The underlying principle of radiotherapy is to prevent tumour cell proliferation by changing their
DNA by exposure to ionising radiation. The damage increases with absorbed dose D , which is quan-
tified by the amount of energy E deposited by radiation in a volume element of tissue with mass m:
D = dEdm [6]. The physical dose unit of ionising radiation in the International System of Units (SI) is
1
Gray [Gy]1. Radiotherapy is based on the fact that most of the fast proliferating cancer cells are more
radiosensitive than the surrounding normal tissue, because of their less effective molecular repair
mechanisms [7].
Figure 1.1: The dose depth profile of X-rays shows
an exponential decrease after an initial built-up
in the surface region of the tissue. In contrary to
this ions have a low dose entrance channel, a finite
range and in a well defined depth a sharp increase
of dose. From [8].
Figure 1.2: SOBP (dashed line) realised as a super-
position of Bragg peaks with different energies and
intensities for delivering dose to an extended tu-
mour . From [9].
Conventional radiotherapy which denotes
the ”original form of radiotherapy” tracing back
to the first treatments starting in 1896 mostly
uses teletherapy, using MV X-rays produced
by a clinical linear accelerator. This radi-
ation is indirectly ionising by producing fast re-
coil electrons, predominantly via the Compton-
effect [7], which either can directly ionise
the target molecule or indirectly produce OH-
with water molecules which diffuse to the tar-
get molecule within a range of 1-3 cm [10].
It was Robert Wilson who proposed in 1946
to use accelerated protons and heavier ions for
cancer treatment [11]. Hadron therapy2 uses
protons or ions and show a more advantageous
depth-dose characteristic relative to photons
(see figure 1.1). As they pass through tissue
they slow down due to atomic or nuclear in-
teractions. The energy loss increases the inter-
action with electrons and leads to a maximum
interaction with a maximum energy transfer at
the end of range called Bragg peak and a sharp
dose fall-off after [9]. To cover the target with
dose a superposition of several pristine Bragg
peaks with different energies and intensities is
applied, shaping a so-called spread out Bragg
peak (SOBP) (see figure 1.2). This restriction of
irradiated volume gives them a superior dose distribution to photons and enables then to deliver a
1 [G y]= [J ][kg ] 2 Here, the term ”hadron therapy” excludes neutrons although they are hadrons in a physical sense. Fast
neutrons are very effective in tumour cells, but do not offer the physical dose advantages of charged particles; This was
proved disadvantageous in the clinic [12].
2
high dose to the tumour whilst sparing normal tissue. If sensitive structures are in the direct vicinity
of the tumour this is especially important.
Figure 1.3: Comparison of proton and carbon
tracks with a DNA molecule. The ionisation events
of protons are far from each other. For carbon ions,
the ionisation density increases strongly at the end
of the track at low energies, making complex DNA
damage more likely (Krämer, GSI).
From the different types of charged particles
believed well suited for radiotherapy, only pro-
tons and carbon ions are used in clinical prac-
tise at the moment [13]. While protons and car-
bon ions show similar dose-depth profiles, they
differ in their radiobiological beam properties:
protons are comparable to photons consider-
ing their relative biological effectiveness (RBE)3
which is set constant to 1.1 relative to 1.0 for
photons for clinical calculations [14]. Carbon
ions show a higher RBE because they cause
more complex DNA damage. The reason for this
is the different way they transfer their energy
on a microscopic scale: carbon ions lose their
energy when passing through matter mainly by
Coulomb-interactions and release a large num-
ber of secondary electrons with low energies
most of which within the keV range. As a
consequence, the secondary electrons deposit
their energy within a very small radius around
the primary track [10], which decreases from
156 µm to 3 µm and 0.06 µm for carbon ion en-
ergies of 100, 10 and 1 MeVu , respectively [15].
The International Commission on Radiation
Units (ICRU) defines the linear energy transfer (LET) of ionising particles in a medium as the averaged
energy dE locally imparted to the medium by a charged particle of specified energy in traversing a
distance dl and is determined by LET = dEdl [6]. LET is generally measured in units of [keV ][µm] . Protons
and photons in a clinical setting have a low linear energy transfer (LET) and carbon ions have higher
ionisation densities along their particle tracks and therefore a higher LET [16]. Ionisations can des-
3 RBE is defined as ratio of the dose of a reference radiation, compared to the dose of a test radiation for achieving the same
biological effect (cell killing). Nowadays most commonly MeV photons are used as reference for clinical comparisons.
3
troy biological molecules and therefore can damage the DNA. Most base-damage, single and double-
strand breaks can be repaired by a very efficient repair system of the cell. However, if the lesions on
the DNA are produced in close proximity (clustered lesions) , the repair mechanism may fail and the
cell dies. Carbon ions reach the necessary high ionisation density within the Bragg peak: as they slow
down their LET reaches values of a few 100 keV per micrometer within one particle track. Lesions
produced by proton and photon tracks are far apart from each other and repairable, several tracks
have to coincidence to produce the necessary ionisation density [17]. Figure 1.3 shows a comparison
of proton and carbon ions tracks in water for decreasing particle energies.
As the RBE increases with LET up to a certain value, beams of ions heavier than Helium(4) show
a much higher LET value in the Bragg peak compared with the entrance region which leads to an
increasing RBE along its path through matter4. This RBE is a very complex function which depends
on LET, type of particle, fraction dose, tissue and cell type, oxygenation state and cell cycle phase. The
exact value of RBE in clinically used heavy ions still needs to be determined [19].
Another benefit from high LET radiation is that the lateral dose fall off is very sharp compared to
proton irradiation, so that organs at risk next to the tumour can be better spared from high doses [20].
Many tumours are deprived of oxygen which make them more radioresistant to low-LET irradi-
ation. The DNA damage by low-LET particles are primarily caused by the secondary effect of oxygen
radicals. If the oxygen partial pressure in the tissue is lower the effectiveness of low-LET will therefore
decrease. High-LET irradiation causes direct damage to the DNA and thus will be less dependent on
oxygen levels within the tumour to cause cell kill. Consequently, carbon ions are the ideal candidates
for treating hypoxic and otherwise radioresistant tumours [21, 22, 23] but it needs to be evaluated
under which circumstances their use is justified [24].
Hadron therapy is used as standalone treatment, as a localised boost therapy in addition to con-
ventional photon radiation therapy, or in combination with other treatment modalities, such as sur-
gery or chemotherapy.
1.3 Side Effects
Unfortunately, radiation has not solely an effect on tumours cells but also normal tissue is irradiated.
Normal tissue complications often limit the maximum dose that can be given to the tumour. There-
fore it is important to use sophisticated methods to spare as much healthy tissue as possible. This
4 For all ions a similar behavior of the RBE connected to an increase in LET is found. But for protons the range of elevated
LET and thus RBE is restricted to the last fraction of a millimeter of range at the distal part of the Bragg peak. Therefore the
global RBE is only increased up to 10% (RBE=1.1). For clinical carbon ions, however, the increase of RBE is mainly restricted
to approximately the last 2 cm depending on the inital energy [18].
4
is expressed by the therapeutic ratio which is determined by the tumour control probability (TCP)
vs. the normal tissue complication probability (NTCP)5 as shown as in figure 1.4. Healthy tissue can
better recover after radiation therapy, while tumour cells are often unable to repair DNA damage.
An optimal strategy to maximise the therapeutic ratio is therefore needed which includes sparing of
critical structures and using multiple entrance channels to distribute the dose around the tumour in
the normal tissue, this is especially important for X-ray radiation with an exponential dose fall off in
material. In addition, the dose delivered to the tumour is split up into smaller doses (fractions) which
exploits the fact that normal tissue recovers faster from irradiation than tumours. When irradiating
with heavy ions it is possible to use higher fraction doses (hypofractionation) because the RBE of tu-
mours increases faster than the RBE of normal tissue when increasing fraction doses [26]. This, and
the fact that the RBE is much higher in the Bragg peak which will be inside the tumour guarantees
sparing of critical structures while escalating tumour dose.
Figure 1.4: Dose-response curve for tumour con-
trol probability (TCP) and normal tissue complic-
ation probability (NTCP). The dashed line depicts
the therapeutic ratio with a maximum at the op-
timal dose Dopt . For a typical good RT treatment,
TCP ≥ 50% and NTCP < 5% which can only be
achieved if the separation of both curves is large
enough. From [25].
Although disease-free and overall survival
are the main benchmark for treatment, side ef-
fects play an important role in the evaluation
of therapies. Therapies with similar outcome
might differ very much for what concerns oc-
curring side effects, and therefore in the con-
sequences they have on the patient’s life. Tis-
sue toxicities can arise during or shortly after
treatment (acute) and months, years and dec-
ades after irradiation. Patients mostly recover
from early effects, however, late effects very of-
ten are irreversible and the limiting factor for ra-
diation doses [27]. Therefore an accurate docu-
mentation of all adverse events is important to
evaluate possible complications, find the likeli-
hood of normal tissue complications to ensure
patient safety, develop strategies for their prevention and find dose limits to maximise tumour con-
trol. If multiple treatment modalities result in similar outcomes, the severity of side effects become
an important factor in comparing different therapies and thus are an important factor in decision
making.
5 Normal tissue complications are named in the literature as side effects, toxicities, or most recently as adverse events.
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In general, particle therapy seems to have advantages because of their dose distribution over con-
ventional X-ray therapy for all tumours where damage to nearby structures can be life altering. For
example ocular melanoma, skull based chordomas, tumours along the spine and head and neck tu-
mours like paranasal sinus and nasopharyngeal tumours. Radiotherapy of the brain can lead to visual,
hearing and hormonal deficits and to a change of neurological and neurocognitive functions [28].
However, when induced, side effects by protons are almost of the same severity as the ones caused by
radiotherapy with photons. Although carbon ions have a much more favourable RBE development
along their path, many years of evaluation of late toxicities for this relatively new treatment modality
are still needed [29, 30].
Unfortunately the success of curing or controlling the primary cancer can go hand in hand with
inducing a secondary malignancy. More advanced photon techniques like conformal and intensity
modulated radiotherapy deliver the same dose to the target but also a low dose to a large volume
(integral dose matters!). However, during proton and carbon ion treatment neutrons are produced
which both could also lead to carcinogenesis [31]. Dose comparisons between intensity-modulated
radiotherapy and proton therapy show either the same or significantly lower risk of secondary malig-
nancies for protons [32]. On the other hand, carbon ion therapy reduces the integral dose to the body
and offers better prospects for cancer cure, however, model calculations estimate a higher risk for de-
veloping a secondary tumour [33]. The latency is usually 15 to 20 years from the inital radiation, while
patients diagnosed at a young age are at higher risk. The knowledge of the probability to develop a
secondary cancer caused by a new treatment modality is a non-negligible factor in decision making
for a therapy pathway and thus it needs to be evaluated very carefully.
Side effects are recorded in standardised scoring systems which might depend on the tumour
entity or even the country. Scoring systems can change over time and different systems may vary in
content and granularity of the recorded events. Finally, it should be mentioned that their recording
is objective to the individual who records it. All this makes it difficult to use and compare data across
clinical trials and an approximate translation between the scoring systems might be necessary.
1.4 Hadron therapy, Clinical Evidence and Needs
Today, worldwide more than 60 centres using protons and 11 carbon ion (dual6) facilities are treat-
ing patients [35]. For the last twenty years, hadron therapy has gained a lot of interest, many cen-
ters have been built with many more in construction or at the planning stage (see figure 1.5). In
Europe, four dual centers with carbon ions and protons are in operation, two in Germany, Heidelber-
6 Carbon ions and protons.
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ger Ionenstrahl-Therapiezentrum (HIT) in Heidelberg and Marburger Ionenstrahl-Therapiezentrum
(MIT) in Marburg, one in Italy, National Centre for Ontological Hadrontherapy (CNAO) in Pavia and
one in Austria, Medaustron in Wiener Neustadt. The latter will be starting to treat patients with car-
bon ions this year, in 2019. (see 1.6).
Figure 1.5: Number of Particle therapy centers
worldwide: protons and carbon ions. From [34]
Figure 1.6: Particle therapy centers in Europe.
From [34]
Hadron therapy is a very complex and tech-
nological complicated type of treatment. Many
technical challenges need to be met in order to
exploit potential advantages of the new treat-
ment method: this includes very accurate ima-
ging to be able contour the planning target
volume as close to the tumour as possible, beam
delivery which can account for moving targets
and precise beam delivery monitoring.
In the radiobiological field there are still
many unanswered questions: What is the biolo-
gical effect of particle therapy on tissue? What is
the potential toxicity? What is the efficacy? Most
data used are derived from in vitro experiments
which are of limited use because the experi-
mental set-up does not capture the real life situ-
ation. More in-vivo data on late side effects are
needed because they have a major influence on
quality of life and thus represent an important
factor for treatment decision making. A refine-
ment of existing biophysical models which in-
terpolate between physical dose and biological
effects and an agreed reporting standard are es-
sential to be able to plan treatments and com-
pare results across different centers [36].
Although hadron therapy is believed to be superior to advanced photon therapies for certain types
of cancers it has yet not been possible to draw definite conclusions from reviews of clinical studies
and no evidence from randomised clinical trials exist which demonstrate any survival advantage [37,
38]. This is especially true for carbon ions which have a greater biological effectiveness than photons
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and protons. Clinical evidence from phase I/II trials suggest this and indicate better cancer treatment
outcomes. However, the comparison between charged particle versus alternative therapies lack safety
and effectiveness [37] and still no clinical evidence from phase III randomised clinical trials exist [39].
Most clinical studies report different endpoints (e.g. 3 or five year survival or 3 or 5 year local control),
use different treatment volumes, report only severe toxicities and compare small patient cohorts [38].
All this makes it difficult to draw convincing final conclusions.
Lodge [38] emphasizes ”the need to establish a tumour registry for patients treated by European
hadron therapy centers to provide a solution to the current lack of coherent published data”. Such an
instrument would help to establish best practice in treatment and facilitate analysis of clinical data
by offering well characterised data across all centers. A single centre with about 500-1000 patients per
year could not provide enough statistical data within an adequate time frame. This holds especially
for malignancies with a low incidence rate, so called rare cancers. Such a registry could also help with
performing comparative trials that should investigate decreased toxicities for tumours near critical
structures with the same local control or increased local control if the both modalities have the same
NTCP. Reduced toxicity would be a convincing argument for hadron therapy, which is already evident
for the use of protons in childhood cancers [40].
Carbon ion therapy is still considered an ”experimental” treatment for most tumour sites [41].
However, the current evidence shows that potential indications for carbon ion therapy are histolo-
gical radioresistant and locally advanced (large) tumours which are growing locally and have a low
tendency to metastasise or tumours which do not respond well or have too severe side effects with
conventional therapy [42]. Tumour sites which are currently accepted as eligible for carbon ion ther-
apy across the hadron therapy centers worldwide are [41]:
◦ Gastrointestinal malignancies (Pancreas cancer, hepatocellular carcinoma, recurrent rectal can-
cer, esophageal cancer)
◦ Head and neck malignancies (adenoid cystic carcinoma, other non-squamous cell carcinomas,
uveal and mucosal melanoma, skull base chordoma and chondrosarcoma)
◦ Extra-cranial bone and soft tissue sarcoma
◦ Lung malignancies (non-small cell lung cancer)
◦ Prostate cancer (high risk prostate cancer)
◦ Gyneacological malignancies (cervical cancer)
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Less clear indications exist for paediatric tumours (fear of secondary malignancies) and brain tu-
mours (glioblastoma, high-grade meningiomas and low-grade gliomas). It is important to establish
those indications and find the best treatment regime like dose and fractionation.
1.5 Medical Information, Tumour Documentation and Databases
The emergence of computers has revolutionised human society in many aspects, and has changed
the way information is and can be used. With the help of information technology data can be stored,
manipulated and used by people for e.g. research, even distributed across the world. Soon it was
realised that databases support the documentation of tumours and help to evaluate all kinds of as-
pects around cancer. Today, many tumour-related databases exist which contain the documentation
of tumours, for treatment and for quality assurance. There has been a rapid development of database
technologies and techniques to support the application and the analysis of data. The use of com-
putational power opens a wide field of additional possibilities to present and process data in a novel
way.
Medical data are very inhomogeneous and the affiliated research is of multidisciplinary nature in-
volving scientists from various backgrounds like hospital information systems, clinical trial cohorts,
cancer registries and other research databases [43]. They are using different methodologies, termin-
ologies and gather different information. Thus, tumour databases usually focus on serving one group
of end-users but there is no interoperability between different user domains [44]. This would in-
clude the possibility to connect distributed databases and enable the exchange and unambiguous
interpretation of data. This information has huge potential which goes beyond its specific foreseen
purpose like daily clinical care. Data is ”underused” and all combined it could be used to find new
knowledge [45].
1.6 Cancer Modelling
Mathematical and computational modelling offer a tool to investigate (complex) system behaviour.
It has been used to describe a variety of phenomenas in natural sciences and engineering [46].
Decades ago, modelling has been introduced to describe tumour growth. Later, more biological
data has become available as well as computational power has increased making the investigation
of a greater number of topics in detail feasible, like e.g. the modelling of tumour progression and
treatment effects.
At present, cancer treatment protocols are mostly evidence-based while deducted from clinical
trials and applied on other patient groups [47]. However, due to inter-patient variability treatment
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may be successful or not. This is a challenge in particular in emerging treatment protocols or new
treatment modalities were analysable data is scarce. Experiments to understand the underlying factors
e.g. for different treatment responses in patients are expensive and time consuming. Cancer mod-
elling could be an alternative tool, hence there is a strong need to develop models which capture
essential interactions and help to understand treatment outcome better [48]. Although these mod-
els use a simplified view to represent certain characteristics of a biological system and thus do not
account for all details in the real scenario, they offer some convincing advantages [49]:
◦ input parameters can easily be changed and different scenarios can be examined.
◦ sensitivity analysis on the parameters can be performed determining the impact of specific
processes.
◦ treatment scenarios can be compared which lead to the same endpoints (or ”iso-effects”).
Although limited, mathematical tumour modelling already plays an important role in various aspects
of cancer management. It is expected to gain more importance by helping to set up clinical trials,
evaluate data and better use clinical information.
1.7 Expected Contribution
In Europe, many particle centers have been built over the last years with more centers on the way.
Among the European hadron therapy community, in particular among the existing and future cen-
ters, there is a strong need for collaboration [34]. However, no computing infrastructure exists to
record, hold and exchange data between these centers. Since building particle therapy facilities de-
mands for a significant investment, there will only be a limited number of such centres, with some
European countries even not having any. This is true especially for carbon ion therapy which will
make it necessary to facilitate cross-border referral. An electronic system would enable high access-
ibility to these centers and at the same time guarantee a safe way to collect well-cured data, for both,
research and clinical routine.
1.7.1 Hadron Therapy Information Sharing Platform (HISP)
The PARTNER”7 (Particle Training Network for European Radiotherapy ) grid project at CERN (European
Organization for Nuclear Research) addressed this setting by developing a prototype Hadron Therapy
Information Sharing Platform (HISP). It was part of a joint project of the PARTNER Work Packages 22,
23, 24 involving Early Stage Researchers D. Abler, V. Kanellopoulos, F. L. Roman (CERN) within the
7 http://partner.web.cern.ch/
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framework of the CERN PARTNER Grid Project (M. Cirilli, A. Di Girolamo, M. Dosanjh, J. Shiers, A.
Valassi), in collaboration with IFIC (G. Amorós, J. Bernabeu, A. Fernández, V. Méndez, J. Salt Cairols),
University of Oxford (J. Davies, S. Harris, K. Peach), University of Surrey (K. Kirkby, N. Kirkby) and the
Cambridge University Hospital NHS Foundation Trust (R. Jena). Its aim was to develop a prototype,
collaborative grid infrastructure to enable the exchange of data and information from heterogeneous
data sources for interdisciplinary and multi-national research as well as a clinical scenario to refer
and follow up patients from a local hospital to an European hadron therapy facility. In a common
effort a Hadrontherapy Information Sharing Platform was designed with an architecture that could
manage data access, integration and retrieval for different user groups ensuring data protection of
clinical data. On the one hand, in the clinical scenario, confidential patient data like diagnosis and
treatment information would be made accessible to doctors distributed across several hospitals. On
the other hand, researchers would be able to work with anonymised data.
The Grid is a collection of resources like computers, storage, databases, services and even medical
devices that can dynamically participate in resource sharing and problem solving in multi-instititutional
virtual organisations (VOs) whilst ensuring strict confidentiality [50]. Resources can be heterogen-
eous in every aspect, geographically distributed and connected by a wide-area network [51]. The Grid
technology was identified to provide an environment for working with distributed sources based on
trust relationships in virtual organisations and being most suitable for meeting the ICT8 challenges
of the health care sector since it ”offers rapid computation, large data storage and flexible collabor-
ation by harnessing together the power of large numbers of computers, from end-users’ desktops to
powerful workstations and clusters of more powerful machines"[51]9.
My thesis will focus on the development of a research database and prediction methods to analyse
clinical data.
1.7.2 A Database for Rare Tumours
The small number of patients treated by hadron therapy make it difficult to form evidence-based
treatment guidelines. In particular this applies to the increasing number of patients with rare tu-
mours which will be treated with carbon ions. The challenge to acquire enough information ”can
be addressed best through multidisciplinary, national and international collaborative efforts among
researchers, clinicians, governmental bodies, and patients” [53]. Therefore there is an urgent need to
8 Information and Communication Technologies 9 Another aspiring distributed computing technology in the health
care sector is Cloud Computing. It is similar to the Grid technology but manages resources centrally and accesses resources
not directly but via a service over the internet. However, only few successfull implementations exist, partly because there
are still many issues of data safety and security that need to be solved [52].
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collect the information of all treated patients in a common research database: 1) to facilitate the ana-
lysis of best practises and 2) to provide the necessary statistics treating those rare tumours. For this
a set of all relevant medical and biological data was compiled and designed into a database model.
The database was designed as a virtual database in HISP which will allow researchers to run in-silico
studies on data it is holding while respecting ethical and legal requirements.
As an use case the model was simplified and applied for an cross-border follow-up tool of adverse
events of patients after hadron therapy. An accurate description of the adverse events that a patient
experiences after treatment is important not only as part of the individual treatment but also as part
of ongoing research about the likelihood of normal tissue complication. Data from clinical routine
can now be used to perform e.g. daily analysis of recorded side effects. A prediction tool based on a
generalised Markov model for adverse events was developed which can directly evaluate data from
the database for decision making.
1.7.3 Analytic Model of Solid Tumours Treated by Radiotherapy
Mathematical modelling can support the understanding of patient-specific response to cancer ther-
apy. These in silico clinical trials can be a valuable tool to optimise patient care and predict treatment
outcome. For this a mathematical model was deduced from the modeling scales of the BJJK-model
which describes tumour growth and radiation treatment in a population of patients with glioblastoma
multiforte (GBM). The BJJK-model consists of a tumour growth and a radiation treatment model on a
cellular level and a population model which constructs patients by assuming that key parameters fol-
low certain statistical distributions. Following Monte Carlo simulation, the BJJK-model can be fitted
to survival data from clinical trials and extract underlying (radio)biological data [54, 55].
The model introduced in this thesis manages to describe local recurrence in solid tumours in a
novel way. It is designed to reflect plausible mechanisms of tumour growth and response to radio-
therapy including realistic sigmoidal growth and the possibility to examine different beam qualities,
e.g. photon, proton and carbon ions, at a microscopic level and their influence on patients. It will
be investigated if characteristics of recurrence patterns for different beam qualities can predict the
outcome and give indication for hadron therapy.
To demonstrate how powerful and underused common clinical data are the model is fitted to real
local control curves of patients treated for skull base chordoma, with photon, proton and carbon ion
radiotherapy published in peer reviewed journals.
Originally it was difficult to compare clinical trial results because the patient cohort (distribution
of irradiated tumour volumes) or the follow up times differed. Now, with the help of the extracted
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parameters of the treatment model in silico clinical trials can be set up with equal treatment para-
meters (e.g. dose), tumour volumes or follow up times and the treatment outcomes for all modalities
can be evaluated against each other. The application proves in the use case of a new treatment mod-
ality how important mathematical models are to understand the effect of treatment and to support
decision finding in evaluating the indication of new therapies. This is particularly important if not
enough clinical data is available.
1.8 Structure of the Thesis
The structure of this thesis is the following: a literature review of the background for designing a tu-
mour database model is given in section 2. This includes an overview of existing tumour databases,
principles of tumour documentation, the documentation of side effects and the concept of a rela-
tional database. Also given is an overview of existing tumour growth and treatment models. The
fundamental research topics are described in section 3 and 4: A common database model for the
documentation of (rare) tumours and their treatment and an analytical model to describe the treat-
ment response to radiotherapy of solid tumours. Section 5 shows the implementation of the tumour
database in a prototype infrastructure for trans-national exchange of scientific and clinical inform-
ation (HISP). Possible applications are covered by a tool for follow-up and an automated prediction
model for side effects. An application of the mathematical model on skull base chordoma is shown in
section 6. Three types of beam qualities are studied with the help of data published in peer-reviewed
papers: photons, protons and carbon ions. An overall conclusion is given in section 7 and finishes
with recommendations for future work. More detailed information and description of the data fields
of the database model and the dedicated SQL code to generate the database can be found in ap-
pendix A.
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2 Literature Review
2.1 Tumour Databases and Tumour Documentation
Knowledge discovery can be defined as ”the non-trivial process of identifying valid, novel potential
useful, and ultimately understandable patterns in data” [56]. Knowledge discovery is very important
in the field of medicine and with the vast amount of data taken today, data-mining10 techniques
become increasingly relevant. Previously, the examination of large data sets, e.g. biomedical data,
was very hard if not impossible. The adoption of computational power introduces new possibilities
to present and process data in a new way.
The data mining of medical data also introduces new challenges due to the ”uniqueness of med-
ical data” [57]. This is reducible partly to the heterogeneity of medical data and to ethical, legal and
social issues that have to be addressed.
Medical data is very heterogeneous because the disease of a patient is described with entities like
images, doctor’s notes or lab work. The interpretation of the physician is difficult to standardise and
doctors need to agree on the same terms to describe the same condition. Test results can be imprecise
and therefore deduced interpretation could contain errors.
Ethical, legal and social issues contain among other things that personal data has to be kept
private and secure. It is necessary to establish guidelines how data is handled and in particular trans-
ferred and who has access rights. This differs between different forms of patient identification: an-
onymous data has the least sophisticated requirements while identified data can only be collected
under significant review by federal guidelines and with the patient giving consent.
Oncology especially is a very complex and multidisciplinary field including not only clinical but
also biological and genetic data that poses demands on the sophisticated exchange of experience.
The basic requirement for this is the acquisition, processing and analysis of data. The introduction of
databases in medicine has led to a more sufficient exploitation of data.
2.1.1 Tumour Documentation
A precise documentation of tumours and their course of disease is an essential key tool for clinical
oncology. A Tumour documentation system can be a tool for involved doctors to retrieve informa-
tion of previous diagnostics and treatment of their patient. All information is coded so that the data
can be analysed. The comparison of results of different diagnostic methods can improve the quality
of cancer diagnoses as well as the comparison of treatment results and their complications can be
10 Data can be examined to identify patterns and establish relationships.
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a powerful quality assurance tool. The correlation of initial diagnostic findings with aetiopathology
and treatment parameters supports the finding of prognostic factors and the evaluation of treatment
courses. Thus the data can be used to plan novel clinical trials. Finally a tumour documentation
system provides epidemiological data and data for scientific research. All this will lead to an improve-
ment in cancer treatment.
Tumour documentation can be divided into basic and organ-specific.
The basic documentation contains information about the patient, the adjuvant11 therapy (radio-
therapy, chemotherapy, medication) and the course of the disease. The documentation is the same
for all tumour entities.
The organ-specific documentation will record specific tumour entity related extra information in
detail about pre-therapeutic data, treatment, pathology, stage and classification. Data sets for differ-
ent tumour entities comprises characteristic handling for each disease and thus varies in content.
National cancer organisations and governmental health programs usually compile their own data
set which they recommend clinicians to use. The meaning of each data field is explained in a data
dictionary as well as the form by which its content needs to be recorded. This is done to assure that
data can be compared and used for analysis. Examples for this are the National Cancer data set [58],
the German tumour documentation [59], the clinical cancer registry data set of the cancer registry
New South Wales Australia [60], the SEER Program Coding and Staging Manual, Data Standards and
Data Dictionary [61] and the CoC’s Facility Oncology Registry Data Standards [62].
2.1.2 Cancer Registries
Cancer registries are institutions which collect data about cancer diseases from multiple sources over
long periods of time.
Clinical or hospital cancer registries are conducted at hospitals or comprehensive cancer centers
with the intent to improve cancer therapy. For this reason data of cancer patients are collected that
contain information about diagnosis, treatment and the course of the disease. Quality and outcome
of cancer therapy can be judged which enables the comparison of different therapies and therapists.
Population-based or epidemiological cancer registries collect and proceed data for the analysis of
cancer incidence rates, survival and mortality in dependence of time and region. The data which is
collected through doctors and pathologists can be used to perceive risks factors and possible causes
for cancer and their prevention. They require a subset of the data set used in the hospital cancer
11 Therapy that is given after the primary treatment to improve the long-term survival of a patient. E.g. after complete
surgical resection of a breast tumour radiotherapy is given to combat micro-metastasis. Neoadjuvant therapy is treatment
given before primary therapy.
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registries.
National cancer registries ideally collect data from all cancer patients of the area they are respons-
ible for. For example England conducts nine regional registries which collect information on cancer
cases with the help of a standard data set of the NHS [63]. The completeness is necessary for a mean-
ingful, unbiased evaluation.
Many countries therefore introduce an act including the obligation to register every tumour case
for epidemiological reasons. For the same reason efficiently working cancer registries do not ask their
patient for consent. Informed consent has legal limitations and leads to loss of completeness. Sweden
and Norway for example have collected data exhaustively without consent and backed by legislation.
Medical data is sensitive and so it is necessary for registries to propose confidentiality guidelines
to protect the individual’s rights. They include an explanation of security measures, security pro-
cedures and conditions for sharing data. Take as an example the ”guidelines on confidentiality in
population-based cancer registries in the European Union” [64] which are adopted by the European
Network of Cancer Registries12.
2.1.3 Clinical Registries Software
ODSeasy [65] is a German-nationwide market-leading commercial software for the clinical docu-
mentation of gynaecological diseases (version 2009), especially breast cancer. It is installed in more
than 300 hospitals in Germany. The manufacturer asthenis GmbH13 claims that it serves the pur-
pose of using it in clinical routine and for quality assurance with a easy and clear structured graphic
user interface. It seems as if the latter is the main reason for its vast national distribution: German
law requires a certain set of quality management data that can be extracted out of the software. Be-
sides, there was an effort to improve breast cancer treatment in Germany during the late 90ties. To
achieve this the German Association of Senology14 and the German Cancer Association15 formulated
a set of requirements to ensure that women were treated by a team of experts and awarded hospit-
als meeting this standard the certificate “certified breast centre” (“zertifiziertes Brustzentrum”). The
necessary component of sufficient tumour documentation is met by ODSeasy; it provides a com-
prehensive documentation from therapy decision (MDT) to follow-up care. Further functionalities
provide support for compliance of evidence-based guidelines and data exchange between hospitals
and general practitioners (GPs).
The Giessener Tumordokumentationssystem GTDS [66, 67, 68] was developed by the Depart-
ment for Medical Information Technology of the University of Giessen for clinical cancer registries
12 http://www.encr.com.fr/ 13 http://www.asthenis.de 14 http://www.senologie.org/
15 http://www.krebsgesellschaft.de/
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and follow-up. By November 2009 it is used in more than 40 cancer centres in Germany. Beyond
the basis tumour documentation 2.1.1 the system contains functions for clinical routine like med-
ical reports, discharge letters and automatic generation of therapy protocols. There is support for
follow-up management through guidelines and treatment support with the help of a tool to design
and assign chemotherapy. With the help of an integrated Arden-Syntax16 trial eligibility of patients
can be checked.
In Germany clinical cancer registries (CCRs) are usually run by Comprehensive Cancer Centres.
Health care is divided between GPs, hospitals and ambulances. Hence information from different
institutions have to be integrated. This fact is supported by GDTS and makes interdisciplinary pa-
tient care in oncology possible there are various interfaces implemented. This enables the import of
administrative, laboratory or radiology data or pathology reports which already are available in the
hospital. On the other hand, data can be exported to other systems like epidemiological cancer re-
gistry (ECRs). This should reduce the cost of data gathering. In Germany more than 90% of the reports
to the ECR (“Gemeinsames Krebsregister”) in the new states are transferred electronically from GTDS
systems into CCRs. All data can be exported for statistical analysis.
2.2 Example Databases
2.2.1 Gene Data Bases
The IARC TP53 Mutation database [69] gathers all TP5317 gene variations which are identified in hu-
mans and tumour samples. Scientist and clinicians can use the database as source for their research
to understand molecular pathology of cancer, to find tumour-specific mutation patterns and to ana-
lyse genotype/phenotype relationships. The Data is manually compiled from peer-reviewed papers
and other databases. Part of the database can be searched through an open access web-portal for
several criteria like mutation spectra, tumour spectra cell lines etc. Data can either be downloaded or
shown online in table and graphs.
The Hospital and Bioinformatics Unit of the Institute Curie established the Human Tumour Data-
Base [70] for basic research in oncogenesis and cancer treatment. The data is used to group tumours
on a molecular level, find bio-markers and gene predictors for prognosis and diagnosis and to dis-
cover new therapeutical targets. Patient information is anonymously stored centrally for genome and
16 The Arden syntax is a language for encoding medical knowledge and can be used for decision making software 17 TP53
is a growth-inhibiting gene which encodes the tumour suppressor protein p53. The protein has several mechanisms to pre-
vent cancer in being able to activate DNA-repair, stop the cell cycle and initiate cell death if the DNA damage is irreparable.
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transcriptome18 analysis. The database access is restricted. Authorised persons only can consult,
query and update the database through a user-friendly interface. The tumour entities which are ex-
amined cover breast carcinomas, uveal melanoma, paediatric tumours and sarcomas.
2.2.2 Treatment Outcome and Prognosis Databases
The college of Life Science and Medicine of the University of Aberdeen designed databases for treat-
ment outcomes: The Colorectal Initiative Tumour Database [71]was developed to determine po-
tential predictive and prognostic markers and novel therapeutic targets. For this reason it includes
clinical details for colorectal tumours and adjacent uninvolved tissue. It also contains molecular ana-
lysis of samples. The Scottish Urology Cancer Database [72] analyses the data of patients that were
treated for urological cancer. Recorded are cases who have been diagnosed a new primary urological
cancer since January 2001 and after. Various hospitals (Aberdeen Royal Infirmary, Gartnavel General
Hospital from Glasgow and Western General Hospital from Edinburgh) agreed on collecting data over
a period of two years. The Lung Cancer Database [73] was created in 2002 by the Medicine Assess-
ment Research Unit to record clinical information on ca 1400 patients with lung cancer. The data
were recorded from April 2000 to March 2002. The Aberdeen Breast Cancer Database [74] was star-
ted in 1999 and was retrospectively populated with data of patients with breast cancer taken out of
the Aberdeen Royal Infirmary’s Patient Records System between 1991 and 1995. The aim is to collect
information of a group of patients over a 10 year follow-up period and evaluate various treatment
modalities. The database includes approximately 2500 patients which undergo a yearly follow-up.
The Non-functioning Pituitary Adenoma Database [75] from Italy was developed to improve
treatment and to evaluate clinical data and post surgery and radiotherapy outcome. Non functioning
pituitary adenoma are rare and have a prolonged natural progression. Therefore the long-term out-
come of this disease is not well established. In 2004, in a retrospective study seven endocrinological
centres in northern-western Italy collected information on demographic, clinical and biochemical
presentation, therapeutic approaches and long-term outcomes of 295 patients were they had been
referred for diagnosis, cure and follow-up. The protocol was approved by local ethical committee of
each hospital.
TumorAGENT [76, 77] manages the data of breast cancer patients and their tumour sample data
to enable translational research19 and thus provide a tool for genome and proteome analysis of tu-
18 The transcriptome is the set of all RNA molecules. The transcriptomes of cancer cells are used to understand the pro-
cesses of carcinogenesis 19 Definition by the The Translational Research Working Group of the NCI: "Translational re-
search transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to
reduce cancer incidence, morbidity, and mortality.”
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mours. The aim is to understand the pathogenesis of breast cancer and help to develop a framework
for cancer treatment. The interdisciplinary database was developed within four years by the depart-
ment of gynaecology and obstetrics of the university hospital of Tübingen and TWT GmbH, a software
company, and is fully operational since July 2005. Implementations can be found in the University
hospital of Tübingen and at the Indiana University, US. The database consists of medical patient in-
formation and tissue management.
The National Cancer Center Hospital East in Japan established a large-scale lung cancer registry,
the Lung Cancer Database [78], for basic and clinical research in 1999. Enrolled are 2506 patients
that were newly diagnosed with primary lung cancer. The data taking was two-fold: The Baseline sur-
vey was done through two patient self-administered questionnaires concerning demographic data,
health habits, psychological factors, follow-up for vital status and food habits. In the hospital medical
and biological data were taken. The protection of personal information was granted through person-
alisation.
2.2.3 National Cancer Registries
ECRIC (Eastern Cancer Registry and Information Centre) [79] is a cancer registry for all malignant
tumours, benign brain and CNS tumours and some precancerous lesions covering about 5.5 million
people in the east of England. The aim is to collect and keep data and make them available for the
national statistics service, health professionals who want see how they perform, researchers and pa-
tients. If incoming information show evidence for cancer (usually pathological information) the case
is registered. About 40 tumour types are recorded, the cancers are staged at ECRIC by experts. Data
sources include data from PATH, PAS, medical records department, radiotherapy databases, MDT,
CWT, Death Cards and other UK cancer registries which can be retrieved electronically as well as
manual input from the registrars. The data feed is almost real-time (there are registries which update
their data only annually). Because ECRIC does not impose a certain format they use different soft-
ware to convert the data to a standard data set. ECRIC also holds the NHS National Brain Tumour
Registry [80] for England. It contains approximately 1 million records from 1971 until now.
RTDS (Radiotherapy Database Project) [81, 82] retrieved clinical and management data from
seven radiotherapy facilities within the UK with the primary aim to commission and monitor ser-
vices. Besides the data will be used by cancer registries, national audit and research programs. Since
April 2011 it is mandatory for all facilities to submit monthly data. Radiotherapy is a machine and
computer intensive field and therefore many data are present in electronic form. These data can be
extracted directly from the radiotherapy equipment software. Before uploaded the data needs to be
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quality assured.
CBTRUS (Central Brain Tumour Registry of the United States) [83, 84] is a national database
which was started in 1992 as a not-for-profit corporation. It includes all primary malignant and non-
malignant tumours of the brain, central nervous system, pituitary and pineal glands, and olfactory
tumours of the nasal cavity. The database describes the incidence and survival rates and can evaluate
diagnosis and treatment. The collected data is the largest aggregation of population-based data of
this tumour entities in the US and provides the base for etiologic studies and tumour prevention. The
database has been developed by compiling data from state cancer registries that include information
on both malignant and non–malignant primary brain tumours.
The SEER database (Surveillance, Epidemiology, and End Results) is a program by the NCI which
studies cancer epidemiology and outcomes [85, 86]. For this reason it collects cancer survival and in-
cidence information from 18 population-based cancer registries throughout the US (covering 26% of
the US). It was created in 1973 and represents a very important source for cancer statistics in the US
(“gold standard”) holding more than 6 million cancer cases. There are various applications for using
the data: The database has been linked to Medicare20 billing data where much more detailed patient
information is available. It is claimed this allows a better investigation of cancer outcomes. SEER data
is very useful on demographics and outcomes of rare malignant diseases. It is possible to see trends
in diagnosis, stage migration21 and survival. Second malignancies, national and regional trends for
treatment and outcome can be investigated. Finally, because there is a sufficient number of patients
across different spectrums of presentation available, the data can be used to prove prognostic models
of patient survival.
NCDB (National Cancer Database) [87] is a nationwide oncology outcome database for all kinds
of tumours in the United States. The aim is to explore trends in cancer care, create regional and state
benchmarks for participating hospitals, and serve as the basis for quality improvement [85]. It col-
lects a vast amount of data from more than 1.400 approved cancer programs. For brain tumours,
it accounts for the largest database of its kind in the US: newly diagnosed cases are identified and
follow-up is conducted on all primary brain tumours from hospitals accredited by the American Col-
lege of Surgeons. Compared to SEERS or CBTRUS it contains more complete information regarding
the treatment of these tumours [83].
The NODB (National Oncology Database) is a commercial product by IMPAC which claims to
20 Health care insurance administered by the US government for elderly and/or disabled people. 21 Change of the dis-
tribution of a cancer stage induced by either a change in the staging system or an improvement in technology for detection
of tumour spread.
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be one of the largest longitudinal22 oncology databases worldwide [88]. It contains data on cancer
incidence, treatment and outcome. In 2009 the database held more than 2 million cases since 1985
from hundreds of oncology treatment facilities nationwide.
2.2.4 European Databases
GENEPI [89, 90]is a project by ESTRO, European universities and institutions with the aim to predict
the effects of irradiation. With the help of a central database, which holds detailed information on
the outcome of a large number of patients who received radiotherapy, radiation effects and genetic
determinants of the variation in individual radio-sensitivity are being evaluated. The database is also
linked to distributed European tissue banks containing samples of normal and tumour tissue. It is the
largest infrastructure of its kind worldwide. European guidelines for research were developed for the
implementation of tissue and data banks. The GENEPI database policy [91] leads to a frame of refer-
ence for researchers to exchange tissue with compliance to existing legislative and appropriate ethical
standards. Participating centres are required to obtain consent from the local ethics committee which
is written down in an informed consent procedure [92]. To ensure data quality a detailed protocol
for processing and storage of tissue samples [93] is given. After the start of recruitment of patients
in February 2004 the database was opened May 2004. In December 2005 6790 patients were recor-
ded with 12017 tissue samples. Approximately 1600 prospective recruited patients, tissue, treatment
parameters and outcome data were available in the central database. By September 2009 the num-
ber of patients included in the database was 10.000. Treatment plans with images and dose volume
histograms can be saved.
Conticabase [94] is an European sarcoma database and tumour bank which provides data for
bone and mesenchymal23 tumours (except GIST24). Conticagist [95] is the corresponding database
for GIST. Both projects were under the auspices of Conticanet, the leading connective Tissue Cancer
Network which was started in 2006. The aim of the projects is to produce a joint effort to understand
these rare tumours. Conticabase has more than 40 registered centres who provide almost 8000 pa-
tients for its database. Conticagist contains data from almost 900 patients. Both databases contain
information on the description of the tumour, treatment and follow-up, tumour sample availability,
molecular biology analyses and a virtual slide system for pathological review of the tumour samples.
To assure data quality a mandatory set of data is needed to enter a patient.
EUROCARE (EUROpean CAncer REgistry-based study on survival and CARE of cancer patients)
22 Data of patients are collected throughout their lifetime. 23 Loose connective tissue of the embryo 24 Gastrointestinal
stromal tumour is a most common mesenchymal tumours of the gastrointestinal tract
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examines the survival of European cancer patients with solid tumours and for this reason collects
anonymised data on more than 13 million cancer cases from epidemiological cancer registries in 23
European countries [96]. On a large random sample of data it also evaluates the outcome treatment
of cancer patients.
2.2.5 Grid-related Cancer Infrastructures
CaBIG (Cancer Biomedical Informatics Grid) [97] was a nationwide network of tools and IT grid
infrastructure in the US which was launched by the NCI to connect doctors, scientists and patients to
share their knowledge, resources and data. The initiative started in 2004 with a three year pilot phase.
By now the technology has been widely adopted, more than 2000 researchers from 700 organisations
and most of the 65 NCI-designated cancer centres are working with caBIG to collect and retrieve data.
The goal was to improve treatment outcome of cancer through prevention, better diagnosis and
detection. For this data from heterogeneous sources need to be searchable and integrable by its users.
This approach might be the foundation for personalised medicine. The underlying infrastructure
caGRID [98, 99], a grid enterprise architecture, is model-driven and service-oriented with some core
tools. The Cancer Common Ontologic Representation Environment (CaCORE) [100, 101] gives the
background to develop new tools and assure syntactic and semantic interoperability. Semantic inter-
operability means that certain controlled standard vocabularies are used that underlies the descrip-
tion of data that different systems can interpret and work with. Syntactic interoperability relies on
common interfaces and protocols in a way that data services and analytic tools can be promoted and
used by all clients. The available tools in CaBIG provide support for clinical trials, pathology, the col-
lection, analysis and management oft basic research data, collection, annotation, sharing and storage
of medical images and the management of biobanks. All software is open-source and open-access.
Information and analytic resources are locally managed and can be securely accessed. The caGRID
uses its own developed querying language CQL which is object oriented. CaBIG also contains a se-
curity framework which fulfils privacy requirements and intellectual properties by means of policies
and procedures while sharing data.
Two examples for databases that where built within the CaGRID infrastructure are EyecancerBig [102]
and LEAD (Lymphoma Enterprise Architecture Database Platform). EyecancerBig is a project to
develop a database with associate tissue bank which contains medical and biological data about eye
cancers. The goal is to create a common terminology and set of standards to pool and share treat-
ment data from eye cancer specialists around the world. This will enable the evaluation of competing
treatment regimes and communication between researchers and doctors. The database will be used
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as a base to develop an ophthalmologic oncology specific electronic medical record system in the fu-
ture. LEAD [103] is a platform which integrates clinical and biomedical informatics research in order
to facilitate the development of new clinical and therapeutic strategies for lymphoma. It uses various
sources to populate the database namely clinical data from Emory university, SEER registry data, can-
cer registry (IMPAC), laboratory, pharmacy and phase 125 lymphoma clinical trials data. Since 2012
the the National Cancer Informatics Program (NCIP) was created as caBIG’s successor program.
The Australian Cancer Grid is the leading project of BioGrid Australia [104], which provides a
platform for clinical and scientific researchers to share and access clinical, laboratory and genetic
data of diseases in existing databases across multiple sites nationwide. The databases holding pa-
tient data can be linked with research and genetic profiling data. The Australian Cancer Grid has
the aim of enabling data sharing on clinical and surgical outcomes of cancer treatment between re-
searchers. The data is located at its hospital or research facility and can be combined for viewing for
authorised persons. The data collection software ACCORD [105] can be used by hospitals as a cancer
registry and outcomes database. There are comprehensive data sets with data dictionaries for sev-
eral tumour streams [106] like brain, breast, colorectal, head and neck, lung, melanoma, sarcoma,
gastro-intestinal, and uro-oncology.
2.2.6 Common Data fields
A basic tumour documentation to be able to evaluate treatment outcome will contain the following
information:
◦ Demographic Data, which are important for the identification of the patient and his tumour
and therefore enable the communication of involved parties. These data should be collected at
the first contact in the hospital.
◦ Pre-treatment data
◦ Data about therapy and progress
◦ pathological data
◦ Follow-up data after the patient was treated.
Genetic databases hold detailed information on mutations like somatic26, germ-line27, polymorph-
ism28, biological properties of p53 mutant proteins and TP53 gene mutation status in human cell-
25 Phase I trials are the first stage of human testing for the safety of a new drug in a small group of healthy persons.
26 Mutation in a body cell which was produced after conception and therefore is not passed on. 27 Mutation in germ
cells which are transmitted to offspring. 28 Variation of a gene which occurs in a population.
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lines.
2.2.7 Conclusion from the review
Depending on the aim there are many different kinds of databases. They might be designed for mo-
lecular research, therapy decision/evaluation, support of clinical routine and quality assurance, in-
tegrated patient’s care, for clinical trials or epidemiological analysis. Their function can vary from
being a pure information repositorry to being a tool which helps to extract additional insights.
An epidemiological cancer registry requires just scarce clinical information on data which de-
scribe the tumour and the progress of the therapy. This serves the purpose of characterising the
behaviour of cancer in a population with its survival sufficiently. To evaluate therapies in an clin-
ical evidence based manner a more detailed record of clinical data is necessary. On the other hand,
Tissue banks are a necessary tool to improve the molecular science of oncogenetics and tumour pro-
gression [107, 108]. However, to describe a tumour disease of an individual in detail, sufficient data
on both, biomedical and clinical data is needed. This is coupled with a much higher effort which is
challenging in clinical routine.
2.3 Database Modelling
A database model is a logical construct which represents the data structure and describes the re-
lationship between different parts of the data. This defines how the information can be accessed,
categorised and manipulated [109]. A good data model will secure data integrity and enable the man-
agement (retrieval or update) and organisation in an effective way. There are several types of database
modelling techniques to design a database. Each of them have their advantages and restrictions, the
rational model being the most used one. It acquired the most popularity mainly because it is simple,
easy to use and can be manipulated via standard query language (SQL).
2.3.1 Relational Databases
The concept of relational databases is deducted from relational mathematics based on set theory. It
was invented by Edgar F. Codd against the background that data should be independent of any storage
or hardware system. In 1970, his influential paper "A Relational Model of Data for Large Shared Data
Banks" [110] first introduced his model. This database system has set a standard the way data is stored
and processed.
A relational database stores data in tables which consist of particular sets of data. This collection
of two-dimensional tables can be linked together. Real world objects are described by abstract entities
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which are represented by their according tables. The database can consist of one or more tables. A
set of fields, also called columns, stores their attributes and their relations amongst each other. The
content stored in each respective column must be of the same type. Every entity instance consists
of a unique record of data (attributes) which are represented as rows in the table. The uniqueness is
guaranteed by a well-defined primary key which is distinct for each table.
Cross-references can be formed between records in different tables, this is also said to be the
cardinality of a given table in relation to another: One to One relation (on record in a table is assigned
to a record in a separate table), One to Many relations (on record in a table is assigned to many records
in a separate table), Many to One (reverse situation) and Many to Many relations (many records in a
table are assigned to many records in a separate table). One to One, One to Many and Many to One
relations can be implemented by storing primary keys from foreign tables, called foreign keys. Many
to Many relations require an additional table which contains the assignment of foreign keys. A data
model representation including the depiction of relations is introduced in section 2.3.7.
2.3.2 Normalisation
Data stored in tables need to be organised in such a way that data duplication and data anomalies are
minimised, data integrity is supported and efficient updates of data in the database is possible. For
this, data fields called attributes are divided into logical and preservable units called tables. The real-
isation of the logical organisation of the data implemented by certain rules is called Normalisation.
Each rule is called a normal form. There are five normal forms, but usually only the first three normal
forms are considered for practical design for the database development ensuring best efficiency and
database performance. The normal forms are considered to be utilised in incremental order.
◦ First normal form (1NF), helps with the basic development of the database: eliminate duplic-
ated columns from the same tables. Create individual groups for related sets of data. Identify
each row of data with an unique column (primary key).
◦ Second normal form (2NF), deals with the removal of duplicate data: tables are in 1NF. Remove
subsets of attributes which apply to multiple records and create a separate table with them.
Link these tables with a foreign key.
◦ Third normal form (3NF): tables are in 2NF. Each column must directly depend on the primary
key. If attributes do not contribute to a description of a key, move them to a separate table (if
the information can be deducted from other data, delete the column).
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2.3.3 Integrity Rules
For good database design it is important that these integrity rules are implied:
◦ Entity integrity: Each primary key within a table has a value that is unique and does not have
a null value. This ensures that each row has a unique identifier by the primary key and can be
properly referenced.
◦ Referential integrity: any foreign key must be one other table’s primary key.
2.3.4 Structured Query Language (SQL)
After Codd described the relational model for databases in 1970, it was IBM who investigated how
to implement his ideas. SQL, initially developed at IBM by Donald D. Chamberlin and Raymond F.
Boyce, was one of the first languages for Codd’s relational model. Today it is the most widely used
database language and open language. SQL became a ANSI standard (American National Standards
Institute) in 1986, and an ISO (International Organization for Standardization) standard in 1987 [111].
Even with the existence of such standards, most SQL code is not completely usable among different
database systems without adjustments (see below the examples).
SQL is an non procedural language called declarative language, however it also includes proced-
ural elements. A database query consists of a single SQL statement which includes all wanted re-
quests. The statement is sent to the database management and e.g. returns a defined data set.
The scope of SQL includes data insert, query, update and delete, schema creation and modific-
ation, and data access control. For this, SQL is composed of a data manipulation (DML) and a data
definition language (DDL). While commands defined in DML will return demanded data sets, com-
mands in DDL will alter the database’s internal structure.
2.3.5 Data Definition Language (DDL)
The DDL allows the creation and deletion of tables in the database as well as the definition of indexes
(keys) and links between tables. Constraints among different tables can be defined by foreign keys.
The most important DDL commands are the following:
◦ CREATE TABLE [table_name] - creates a new database table
◦ ALTER TABLE [table_name] - alters (changes) a database table
◦ DROP TABLE [table_name] - deletes a database table
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◦ CREATE INDEX [index_name] ON [table_name (column_name)] - creates an index (search key)
◦ DROP INDEX [table_name.index_name] (MS SQL Server), [ALTER TABLE table_name] DROP
INDEX [index_name] (MySQL), DROP INDEX [index_name] (DB2/Oracle), DROP INDEX [in-
dex_name ON table_name] (MS Access) - deletes an index in a table
2.3.6 Data Manipulation Language (DML)
The DML includes the syntax for complex queries as well as for updates, insertions and deletions of
data records. The most basic manipulation commands are listed below:
◦ SELECT [column_name,column_name] - extracts data from a database table
◦ FROM [table_name] - notifies the database engine to return all fields in the selected tables.
these fields become the columns in the new record set
◦ UPDATE [table_name] - updates data in a database table
◦ DELETE FROM [table_name] - deletes data from a database table
◦ INSERT INTO [table_name] - inserts new data into a database table
◦ WHERE [column_name operator value] - restricts the rows returned to only rows containing the
data specified in the SQL statement
2.3.7 Data Model Representation: Entity Relationship Diagram (ERD) and Crow’s Foot Notation
A common way to design and present data models for databases is a technique called Entity Relation-
ship Diagram (ERD) with Crow’s Foot Notation.
As mentioned in section 2.3.1 the relationships One to One, One to Many, Many to One and Many
to Many exist. Further it is possible to define which possible cardinality an entity can take in a rela-
tionship:
◦ One and Only One
◦ One or Many
◦ Zero or One or Many
◦ Zero or One
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With the cardinality further restrictions on the relationship between entities can be added. Graphic-
ally the relationships in data models can be described with Crow’s Foot notation (figure 2.1).
Also, relationships can be strong (identifying) or weak (non-identifying):
◦ Strong relationship: the entity (child) is dependent on another entity (parent). The primary
key of child entity will contain the primary key of parent entity. In a graphical model, strong
relationships are pictured with solid lines.
◦ Weak relationship: the entity’s existence is independent of other entities. The primary key of
child entity does not contain primary key of parent entity. Relationships will be depicted with
dotted lines.
One and Only One Zero or One
One or Many Zero or One or Many
Figure 2.1: Crow’s Foot notation symbols
2.3.8 Data Modelling Process
The development of a database model involves three steps:
1. Conceptual Model: at first, all entities and relationships with cardinalities are identified.
2. Logical Model: attributes (columns) of the entities and their types (data types) are identified.
Note that the types are still platform independent. The final relationships between entities are
defined. Normalisation (section 2.3.2) is performed.
3. Physical Model: data structures are specified for a certain database and it is platform-specific.
This means that a physical model designed for a database usually can not be implemented in
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another database. E.g. column types generated for SQL SERVER with the data type VARCHAR
cannot be implemented in ORACLE database because this data data type is invalid for it. Gen-
erate the SQL scripts to employ the database.
2.3.9 Advantages of a Relational Data Model
Relational database models allow the data to be stored in smaller logical and easier maintainable
units. The advantages for using relational databases are that data duplication is reduced or even in-
hibited. This leads to improved data integrity. Data can be stored in tables and distributed physically
among various places. The access to the database is independent of applications and programs. Data
can be shared among various users. Simple queries retrieve data from all tables.
2.4 Documentation of Side effects
2.4.1 Side Effects of Radiotherapy
Radiotherapy can not be sensed by the patient. Many patients though will experience some reactions
of their normal tissue. They vary in strength, type and location, depending on which part of the body
was treated and what amount of normal tissue was affected by the radiation treatment. The reason for
this is that radiation harms both, cancer cells and normal tissue. Therefore, the aim in radiotherapy
to give a maximum possible dose to the tumour29 is limited by the damage through the dose delivered
to the surrounding normal tissue through treatment.
The toxicity arising after tissue irradiation is classified into early (acute, sub-acute) and late. Acute
effects usually appear during or shortly after treatment, sub-acute a few weeks or months delayed30,
whereas late effects can manifest between 6 months, years and decades.
The effects of acute side effects are due to cytotoxicity31 to fast proliferating normal cells like skin,
gastrointestinal tract and the haematopoetic system32. This leads to an impairment of of cell produc-
tion [112]. Consequences are often inflammation (e.g. dermatitis, mucositis, cystitis, bone marrow
suppression). Acute side effects are usually reversible.
On the contrary, late toxicities are mostly irreversibly and therefore generally dose-limiting. These
side effects occur in slowly proliferating cells and affect organs like kidney, heart and central nervous
system. The common pathway for most late effects is that radiation induces small vessel injury and
the loss of parenchymal cells33 [7]. As the life expectancy for many cancer patients is increasing with
29 The higher the dose the higher the chance to control the tumour growth. 30 The cut-off time to distinguish early from
late effects has arbitrarily been set to 90 days after the onset of radiotherapy [112]. 31 Cytotoxicity is the quality of being
toxic to cells. 32 Blood-making organs. 33 Any cell that is a functional element of an organ such as the alveoli in the
lung.
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the improvement of detection and treatment methods, late effects become relevant for long term
survivors.
Structural damage to normal tissue is directly related to the cell radiosensitivity which varies for
different cells. Functional damage, however, depends on organ physiology, and the irradiation of the
same volume in different organs can lead to a variable loss of functionality.
Toxicities can include fibrosis, atrophy, vascular damage, hormone deficiencies and secondary
malignancies. Late effects can especially have a negative impact on the quality of life of the patient,
and therefore should be taken into consideration when a treatment decision is made [113] or a ther-
apy concept is evaluated. Because they can worsen over time, a continuous and sufficient long term
follow-up is necessary. This should be considered especially for secondary malignancies where the
general assumption is that they develop at the earliest 10-15 years after irradiation.
The dose-response34 of normal tissue to develop toxicities has an onset, increases with dose and
finally saturates (see figure 1.4). This holds for all patients; however, the onset and steepness of a
dose-normal tissue damage curve can vary between individuals [114]. Normal tissue responses of
different patients to the same dose show for most of them an approximate Gaussian distribution.
In addition, there are some extremely rare cases of extraordinary radiosensitivity associated to DNA
repair disorders [115]. A schematic graph of the normal tissue response distribution to radiation can
be found in figure 2.2.
The reasons for variable radiosensitivity are manifold. Patient-related factors like age, smoking
habits, certain diseases (e.g. diabetes) etc. have an impact, as well as treatment-related factors like
total dose, fractions, irradiated volume and concomitant chemotherapy. In the past there have been
many studies on potential genetic markers for radiosensitivity, like genes involved in DNA damage
response, oxidative stress, radiation fibrogenesis and endothelial cell damage. A recent review [117]
summarises that those studies identify some associations but altogether the genetics of normal tissue
radiosensitivity is still unravelled.
The most radiosensitive patients determine the maximum dose. Therefore it would be desirable
to be able to identify the individual radiosensitivity before treatment [118].
2.4.2 Scoring Systems
A variety of scoring systems are in use for reporting toxicities. Depending on the tumour location,
several normal tissues can be irradiated and show organ-specific reactions. Each reaction is rated
according to its severity (see table 2). Since side effects do not necessarily occur directly after irra-
34 Relationship between a dose (radiation, medication) and the effect on an organism.
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Figure 2.2: Schematic representation of the frequency distribution of normal tissue reactions
amongst patients which receive the same photon radiation treatment shown in arbitrary units. There
is a range amongst the patients with normal radiosensitivity which follow an approximate Gaussian
distribution and some very rare cases of extremely high radiosensitivity: ”overreactors”. Adapted
from [116].
diation and their severity can develop over time, it is necessary to record them regularly and over a
sufficiently long time.
In 1979, the WHO35 introduced criteria for acute and sub-acute side effects [119], the National
Cancer Institute (NCI) created the Common Toxicity Criteria (CTC) for Chemotherapy in 1982, and a
different scale for acute effects for radiotherapy, was published by RTOG36 in 1985 [120] (RTOG Acute
Radiation Morbidity Scoring Criteria).
As radiotherapy causes different early and late effects (in contrast to chemotherapy), efforts were
soon made to record those toxicities systematically in different scoring systems. For late effects, ori-
ginally a late morbidity37 scoring scheme by RTOG/EORTC existed [120], and this was was used to
develop in a combined effort the late effect scale LEnT SOMA [121, 122, 123].
With the goal of integrating side effects from chemotherapy, radiation and surgery, both, the NCI
CTC and the RTOG Acute Radiation Morbidity Scoring Criteria, were intended to be replaced in 1998,
as a result of an international harmonisation effort38: the Cancer Therapeutics Evaluation Program39
released the Common Toxicity Criteria version 2.0 (CTC v2.0) [124]. More than 260 individual adverse
35 World Health Organizationhttp://www.who.org 36 Radiation Therapy Oncology Group http://www.rtog.org 37 Term
used to indicate sickness or poor health. 38 The Review committee involved representatives of major clinical trials groups
(in Canada, Europe, Japan, USA), the pharmaceutical industry, the FDA and the Committee for Proprietary Medicinal
Products (CPMP). 39 Part of the NCI
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Grade Side effects Intervention Example: Mucositis oral41
(CTCAE v4.0)
1 mild clinical-diagnostic observation
only, intervention not indicated
Asymptomatic or mild symptoms;
intervention not indicated
2 moderate minimal, local or noninvasive
intervention indicated
Moderate pain; not interfering with
oral intake; modified diet indicated
3 severe hospitalisation or prolongation of
hospitalisation indicated
Severe pain; interfering with oral
intake
4 life-threatening or
disabling
urgent intervention indicated Life-threatening consequences;
urgent intervention indicated
5 lethal - Death
Table 2: Principles of grading side effects, adapted from [128]
events (AE)40 were included, with more than 100 applicable to acute radiation effects. This version
improved the evaluation and grading of acute toxicities for all modalities [125] and then became the
international standard for reporting acute adverse events in clinical trials.
Finally, in March 2003, Version 3.0 of CTC, which was renamed to the Common Terminology Cri-
teria for Adverse Events (CTCAE) [126] and included the scoring of late effects, was released. It is the
first comprehensive, multi-modality scoring system for reporting the early and late effects of cancer
treatment. CTCAE v.4 was published in May 2009 and replaced by CTCAE v.5 in November 2017 [127].
Differences were changes in some grades.
An overview of the most common systems is given in table 3. Not mentioned are more detailed
scoring systems for the description of certain areas like oral mucositis [129].
Ideally, the clinician is able to record toxicities in a way that represents the subjective impression
of side effects of the patient. The remaining problem is defining ”acceptable” toxicity. This usu-
ally varies depending on the patient’s or physician’s view. It has been shown that patient-reported
outcome measures (PROMs) provide much more information on side effects and symptoms than
the doctors report [130]. Also, the AEs reported by physicians do not indicate patients’ stress well
enough. For some time now the Christies hospital42 in Manchester, UK, has developed question-
naires for patients and doctors to record side effects for various organs and body parts (scored by
LENT SOMA [131] and CTCAE [132]). Also, there have been recent efforts by the NCI to incorporate
subjective measures in the CTCAE [133].
In clinical trials, a distinction is made between adverse events and serious adverse events43 (SAEs).
40 The term ”side effect” can either describe a therapeutic or an adverse effect. However, the latter is meant by the usage in
this context. For this reason ”adverse event” is the official terminology nowadays. 41 A disorder characterised by inflam-
mation of the oral mucosal 42 http://www.christie.nhs.uk/ 43 Any event which causes death, permanent damage, birth
defects or the requirement of hospitalisation. For clinical trials the SAEs are specifically described in the study protocol.
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All SAEs need to be reported in clinical study reports.
At present, various systems are used for the side effects recording of treatment with radiother-
apy [134] (see also table 3).
2.4.3 Problems comparing Scoring Systems
Acute toxicity reporting is fairly standardised, but there is no consensus on how late normal-tissue
effects are best quantified. The awareness and grading of side effects caused by cancer treatment
is a critical endpoint in clinical trials [135]. However, objective scoring systems are difficult to use
because the criteria are not necessarily applied in a uniform way. The interpretation of the extent
of symptoms can vary very much. Therefore, only crude changes are reflected in the toxicity scores.
Even if subjective assessment is included, scores can vary due to different symptom management.
This can be illustrated with a study of accelerated radiotherapy (CHART), were scoring was consistent
within one institution but varied between centres [136]. If there is a small number of severe toxicities,
a large number of patients is needed to evaluate differences in therapies. Also, when evaluating late
effects one has to consider that these effects might have a long latency time and patients therefore
could die before assessment.
Different scoring systems describe effects in different ways and with different granularity. Up to
now, the prevailing opinion is that there are serious difficulties in comparing multiple scoring sys-
tems.
Generally toxicities are under-reported by observers, which leads to an underestimate of toxicity
burden. At the same time, differences in reporting can be observed whether the reporting is done by
a physician, a nurse or the patient himself [137].
All this complicates comparisons of treatment outcomes between trials and centres.
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Name Acute Late Modality Grades # Scales, Organs yr
WHO[119] x CHX 0 (baseline) 28,9 1979
CTC v1 x CHX 18,13 1983
CTC v2[124] x All: SX,RT,CHX,
surgery, biological, etc. But does not
incorporate all RT reactions.
0 (no symptoms)-4 (severe),no death
includes for late effects the
EORTC/RTOG scoring in the
appendix
260,22 1998
CTCAE v3[126] x x
All
1(mild symptoms) - 5(death) Not all
grades for every AEs exist. Especially
grade 5 (death) is not specified for all
AEs
~900,26 (all)
(ca 570 criteria, with anatomic
sub-classifications 900)
2003
CTCAE v4[138] x x
All
1(mild symptoms)-5(death).
Harmonised with MedDRA ~900,26 (all)
(ca 790 criteria, with anatomic
sub-classifications 900)
2009
RTOG[120, 139] x RT
0 (baseline) - 4 (severe)
14,13 1985
RTOG/EORTC[120,
140]
x
RT 0 (no symptoms) - 5 (death)
17,17 1985
LENT-SOMA[141] x RT. Distinguishes between signs,
symptoms, treatments and
investigations.
0 (no symptoms, baseline) - 4
(severe), no death.
Note: no secondary malignancies
included!
>150, 1995
Table 3: Overview of Commonly Used Scoring Systems. Abbreviations: RT radiotherapy, CHX chemotherapy, SX surgery.
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2.4.4 Conclusions
Besides the treatment outcome the accurate description of early and especially late side effects that
a patient is experiencing after undergoing hadron therapy treatment is not only important for doc-
umenting the individual course of a patient but also of great interest of ongoing research. The like-
lihood of developing normal tissue complications are dose limiting and thus can have an effect on
local tumour control. If multiple treatment modalities result in comparative outcomes, the severity
of side effects become an important factor in comparing different therapies.
To be able to compare data of side effects recorded in different Scoring systems, an (approximate)
translation between them is necessary.
2.5 Models of Tumour Growth and Their Application to Therapy
The knowledge to model the dynamics of tumour growth and treatment may support the finding of
more effective treatment plans. The role of mathematics in modelling is to explain recorded data and
be able to predict future outcomes. Ideally a mathematical tumour model should satisfy the following
criteria [142, 143]:
◦ have a physiological basis
◦ minimum of parameters
◦ fit experimental data
◦ variables of the model should be measurable
◦ give good prediction
◦ improve the understanding of the real situation: on a microscopic and macroscopic level
Modelling of cancer can involve different length scales: molecular, intracellular, multi-cellular, tissue,
organ, whole human and society & culture [54]. Reviewed here are models on the multi-cellular level
which represent growth rates of cells and their reaction to radiotherapy. The goal is to understand the
response of a group of patients to treatment.
2.5.1 Growth Models
Tumour growth in-vivo is sigmoidal, showing only briefly exponential characteristics and then slow-
ing down until a maximum number of tumour cells is reached. A huge variety of cancer growth mod-
els have been developed in the past decades. Some of them describe the volume or cell number
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growth of empirically by using ordinary differential equations to match the growth measured growth
characteristics. Other models take also spatial information into account and are expressed in terms of
partial differential equations. Finally, the introduction of computing power enables a more realistic
depiction of complex dynamics of tumour growth using in silico modelling.
The earliest models of tumour growth used diffusion models. In 1966 Burton [144] who developed
a diffusion model which examined the blood supply and oxygen distribution in a spherical tumour
trying to relate it to Gompertzian growth. The original Gompertzian equation was applied to the study
of growth in biology and economics because it could describe exponential retardation. It is only one
out of a class of sigmoidal functions (which are described in detail in section 4.2) yet together with
the logistic growth function the most commonly used one. Laird [145, 146] showed that Gompertzian
tumour growth in vivo could be very well described by this growth pattern.
The simplest modelling assumptions is that the tumour contains of one cell type, has no spatial
variation and no explicit mention of growth factors, nutrients and vascularity. The volume or cell
number is empirically described using ordinary differential equations. The general model has the
form of
dN
dt
=G(N ) with N (t = 0)=N0 . (2.1)
with G(N ) describing the dynamics of tumour growth. Examples for homogeneous growth mod-
els are e.g. G(N ) = kN , where k denotes the proliferation rate and depicts here exponential growth.
Another example is G(N )= kN (t )αx (1− [d N (t )]x ), a family of curves which can saturate depending on
the choice of α.
By fitting the models to empirical data different growth kinetics of tumours can be compared and
used to assess the impact of chemotherapy or radiation therapy. Naturally it is difficult to relate the
model parameters to measurable ”real” variables.
Other work described a homogeneous cell population with partial differential equation models
restricted to rotation symmetrical geometries [147]. These model can add information on the struc-
ture of the tumour spheroid and supports the understanding of tumour growth in two or three di-
mensions.
Gyllenberg and Webb [148] explained Gompertzian growth by expressing the rates of cells trans-
itioning reversibly between the proliferative and quiescent states as a function of tumour cell number,
therefore including variable growth fractions. Cell quiescence is reasoned as a mechanism to explain
characteristic sigmoid growth curves. The model produces naturally a diminished growth fraction for
a larger tumour because the increasing volume leads to a larger fraction of quiescent cells.
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Other developments include the use of cellular automata where individual cells are simulated and
biophysical rules are applied [149]. However, these models are difficult to study analytically even for
very small sizes, and patient related tumour sizes cannot be studied with an acceptable computa-
tional cost. Similar problems with other tumour growth models arise which make them unsuitable
for application on patients.
2.5.2 Mathematical models for RT
In the literature several approaches to model radiotherapy treatment can be found. There is a great
difference between modelling an individual tumour or the outcome of therapy of a pool of patients.
The modelling of the behaviour of a single virtual tumour will focus in much more detail on under-
lying intra-cellular, sub-cellular and multi-cellular effects. Goals of this approach could be getting a
deeper insight on cancer biology [150, 151, 152, 153]. Due to their complicated and/or computing
intensive nature they are not well suited to be applied to real clinical data.
A patient pool oriented strategy is to set up a model which tries to extract radiobiological informa-
tion from clinical data. Kirkby et al. [154] introduced a three component model to describe the treat-
ment of Glioblastoma with radiotherapy. It includes the modelling of a patient, a treatment model
and a clinical trial or population model. The patient model describes the (exponential) growth char-
acteristic of the cancer cells through an ordinary differential equation, the interaction of normal and
tumour cells and defines the patient’s death, when the number of cells drop below a critical number.
The model of treatment calculates the effect of therapy on the number of tumour cells. It is assumed
that normal cells are not killed by radiation and that each fraction will kill the same amount of cells.
To match clinical data e.g. from clinical trials, the population model assumes certain distribution
parameters to simulate a patient cohort. The parameter which are varied are the number of normal
cells, the tumour doubling time, the constant rate for damage to normal cells, delay before treatment
and the critical number before a patient dies. With the help of Monte Carlo simulation a patient pool
is generated which is fitted to actual clinical data. The model can be used to help with the design of
clinical trials, for example dose escalation studies.
Another model with a slightly different set-up is predicting the outcome of radiotherapy in cer-
vical cancer [155]. The kinetic model includes the effects of three major radiobiological processes: ra-
diosensitivity, tumour repopulation and the resolving of dead cells with the help of image-based ana-
lysis of tumour volume regression. The main model equations are two differential equations which
couple these processes. The model parameters were fitted and evaluated for individual patient data
and patient groups independently to find prognostic factor for outcome prediction. The interesting
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aspect here is the incorporation of the resolvement of dead cells and the comparison between differ-
ent patient groups to test the significance of differences of model parameters.
2.5.3 Conclusion
For the modelling of patients treated with radiotherapy a appropriate model is needed. Tumour
growth must be modelled in a simple yet informative way capturing the essence of the mechanism
of tumour growth. The 2-compartment model seems to cover that need while describing the main
characteristics (sigmoid growth) with biological means (quiescent and proliferating cells). The model
of Kirkby et al. [154] was successfully applied to clinical data and seems like a rational approach to
cover effects of radiotherapy. All required information can be extracted from patient data. A simpli-
fied version of cell cycle effects on treatment can be evaluated introducing proliferating and quiescent
cells.
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3 Design of a Rare Tumour Database for Hadron Therapy
The small number of patients treated by hadron therapy make it difficult to form evidence-based
treatment guidelines. In particular this applies to the increasing number of patients with rare tumours
which will be treated with carbon ions. There is an urgent need to collect the information of all treated
patients in a common research database: 1) to facilitate the analysis of best practise and 2) to provide
the necessary statistics treating those rare tumours. For this a set of all relevant medical and biological
data was compiled and designed into a database model.
3.1 Tumour Classification and Their Coding for Documentation
In a clinical environment it is necessary to characterise tumours in a way that it helps the physician
to find a suitable treatment, give hints for prognosis and facilitate communication. For this reason
such a classification should be precise and reproducible.
The current methods of clinical tumour classification are based on the description of the tumour
by its biological potential (benign vs. malignant), the localisation (organ), the cells of origin (typing),
its differentiation44 (grading) and the extent of the tumour spread (staging). The stage of a tumour is
usually the most influential factor for the tumour’s clinical course and treatment
Benign Malignant
Mainly encapsulated Non-encapsulated
Usually non invasive Invasive
Highly differentiated Poorly differentiated
Slowly growing Fast growing
No metastases Metastases
Table 4: Characterisation of tumour beha-
viour [156]
response [157], an important exception though are
many soft tissue sarcomas [158] where the grade is of
greatest importance. The classification based on where
the tumours originated from is important to predict
the behaviour of the tumour: ectoderm and ecdoderm-
derived tumours tend to metastasise via lymphatics,
mesenchyme-derived tumours via blood [157].
The following sub-chapters will give an overview of
the information which needs to be recorded and their
state of the art way to describe and code it.
3.1.1 Biological Behaviour, Typing And Tumour Localisation
Tumours can be divided in benign, malignant and semi-malignant neoplasms [158]. This is very
useful in a clinical setting when determining the prognosis in a patient. This classification though
does not give any insight if studying tumours on a molecular level.
44 In cancer this describes how much the tumour cell resembles normal cells. Well-differentated tumour cells look like
normal cells and usually grow and spread more slowly than poorly differentiated cells.
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Tab. 4 shows that the main difference in behavioural characteristics between malignant and be-
nign is the development of metastasis. Metastasis are cells from the primary tumour which spread
through the blood or lymph system and develop a secondary tumour at a different location of the
body. Prerequisite for this is that the tumour grows invasive45. Furthermore do not all invasive grow-
ing tumours metastasise. In this case they are called semi-malignant.
Tumours are distinguished by the site of origin (e.g. brain, breast, lung, etc.) and the type of cell
the tumour resembles and the tissue it presumably originated from. Most commonly, tumours are
named after their biological behaviour (benign, malignant) and the histogenetic origin tissue they
originated from [159]. Generally, there is no standardised way of denominating tumours (for an over-
view of synonyms see [160]).
Benign tumours of non-epithelial origin have a striking similarity to their physiologic tissue of
origin. Therefore they are usually described through the tissue of origin with the suffix -oma [161].
Examples: Myoma is a benign tumour of muscle cells, chondroma is a benign tumour of the cartilage.
Examples of tumours that have the suffix -oma but represent a malignant tumour are seminoma,
lymphoma, melanoma and chordoma.
Benign tumours of epithelial origin mostly are either called papilloma, which is arising from su-
perficial epithelia, or adenoma, which has its roots from glandular, parenchymal, or mucosal epithe-
lium of internal organs46. Names can also be a mixture of microscopic and macroscopic appearance.
For example, cystadenoma refers to a benign tumour arising from gland cells while forming a cyst.
Malignant Tumours are grouped in six major categories [162], different histological types of tu-
mours may react differently to treatment. Knowing the histology of a cancer enables to chose the best
treatment plan:
1. Carcinoma: Cancer arising from epithelian47 cells. Their morphological structures can specify
the name. Examples: Adenocarcinoma is a cancer of epithelia originating in glandular tissue.
Squamous cell carcinoma (SCC) is a malignant tumour of squamous epithelium48. Carcinoma
are the most common cancers accounting for 80-90%.
2. Sarcoma: Malignant tumours from tissue of mesenchymal origin49 like bone, tendons, cartil-
age, muscles and fat cells. Soft tissue sarcomas are derived from soft tissue like fat, muscle,
nerves, fibrous tissues, blood vessels, or deep skin tissues. It has been suspected that they de-
45 Tumour growth into adjacent structures with blood vessels or lymphatics. 46 Such as the lungs, breasts, colon, pro-
state, stomach, pancreas, and cervix 47 Epithelian tissue is one of the four fundamental tissues. It covers cavities and
surfaces of structures. 48 This is the most superficial layer of epithelium consisting of flat, scale-like cells called squam-
ous cells. 49 Embryonic connective tissue.
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velop from mesenchymal stem cells (MSC) [163].
3. Myeloma: Cancer that originates in the plasma cells of bone marrow.
4. Leukaemia: Disease of the bone marrow, the site of blood cell production. Usually associated
with the overproduction of immature white blood cells.
5. Lymphoma: Solid Cancer which develops in the glands or nodes of the lymphatic system.
6. Mixed tumour: Several cell types from different tissues are present in a tumour.
Other cancer types include tumours from pluripotent cells50 containing tissue elements from all three
germ layers51 is called a teratoma. Blastomas describe a tumour from precursor cells52 which re-
semble immature or embryonic tissue. They are usually found in children.
If the tumour cells do not look like the tissue of origin anymore they are called anaplastic or un-
differentiated.
In some special cases the disease is named after the doctor who first described it: Ewing’s sar-
coma, Wilm’s tumour (nephroblastoma) and Hodgkin’s lymphoma.
In rare cases the primary cancer cannot be found. It is called ”cancer of unknown primary”.
The international standard for the nomenclature of histologies is the International Classification
of Diseases for Oncology (ICD-O), see 3.1.3. However, also other classifications coexist (e.g. Gosecki,
Laurén and Ming classification for gastric cancer [164]).
3.1.2 Grading
Although having the same histological origin, tumours can behave very differently. There is a close
connection between their morphology and prognosis53. Poorly-differentiated tumours will most likely
behave more aggressive towards metastasising and growth than highly differentiated cells. However,
this relationship again is highly tumour specific. E.g. the grading of soft tissue sarcoma describes
its behaviour very well, lung carcinomas usually progress very aggressive regardless of the differenti-
ation [158].
Grading is performed by a pathologist who examines the tumour tissue specimen which was pre-
viously extracted by biopsy or surgery under the microscope.
50 A stem cell that has the potential to differentiate into any foetal or adult cell type. 51 During embryogenesis three
primary layer of cells are formed from which the different tissues and organs develop. 52 Partially differentiated cell
which usually is unipotent and lost most or all of the stem cell multipotency. It can differentiate into one cell type. 53 The
likely course of a disease.
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Several factors like mitotic rate54, hypercellularity55, vascular proliferation56, necrosis, atypia57,
growth patterns, nuclear grading etc. are examined.
The schemata for this are not uniform but tumour-specific: leiomyosarcoma is graded by at atyp-
ical cytological characteristics, Adenocarcinoma of the prostate by looking at their growth pattern and
for grading ductal carcinoma of the breast both is investigated. Increasingly, tumours now are graded
with the help of other methods like immunohistochemical staining with antibody Ki-67 to recognise
cell proliferation (e.g. brain astrocytoma) and make it possible to determine the progression of tu-
mours whose grade could not be determined before. Some tumours do not have a grading schema
(e.g. mesothelioma according to the UICC58), others are automatically defined by their histological
classification as high-grade (Small and large cell lung carcinoma, rhabdomyosarcoma of soft tissue)
or low-grade (small lymphocytic lymphoma).
The most common grading system classifies primary tumours into G1 (well differentiated, high
resemblance to the original tissue), G2 (moderate differentiated), G3 (poorly differentiated), G4 (not
differentiated resp. anaplastic) or GX (it is not possible to evaluate the grade of differentiation) [165].
However, other, organ-specific grading systems coexist e.g. for prostate cancer the Gleason score [166]
and for breast cancer the Bloom-Richardson system [167]. Tumours of the central nervous system can
be graded according to the WHO (Grad I-IV) [168].
Soft tissue sarcomas are classified through histological grading.
All grading systems are only applicable to untreated, primary tumours. Although there have been
some efforts to develop a grading system for metastasis [169] and recurrent tumours, there exists no
common agreement [170].
Grading is a key factor in decision-making for therapy, in particular if adjuvant radiation therapy
and specific chemotherapy protocols are useful [171].
Therefore it is important to implement effective grading strategies to avoid inconsistencies. Grad-
ing systems can change over time [168] to maximise prognostic significance. The ICD-O code holds
one digit for histological grading, see 3.1.3.
3.1.3 ICD-O
The International Classification of Diseases for Oncology (ICD-O) has been used since 1976, princip-
ally in tumour or cancer registries, for coding the site (topography) and the histology (morphology)
of neoplasms. ICD-O has been derived from the International Statistical Classification of Diseases,
54 The mitotic rate gives the proportion of cells in tissue undergoing mitosis. 55 The tumour contains a large number of
cells. 56 blood vessels growing into the tumour. 57 Structural abnormality in a cell 58 Union for International Cancer
Control (http://www.uicc.org/)
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Injuries and Causes of Death (ICD), a medical classification list, both developed by the World Health
Organization (WHO).
ICD-O Code
/0 Benign
/1 Uncertain whether benign or malignant
Borderline malignancy
Low malignant potential
Uncertain malignant potential
/2 Carcinoma in situ
Intraepithelial
Noninfiltrating
Noninvasive
/3 Malignant, primary site
/6 Malignant, metastatic site Malignant,
secondary site
/9 Malignant, uncertain whether primary
or metastatic site
Table 5: 5th digit behaviour code (from [172]).
ICD contains codes for diseases, signs and
symptoms, abnormal findings, complaints, social
circumstances, and external causes of injury or
diseases[173]. Chapter two of ICD was always ded-
icated to neoplasms. ICD contains four digits, the
first one being a letter (C for malignant behaviour, D
for other), the following three digits are numbers de-
scribing the location, while the last one is separated
by a dot describing the location more in detail.
There are some basic differences between the
structures of ICD and ICD-O: In ICD, the topographic
code describes the behaviour of the neoplasm, there-
fore needing 4 different characters e.g. for describ-
ing lung cancer: lung malignant (C34.9), secondary
or metastatic (C78.0), In situ (D02.2), Benign (D14.3),
Uncertain and unknown (D38.1). Only few histo-
logical types are listed in ICD, which makes it im-
possible to distinguish e.g. between an adenocarcinoma of the lung and a squamous cell carcinoma
of the lung (both C34.9).
ICD-O contains a dual classification system which describes the topography and the morpho-
logy [172]. The topography code describes in detail the location of origin of the neoplasms, the mor-
phology code describes the histology of the tumour and biological behaviour, see tab. 5. An extra
one-digit code for histologic grading can be used. Only malignant tumours may be graded, while
the grading scheme is highly subjective and only relating to adverbs ”well”, ”moderately” and ”poor”
when describing the differentiation, see tab. 6. For a lymphoma or leukaemia, this digit is used to
identify T-, B-, Null-, and NK-cell origin. Explicit rules for coding exist [174, 172].
The structure of the codes are:
◦ Topography: C __ __
site
. __ ;
subsite
e.g. C50.2 (Breast.upper inner quadrant)
◦ Morphology: M- __ __ __ __
histology
/ __ __ ;
behavior grade
e.g. M-8140/3 1 (adeno-/carcinoma well-differentiated
= well-differentiated adenocarcinoma)
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ICD-O is updated regularly, ICD-O-3 is the current edition.
ICD-O Code
1 Grade I Well differentiated,
differentiated,
Not otherwise specified
2 Grade II Moderately differentiated
Moderately well
differentiated
Intermediate differentiation
3 Grade III Poorly differentiated
4 Grade IV Undifferentiated
Anaplastic
9 Grade or differentiation not
determined, not stated or not applicable
Table 6: 6th digit code for histologic
grading and differentiation (from [172]).
It has been made an effort to include new terms that
have appeared in the recent literature, terms for neo-
plasms from other classification schemes have been in-
cluded. There are conversion algorithms to older coding
systems (ICD-O) and other systems (e.g. ICD-10, ICD-9)
available [175].
However, ICD-O is a coded nomenclature and not
a classication scheme for neoplasms. To describe neo-
plasms in a sufficient biological way, a more specified clas-
sification may be needed.
3.1.4 Staging
Cancers of the same location and histology often show
the same progression and similar outcomes. Staging de-
scribes the extend of spread of a malignant tumour and
which simultaneously denotes how far the natural history
of the cancer has already evolved. The stage of the disease
is the basis for the treatment decision and is furthermore
a predicting factor for survival while evaluating results of therapies [159]. By introducing consistent
criteria it is possible to treat patients with the same tumour at the same stage equally or if new treat-
ments are tested to compare them with established standards.
The analysis of the stage is done at diagnosis with the help of physical exam and/or imaging (clin-
ical staging) which is used as a guide for the primary therapy, sometimes after biopsy or surgery,
where the tissue is examined microscopically (pathologic staging) [176]. Pathologic staging can vary
from the clinical staging and is mainly used to estimate the prognosis, report results and for adjuvant
therapy decisions [158]. Restaging is used to determine the best treatment options when the tumour
has grown back.
For solid tumours the classification usually includes the size of the tumour, how far it invaded
surrounding tissue and if it includes proximate lymph nodes or other organs. The descriptors of the
most commonly used staging system, the TNM-classification is based on this. This staging system is
organ-based and is also used for most of the rare tumours.
There are some cancers though which do not follow this course e.g. brain tumours or leuk-
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aemia because the extent of the disease can not be described through the anatomical spread but
only through other characteristics.
3.1.5 TNM Staging System
T
0 No primary tumour
1-4 Increasing size and/or local extent
of the primary tumor
is Carcinoma in situ
X Not assessable
N
0 No regional lymph node metastasis
1-3 Increasing involvement of regional
lymph nodes
X Not assessable
M
0 No distant metastasis
1 metastasis to distant organs
(beyond regional lymph nodes)
X Not assessable
Table 7: Values to classify a tumour (ac-
cording to [177]. There are denotations
by sub-classifications possible when greater
specificity is needed (eg. Tla, 1b or N2a, 2b
as with breast and prostate).
The most universally accepted staging system is de-
veloped by the International Union Against Cancer59
(UICC) and the American Joint Committee on Can-
cer60 (AJCC), which use the same categories [178].
There are other staging systems which are based on
the TNM Classification e.g. staging of ovarian cancer
by the International Federation of Gynaecology and
Obstetrics61 (FIGO).
The TNM classification is describing the anatom-
ical extent of cancer [177]. This it based on record-
ing the tumour size (T), the absence or presence and
its extent of regional lymph node metastasis (N) and
the absence or presence of distant metastasis (M) (see
tab. 7).
There are prefix modifiers which describe how
the stage was evaluated: pre-therapeutic, clinical sta-
ging can be denoted as cTNM or just TNM, the histo-
pathological classification after surgery is indicated
by pTNM. Autopsical staging of a tumour is called
aTNM. Relapsed tumours which occur after a disease-free interval are indicated with a prefix ”r”.
The stage of tumours after neo-adjuvant therapy is denoted with the prefix ”y”. This distinction is
necessary because those cases are not comparable with an untreated tumour.
For example pT1pN0M0 describes a small, localised tumour where T and M were examined patho-
logically and M only clinically (imaging). rpT1N0M0 would be the nomenclature for a relapsing tu-
mour with the same characteristics.
To specify the certainty of the clinical findings more detailed, a descriptor ”C-factor” (C1-C4) can
be added after each TNM category. C1-3 roughly corresponds to clinical and C4 to pathologic staging.
For completing the TNM classification, existing metastasis are recorded with the following codes:
59 http://www.uicc.org/ 60 http://www.cancerstaging.org/ 61 http://www.figo.org/
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Pulmonary PUL, osseous OSS, hepatic HEP, brain BRA, lymph nodes LYM, bone marrow MAR, pleura
PLE, peritoneum PER, adrenals ADR, skin SKI and other OTH.
The TNM classification is used for most forms of cancer, except brain tumours and haematolo-
gical malignancies. Because the tumour stages are related to the natural history of every particular
cancer, for each specific organ tumour (or part of an organ tumour) the TNM classification is determ-
ined individually. The classification is updated regularly, the 7th edition took effect in January 2010.
Increasingly other findings like genetic attributes are included [171]. The newest edition introduced
new classification for several malignant tumours, announced major changes in existing tumour clas-
sifications and dropped the category ”MX” for describing distant metastasis [179].
3.1.6 Prognostic Staging
When using the TNM classification system a very precise description of the extent of the disease is
achieved. However, there are many TNM categories and some combinations of T, N, M will have
similar prognosis. Thus, combinations are grouped into stage groups to help to plan the treatment,
facilitate the evaluation of results of treatment and give an indication of prognosis. Depending on the
stage therapy can be curative or palliative.
The overall stage of tumours are usually described in the following categories:
◦ Stage 0: carcinoma in situ, pre-invasive neoplastic growth.
◦ Stage I: the tumour is confined to the organ of origin.
◦ Stage II: the tumour is locally advanced.
◦ Stage III: metastasis to proximate lymph nodes.
◦ Stage IV: metastasis spread further throughout the body.
Each stage may be subdivided into A,B,C, etc., if it is useful for treatment recommendations and re-
porting.
Other factors like cell type and tumour location within an organ can have an effect on the pro-
gnosis (e.g. cancer of the oesophagus are mainly either squamous cell cancers or adenocarcinomas
and staged differently. The stage also depends on whether the cancer is in the upper, middle, or lower
third of the oesophagus. A few tumour entities use for the overall staging extra information like tu-
mour grade (soft tissue sarcoma), age (thyroid carcinoma) or tumour marker levels (prostate).
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Figure 3.1: Work-flow of the data entries for tumour documentation. Red colour denotes the different
stages of the documentation in temporal order (arrows). The other fields contain the information
grouped by colour for patient, each tumour and its treatment data taken at certain points in time.
3.2 Documentation of Therapy and Treatment Outcome
The documentation of therapy and treatment outcome is obviously important for the evaluation of
a treatment modality. However, the documentation is straight forward and an extensive overview of
the required data fields is given in detail in appendix A.1. Just as important is the documentation of
toxicities caused by therapy. A review of the documentation of side effects and their pitfalls was given
in the previous chapter, section 2.4.
3.3 Work-flow Tumour Documentation
Figure 3.1 gives an overview of the data which are taken for documenting tumours in their sequence
of events. Although as principle designed for tumour registries (see section 2.2.3), the work-flow is
valid for any tumour documentation and should be considered for the architecture of the database
model.
3.4 A Database Model for the Documentation of Side effects
Patients which undergo radiotherapy usually experience side effects of this treatment and/or con-
comitant therapies. The recording of those toxicities is done in distinct time intervals and serves
mainly the following three aims [135]:
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◦ It is part of the quality assurance in clinical practise,
◦ The establishment of type, incidence and severity of effects for specific therapies informs pa-
tients, medical doctors and health-care managers within the scope of treatment decision mak-
ing,
◦ It helps to understand the pathology of these effects to develop strategies for their prevention
or improvement.
The data model presented here was developed to record all information which is relevant in a clinical
setting in order to document and to evaluate side effects of radiotherapy. The data fields needed for
this task are a subset of the data which was compiled for the documentation of tumours treated by
hadron therapy A.1. Not included in this data model is information on the course of the disease, in
particular the tumour response to the therapy.
An overview of the database schema developed to accommodate this information can be found
in figure 3.2.
The data model efficiently organises the data in tables without redundancy and ensures that re-
lated data is grouped in tables, as well as that data dependencies make sense (normalisation). The
goal is to reduce the amount of space of the database and store the data in a logical way within a
clinical setting.
For the evaluation of side effects, the relevant information concerns the patient (e.g. age and sex)
and the personal characteristics which can have an influence on normal tissue reaction to radiation
and chemotherapy such as comorbidities (diabetes, heart problems) and life habits (e.g. smoking).
This information is recorded in the tables PATIENT_ANONYMOUS, CONCOMITANT_BEHAVIOR and
CONCOMITANT_DISEASE. Bound to each patient is the tumour and its treatment which will be fol-
lowed up. The detailed description on the tumour can be found in the tables TUMOUR and STA-
GING. The treatment modalities are captured with the tables THERAPY, CHEMOTHERAPY (with the
sub-table AGENT), RADIOTHERAPY (with the sub-tables BEAM and TARGET_VOLUME), SURGERY
and OTHER_THERAPY. This design enables both, the recording of a simple treatment e.g. only ra-
diation of the tumour and complex, multimodal regimes which can involve various therapies at the
same time and/or in sequential order. Because former radiotherapy treatments can have an effect on
normal tissue reactions during the present treatment, the above mentioned tables will also be used
to record information on the history of the patient.
Finally, the information which will be taken repeatedly after treatment to follow up the patient’s
normal tissue reactions, will be saved in the tables OBSERVATION, VITAL_STATUS, SIDEEFFECT and
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DOCTOR. The side effects recorded by both, doctors and patients, will be saved in the same table. A
particular feature is the possibility to record single side effects in the scoring system of choice.
For a more detailed description of the variables in each table, their predefined values and data
types, please see appendix A.3. The corresponding SQL code to generate the database can be found
in appendix A.2.
Finally, this data model can be easily generalised to a system which could be used for tumour
documentation. In the simplest case, only one additional table has to be added (linked to the table
OBSERVATION) which holds information on the tumour response, e.g. status of the tumour (remis-
sion, progression etc.). The data model is not specific for rare tumours and can be used for create a
comprehensive tumour database. It is suitable for any tumour treatment, but especially radiotherapy
including hadron therapy because it holds very detailed information on the treatment modality. For
this the information on clinical trial forms were included and for more detailed information even the
treatment plan.
With the help of this more comprehensive data set it will be possible to develop outcome predic-
tion models and give indications for hadron therapy.
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Figure 3.2: Relational data model (Crow’s Foot notation).
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4 Mathematical Modelling of Solid Tumours and Their Treatment
4.1 Introduction
Clinical data are usually used to extract information on patient level of survival or regression prob-
abilities for a certain treatment set-up. The results of the study are very much dependent on how the
investigation is done. In radiotherapy common questions are: efficiency and refinement of treatment,
finding parameters for indications, comparing different ways of giving treatment and reduce side ef-
fects. At present, cancer treatment protocols are mostly evidence-based while deduced from clinical
trials and more or less successfully applied to other patient groups [47]. This is a challenge in par-
ticular in emerging treatment protocols or new treatment modalities where analysable data is scarce
or very limited. Trials to understand the underlying factors e.g. for different treatment responses in
patients are expensive and time consuming. Cancer modelling could be an alternative tool which
would be faster and cheaper, hence there is a strong need to develop models which capture essen-
tial interactions and help to understand and predict treatment outcome better [48]. Although these
models use a simplified view to represent certain characteristics of a biological system and thus do
not account for all details in the real scenario, they offer some convincing advantages for example like
input parameters can easily be changed and different scenarios can be examined [49].
Since tumour volume is regarded as a benchmark of treatment response [180], the aim is to de-
pict the growth of tumours and their reaction to treatment. It is sought to use the models to compare
data from different clinical trials and combine them to find answers for best possible radiotherapy
treatments for solid tumours. In this chapter a model based on the BJJK-model [54, 55] is introduced
which allows acquisition of a deeper insight and understanding on biological properties using clin-
ical data from patients treated with radiotherapy. The model strives to understand different beam
qualities at a microscopic level and their influence on patients. Like the BJJK-model this model will
be comprised of different modelling scales. It consists of
◦ a tumour growth model at patient level,
◦ a treatment model on cellular level, and
◦ a population model describing the study cohort.
The original BJJK-model uses one kind of tumour cells which grow exponentially. However, it has
been shown that tumour cells grow sigmoidally, which is defined by inital positive accelerated growth
rate which increases rapidly approaching an exponential (constant) growth rate and then declining in
a negative acceleration phase until at zero growth rate the growth stops. Exponential growth (constant
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growth rate leading to unlimited cell growth) only captures small tumours or in-vitro growth rather
well [142]. The new patient model uses an analytic sigmoidal growth function (see section 4.2) which
describes in-vivo growth characteristics of solid tumours more accurately.
The literature shows that the quiescent cell population is a stumbling block for many cancer ther-
apies because they either target proliferating cells (as with chemotherapy) or are less effective on
quiescent cells (radiation therapy) [181, 182]. Therefore it seems important to model at least two dif-
ferent cell types: cells which are cycling and cells which are in cycling arrest but can change back to
the growth fraction. The idea of mapping an underlying physiological model (Gyllenberg and Webb
two-compartment model [148]) to a specific growth model, Gompertzian growth, was performed by
[183] and will be generalised to all sigmoid growth functions here. It incorporates the change of ra-
tio over time for the different cells (see section 4.3). The treatment model includes the fractionation
schema and differing radiosensitivities for proliferating and quiescent cells (see section 4.4). It allows
to account for a non-constant response to therapy and naturally incorporates repopulation. This is
a further development of the original model which applied all fractions at once, did not account for
regrowth and could not model differences between in-vivo and in-vitro characteristics of tumours.
Finally, the population model simulates a cohort of patients with the Monte Carlo method assuming
that parameters of the the patient and treatment model follow certain probability distributions (for
examples see section 4.5.4). Fitting the local control curves of in silico clinical trials based on the
above model to actual trial data will enable to draw conclusions from clinical data to microscopic
characteristics of tumour cells. The model can be applied to all solid growing tumours. It can be used
to answer the following questions:
◦ What effect would an increasing radiation dose have on the regression rate?
◦ How do different beam qualities relate to the distribution of radiosensitivity?
◦ Which parameters of the tumour are of strong prognostic value?
The answers to these questions could be used to assist in designing clinical trials, compare clinical
results between radiotherapy using X-rays, protons and carbon ions and, in particular, give treatment
indication for hadron therapy.
4.2 Tumour Growth Model
Tumour growth is characterised by unrestricted cell growth. However, the lack of nutrition, oxygen
and possibly space can lead to a deceleration of growth until it stops, and a maximum cell number
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which can be reached. Commonly used models to describe this sigmoid tumour growth are exponen-
tial, Gompertzian, Bertalanffy and the logistic (Verhulst) model. In the past it has been shown that
the best fit of experimental data of growth of different tumour entities varies between these growth
functions [142]. In the following, sigmoid growth functions are derived from a common function, the
generalised Verhulst equation.
4.2.1 Generalised Bertalanffy equation
Tumour growth is determined by an increase and loss of tumour cells. A general form to describe
such a system is the generalised Bertalanffy equation62 [143]
N˙ (t )= aN (t )α−bN (t )β. (4.1)
N denotes the number of Tumour cells, t the growth time and a,b >= 0. a,b,α,β influence the
growth rate: aN (t )α expresses the increase of cells, whereas bN (t )β describes the loss.
We rewrite the equation with the following transformations a = kx , β= x+a and b = ad x as a base
to derive a class of differential equations with a physiological meaningful structure for cell growth:
N˙ (t )= kN (t )
α
x
(
1− [d N (t )]x) , (4.2)
where k,d > 0 and thus x > 0 . Any 1d >N (t ) yields N˙ (t )> 0 and thus the cells number is increasing
over time until 1d is reached. In the following, this maximum number of cells will be denoted as
1
d =N∞.
4.2.2 Generalised Verhulstian Model
The growth models that will be examined here can all be deducted from the generalised Verhulst
equation [184]. The latter itself can be deducted from eq. 4.2 by setting α= 1:
N˙V (t )= kNV (t )
x
[
1−
(
NV (t )
N∞
)x ]
. (4.3)
With the inital condition N (t = 0)=N0 the solution is
NV (t )=N∞
[
1−e−kt
(
1−
(
N0
N∞
)−x)]−1/x
. (4.4)
62 Abbreviations: X (t = 0)= X0, dXdt = X˙ and d
2 X
d2t
= X¨ .
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For simplification we introduce
γV (NV )= k
x
[
1−
(
NV (t )
N∞
)x]
≥ 0, (4.5)
and likewise
γ0,V = γV (N0)= k
x
[
1−
(
N0
N∞
)x]
≥ 0. (4.6)
Then eq. 4.3 and eq. 4.4 can then be rewritten as
NV (t )=N∞
[
1−e−kt
(
1−
(
N0
N∞
)−x)]−1/x
, (4.7)
N˙V (t )= γV (NV )NV (t ) , also (4.8)
N¨V (t )=
(
γV (NV )−k
(
NV (t )
N∞
)x)
γV (t )NV (t ) . (4.9)
For all times −∞≤ t < ∞ it is N˙ > 0, thus the function NV (t <∞) is strictly increasing and hence
the inverse function exists
t (NV )= 1
k
ln
[
(N∞/N0)x −1
(N∞/NV )x −1
]
= 1
k
ln
[
γ0,V
γV (N )
(
NV
N0
)x]
. (4.10)
Specifically, t < 0 for NV <N0 and t is not defined for values 0≥NV ≥N∞.
The function has an inflection point for N¨ = 0, where the growth rate changes to deceleration, at
N turnV =N∞
(
1
1+x
)1/x
and t turnV =
1
k
lg
[
1
x
((
N∞
N0
)x −1)] . (4.11)
Adding a constant value (∆t > 0) to an augment of a function leads to a left shift of the function
along the x-axis. It can easily be shown63 that NV (t +∆t , N0) = NV (t , N∗0 ), where the new initial cell
number is given by
N∗0 =
(
e−k∆t
(N0N∞)x
[(
ek∆t −1
)
N x0 +N∞
])− 1x
. (4.12)
4.2.3 Exponential Growth
The exponential growth implies a constant rate of increase, therefore a constant doubling time and
no cell loss. In this case d = 0, x = 1, thus γE = k = const., and the differential equation becomes
63 It is NV (t + ∆t ) = N∞
[
1−e−k(t+∆t ) (1− (N0/N )−x )]−1/x = N∞ [1−e−kt e−k∆t (1− (N0/N )−x )]−1/x . Substitute
v = e−k∆t , w =
(
N∞
N0
)x
and y = (N∞/N∗0 )x . Finally, solve v(1−w)= (1− y) for y.
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N˙E (t )= kNE (t ). (4.13)
The solution of the eq. 4.13 is
NE (t )=N0ekt . (4.14)
For small t an exponential growth seems reasonable. However, the equation implies limitless
growth and therefore has shortcomings when describing tumour growth over a longer time period.
In the literature tumour growth rates are usually characterised by the tumour (volume) doubling
time (DT). It assumes a constant rate of growth and is defined by
DT = ln2
k
. (4.15)
4.2.4 Logistic Growth
The logistic growth model was introduced by Verhulst in the 19th century to describe growth of a
population based on finite resources [184]. It takes into account that the growth is limited by the
possible density of cells due to available resources like nutrients and oxygen. The growth rate is then
proportional to the momentarily number of cells and the difference of the total resources available
and presently used ones.
The the differential equation can be derived from eq. 4.3 by setting x = 1:
γL(NL)= k
(
1− NL(t )
N∞
)
, (4.16)
N˙L(t )= γL(NL)NL(t ) . (4.17)
The sigmoid shaped solution is
NL(t )=N∞
[
1+
(
N∞
N0
−1
)
e−kt
]−1
(4.18)
It has been shown that there are patients whose tumour growth data are well fitted to this growth [142].
However, there is no physiological basis for choosing the exponent.
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Figure 4.1: Comparison of exponential, Gompertzian and logistic growth. Both, the logistic and the
Gompertzian growth curve show a sigmoid shape. Their rate of growth are increasing and reaches the
maximal rate, indicated by dots, at
(
ln[ln[N∞/N0]]
k ,
N∞
e
)
for Gompertzian growth and at
(
ln[N∞/N0−1]
k ,
N∞
2
)
.
After this the rate is constantly decreasing to zero, where the cell number reaches N∞. The time scale
is given in arbitrary units.
4.2.5 Gompertzian Growth
The Gompertzian equation was originally developed to study human mortality, but was then used
by Albert Casey (1937) to fit tumour growth [142]. In the 1960ties, Laird analysed and mapped the
dynamics of tumour growth to Gompertzian growth [145, 146]: tumours will initially grow approxim-
ately exponentially and then their growth is slowing down more and more.
The differential equation of Gompertzian growth can be derived from eq. 4.3 with limx→0 and
L’Hopital’s rule64:
γG (NG )=−k lg[NG (t )/N∞] (4.19)
N˙G (t )= γG (NG )NG (t ) . (4.20)
The solution that can be found to
NG (t )= lim
x→0 NV (t )=N∞ (N0/N∞)
e−kt , (4.21)
where N (t = 0)=N0.
Usually Gompertzian cell growth for N (0) = N0 is described by factorising the normalised equa-
tion from above (N0 = 1) with an inital cell number N0 [183, 142] :
64 If limx→c g (x)= limx→c h(x)= 0or∞, and limx→c g
′(x)
h′(x) exists, then limx→c
g (x)
h(x) = limx→c
g ′(x)
h′(x) .
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NG ,Nor m(t )=N0N 1−e
−kt
∞ . (4.22)
Note that this equation is not the general solution of eq. 4.19. Here, the final number of cells will
be dependent on the initial number N0: Nmax =N0N∞.
However, assuming that the final maximum size and the momentarily growth rate is dependent
on available nutrition and not on an inital number of cells when describing patients with different
initial tumour sizes, it is more obvious to use the general solution for describing tumour growth of a
patient cohort. Hence in the following the general solution of eq. 4.21 will be used.
A graphical comparison of all deducted growth functions is shown in figure 4.1.
4.3 Two-Compartment Model Applied to Growth Models
The cell cycle of eukaryote cells65 has four phases (see figure 4.2) which result in two daughter cells:
◦ G1 (gap phase), in which the cell grows and prepares to synthesise DNA,
◦ S (synthesis phase), in which DNA is synthesised,
◦ G2 (second gap phase), in which the cell prepares to divide, and
◦ M (mitosis phase), in which cell division occurs.
Cell cycling times of mammalian cells can vary from 9 hours in crypt cells in the intestinal epithelium
to stem cells in resting mouse skin with cycle times of more than 200 hours. The differences result
mostly from the varying length of the G1 phase, the M,S and G2 phase do not vary very much [7].
The radiosensitivity of dividing cells vary throughout the cell cycle. Cells in the G2 and M phase
are most radiosensitive, less sensitive in the G1 phase and least sensitive in the S phase. Cells with
longer cell cycling times and very long G1 phases show a peak of radioresistance in early G1 [185].
Consequently, faster growing cells must be more radiosensitive which has been confirmed in human
xenograft models [186].
The G0 phase (resting phase) is a period in the cell cycle in which cells exist in a quiescent state.
The cell is neither dividing nor preparing to divide and occurs outside of the cell cycle [188]. In the
human body, cells can remain quiescent for a long time, possibly indefinitely which is characteristic
for fully differentiated cells (e.g. neurons). Some cells enter the G0 phase only semi-permanently (e.g.
kidney, liver, stomach cells) and other constantly divide, e.g. epithelial cells.
65 These include human and tumour cells.
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Figure 4.2: Cell cycle (From [187]).
Many Cells in solid tumours are quiescent but can still return to the proliferating cell cycle [189].
The quiescent state is caused to some degree by hypoxia via the cyclin-dependent kinase inhibitor
p27kip1 [190] and the depletion of nutrition in the tumour core which is due to poor vascular sup-
ply [191]. Those cells can be refractory to anticancer agents [192] and show a significantly reduced
radiosensitivity to gamma rays [193, 191]. Therefore, the control of quiescent cells is thought to have a
great influence on the outcome of anticancer radiotherapy and thus seems to be important to model.
In the following we will make a distinction between proliferating and quiescent cells
Tumours have high cell loss factor: cells die as a consequence of rapid growth to keep up with an
adequate vascular supply and due to apoptosis and immunological surveillance [194]. Cells are also
lost from the tumour lump because of metastasis and exfoliation [195]. The cell loss in vivo may be
as high as 50 % [196] or even up to almost 100 % [197]. Thus, the increase of tumour cells is governed
mainly by three factors: cell cycle time of the proliferating cells P, the fraction of P and the amount of
cell loss.
An approach to take these differences between tumour cells and cell loss into account and to
explicitly model quiescent cells in relation to proliferating tumour cells is to use the Gyllenberg and
Webb model [148] which consists of two compartments and is explained in section 4.3.1. This physiolo-
gical model will then be mapped to a specific growth characteristic like exponential, logistic or Gom-
pertzian growth (see section 4.2) to be able to describe growth of different cell types (see section 4.3.3).
Kozusko and Bajzer [183] studied this map for Gompertzian growth (eq. 4.22). We will use a similar
58
approach here to map the generalised Verhulst equation to the Gyllenberg-Webb model. From there,
Gompertzian, logistic and exponential growth can be deduced by performing simple limit considera-
tions for parameters in the generalised function. The derivation in this thesis is more comprehensive
and exceeds the work of [183], offering a better understanding of restrictions when creating growth
functions for proliferating and quiescent cells deduced by an overall growth function when using the
2-compartment model.
4.3.1 Gyllenberg and Webb Two-Compartment Model
A tumour consists of proliferating, quiescent and (metabolic) dead cells. Figure 4.3 shows the 2-
compartment-model which was proposed by Gyllenberg and Webb [148]. The model is very simple
but incorporates the basic physiological phenomena: cells can change from the quiescent compart-
ment into the proliferating compartment and vice versa. These transition rates are no fixed constants
but some arbitrary functions of the total number of cells. Cells can be lost from both compartments
with cell loss rates µq and µp and proliferating cells grow with the growth rate β.
The model explains that tumour growth is only due to clonogenic cells: Quiescent tumour cells
can become proliferating and vice versa (see previous section). Sigmoid growth is caused by a decline
in growth rate which occurs when the number of tumour cells increases leading finally to a satura-
tion of tumour growth. In the 2-compartment model this can be explained through a the vanishing
number of proliferating cells the bigger the tumour growths (see figure 4.4).
Figure 4.3: Two-compartment-model by Gyllenberg and Webb. Here, P and Q denote proliferating
and quiescent cell sub-populations, r1 and r0 are the transition rates between P and Q. µq,r describe
(constant) cell loss rates (death) and β the (constant) proliferation rate.
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For the model the following set of ordinary differential equations can be found [183]:
P˙ (t )= [β−µp − r0(N )]P (t )+ ri (N )Q(t ), (4.23)
Q˙(t )= r0(N )P (t )− [ri (N )+µq ]Q(t ), (4.24)
N (t )= P (t )+Q(t ), P0+Q0 =N0 . (4.25)
Inserting eq. 4.23,4.24 into the differentiated eq. 4.25 yields
N˙ (t )= (β−µp )P (t )−µqQ(t ). (4.26)
Finally, eq. 4.25 into eq. 4.26 and solving for P gives
P (t )= N˙ (t )+µq N (t )
β−µp +µq
. (4.27)
4.3.2 Net Transition Rate and Constraints
Looking closer at β−µp we find when inserting eq. 4.25 into eq. 4.27
N˙ (t )= (β−µp)P (t )−µqQ(t ) . (4.28)
For any saturated tumour growth N˙ (t →∞)= 0 and therefore
(
β−µp
)
P∞ =µqQ∞ , (4.29)
with P∞ = P (t →∞)≥ 0 and Q∞ =Q(t →∞)≥ 0. Thus, it is necessary that
β−µp ≥ 0. (4.30)
For any unsaturated growth with N˙ > 0, e.g. exponential growth,
(
β−µp
)
P∞+ N˙ |t→∞ =µqQ∞ , (4.31)
and again, eq. 4.39 holds.
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We define the net transition rate as
Φ(N )= r0(N )P (t )− ri (N )Q(t ) . (4.32)
IfΦ(N )>0, there are more proliferating cells changing to quiescent cells than the other way round.
It is
P˙ (t )= (β−µp)P (t )−Φ(N ) . (4.33)
Inserting eq. 4.27 and its derivative into eq. 4.33 results in the solution of the net transition rate
governed by the underlying growth characteristics
Φ(N )= N˙ (t )
(
β−µp −µq
)− N¨ (t )+µq N (t )(β−µp)
β−µp +µq
. (4.34)
Eq. 4.27 characterises the solution for the number of proliferating cells depending on the under-
lying growth characteristic. However, the solutions have constraints, as both transition rates, r0(N )
and ri (N ) need to be ≥ 0. Use eq. 4.25 and eq. 4.32 = eq. 4.34 to find the relationship between r0 and
ri :
r0 =
(
β−µp
)
µq N (t )+
((
β−µp
)−µq) N˙ (t )+ ri (N (t )−P (t ))((β−µp)+µq)− N¨ (t )
P (t )
((
β−µp
)+µq) (4.35)
=
(
β−µp
)
N˙ − N¨ + (N (β−µp)− N˙)(µq + ri )
µq N + N˙
≥ 0, (4.36)
and, likewise
ri =
(
µ1N + N˙
)(
r0−
(
β−µp
))+µq N˙ + N¨
N
(
β−µp
)− N˙ ≥ 0. (4.37)
.
The equations above state the general relationship between r0 and ri and their constraints. They
are specified through eq. 4.8, eq. 4.9 for generalised Verhulstian growth:
r V0 =
(
β−µp −γV
)(
r Vi +γV +µq
)+γV k ( NVN∞ )x
γV +µq
≥ 0, (4.38)
where γV is given by eq. 4.5.
While the last term γV k
(
N
N∞
)x ≥ 0, any r Vi (N )≥ 0 can be used to comply with r0 ≥ 0 as long as
β−µp −γV ≥ 0. (4.39)
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Also, if β−µp −γV < 0, no r Vi ≥ 0 exists that r V0 (N )≥ 0.
Conversely, it is
r Vi =
r V0
(
γV +µq
)−γV k ( NVN∞ )x
β−µp +γV
− (γV −µq)≥ 0 (4.40)
r V0 ≥
γV k
(
NV
N∞
)x + (β−µp +γV )(µq +γV )
γV +µq
. (4.41)
In order that r Vi ≥ 0, r V0 can not be arbitrarily be picked but must satisfy eq. 4.41.
Equations 4.39 and 4.41 also hold for logistic, exponential and Gompertzian growth functions
after applying their limit considerations.
4.3.3 Quiescent and Proliferating Cell Populations for Various Growth Models
Finally, the explicit functions for the proliferating and quiescent cell population of the Gyllenberg-
Webb model is expressed which predict the above specified growth models. Eq. 4.27 from the Gyllenberg-
Webb model is valid for any growth curve and yields for t = 0
1
β−µp +µq
= P0
N˙ (t )|t=0+µq N0
. (4.42)
Inserted again in eq. 4.27 it yields
P (t )= N˙ (t )+µq N (t )
N˙ (t )|t=0+µq N0
P0 . (4.43)
To find the function for the general Verhulst growth model eq. 4.3 at t = 0 is used
N˙V (t )|t=0 = kN0
x
[
1− (N0/N∞)x
]= γV ,0N0 , (4.44)
with γV ,0 = kx
[
1−(N0/N∞)x
]
. Inserting eq. 4.44 and eq. 4.3 in eq. 4.43 gives as an result the growth
function of proliferating cells
PV (t )= NV (t )P0
N0
· xµq +k
[
1− (NV (t )/N∞)x
]
xµq +k
[
1− (N0/N∞)x
] =NV (t )PNorm · µq +γV (NV )
µq +γV ,0
(4.45)
where P0 denotes the inital number of proliferating cells and P0/N0 = PNorm is the inital fraction
of proliferating cells which can take values between 0 and 1, inclusive. NV (t ) follows eq. 4.4. The
function for quiescent cell growth is given by QV (t )=NV (t )−PV (t ).
The deduction of the exponential, logistic and Gompertzian growth functions for proliferating
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cells can be done with the same limit considerations as in section 4.2, thus
PE (t )= P0NE (t )
N0
=NE (t )PNorm for exponential growth, (4.46)
PL(t )= P0NL(t )
N0
· µq +k(1−NL(t )/N∞)
µq +k(1−N0/N∞)
=NL(t )PNorm ·
µq +γL(NL)
µq +γL,0
for logistic growth, (4.47)
PG (t )= P0NG (t )
N0
· µq −k lg[NG (t )/N∞]
µq −k lg[N0/N∞]
=NG (t )PNorm ·
µq +γG (NG )
µq +γG ,0
for Gompertzian growth.
(4.48)
The following figures are given to demonstrate the impact of the different parameters of the growth
model, the parameters used have been picked at random and might not represent realistic values:
figure 4.4 pictures cell growth for the quiescent and proliferating compartment for the same over-
all growth function and different cell loss factors µq for quiescent cells. A higher cell loss factor for
quiescent cells leads naturally to a higher proportion of proliferating cells. Figure 4.5 shows that the
number of proliferating cells for Logistic and Gompertzian growth are not necessarily monotonously
increasing in contrast to exponential growth, were the map of the Gyllenberg-Web model leads to an
exponential increase of proliferating cells and the ratio between both compartments is constant and
defined by PNorm.
The corresponding functions for the quiescent cell populations can be found using the general
equation QX (t )=NX (t )−PX (t ).
4.3.4 Characteristics of the Gyllenberg-Webb Model for Sigmoid Growth
With the help of the derivative of Eq. 4.27 after time the function of the number of proliferating cells,
P (t <∞), is examined for stationary points:
P˙V (t )=
N¨V (t )+µq N˙V (t )
β−µp +µq
(4.49)
=
γV (NV )NV (t )
[
γV (NV )−k
(
NV (t )
N∞
)x]+µqγV (NV )NV (t )
β−µp +µq
!= 0 (4.50)
γV (NV )−k
(
NV (t )
N∞
)x +µq != 0 (4.51)
⇐⇒ N statV =N∞
(
k+xµq
k (1+x)
) 1
x
. (4.52)
The growth curve of proliferating cells has a stationary point for N statV , as long as
k+xµq
k(1+x) < 1, be-
cause cell numbers greater than N∞ cannot be reached. The existing stationary point is a maximum
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Figure 4.4: Time evolution of the number of proliferating, quiescent and all cells for Gompertzian
growth and different cell loss rates from the quiescent cell pool. N0 = 1, N∞ = 1012 and k = 0.04. The
initial fraction of proliferating cells is PNorm = .7 for all graphs and is depicted here for different cell
loss factors for quiescent cells µq . Note that the last plot for vanishing cell loss rate is a log-linear plot
to be able to detect the proliferating cells. The time scale uses arbitrary units.
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Figure 4.5: Comparison of logistic and Gompertzian growth characteristics for proliferating cells for
different inital fractions PNorm. The initial number of cells is N0 = 100, the maximum number of total
tumour cells has been set to N∞ = 10.000. k = 0.45 for Gompertzian, k = 0.85 for logistic growth
to have a similar overall growth curve. Both graphs show a decrease in proliferating cells after the
tumour reached a certain tumour volume. The time scale uses arbitrary units.
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as P¨ < 0 for all NV <N∞.
With eq. 4.52 we find in particular for both growth characteristics, logistic and Gompertzian, that
the function for the proliferating cells have a maximum for
N statL =N∞
k+µq
2k
as long as
k+µq
2k
< 1, (4.53)
N statG =N∞e
µq
k −1 as long as e
µq
k −1 < 1. (4.54)
However, for exponential growth the proliferating cells are strictly increasing and hence, no sta-
tionary point exists.
Likewise, the growth of the quiescent cell compartment for NV <N∞ is examined. With
Q˙V (t < t∞)= N˙V (t )− P˙V (t )=
(
β−µp
)
N˙V (t )− N¨V (t )
β−µp +µq
(4.55)
= N˙V (t )
β−µp −γV (NV )+k
(
NV (t )
N∞
)x
β−µp +µq
> 0, (4.56)
therefore QV (t < t∞)is strictly increasing as long as eq. 4.39 is satisfied.
In the next step, we want to express β−µp in terms of the variables which are used to describe
the tumour growth containing proliferating and quiescent cells and then overlook the consequences
arising from eq. 4.39. With eq. 4.28 β−µp can be expressed commonly for generalised Verhulstian,
exponential, logistic and Gompertzian growth using N˙ = γN :
β−µp =
˙N (t )+µq N (t )
P (t )
−µq (4.57)
=
(
γ(N )+µq
)
N (t )
P (t )
−µq (4.58)
t=0=
(
γ0+µq
)
N0
P0
−µq =
γ0+µq (1−PNorm)
PNorm
≥ 0. (4.59)
To examine the constraints for given parameters k, N0, N∞and µq , eq. 4.59 is inserted into eq. 4.39
γ(N )
!≤β−µp =
γ0+µq (1−PNorm)
PNorm
(4.60)
0
!≤µq (1−PNorm)+
(
γ0−PNormγ(N )
)
. (4.61)
It is
d
dN
γV (N )=− k
N∞
(
NV (t )
N∞
)x−1
< 0, (4.62)
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Figure 4.6: Comparison of the growth fraction defined by the ratio of proliferating cells to overall
cell number P/N for Gompertzian growth, different quiescent cell loss rates µq and initial growth
fractions PNorm. For both graphs N∞ = 10(12) and k = 0.2. Human Squamous Cell Carcinoma [198]
in-vitro have a mean growth fraction of 0.25, which corresponds within the detectable cell size with
an initial growth fraction of PNorm 0.3.
and also generally ddN γ < 0 for logistic, exponential and Gompertzian growth. Hence, all γ(N ) are
strictly decreasing. Therefore, for t ≥ 0 the inequality γ(N )≤ γ0 holds and thus
0
!≤ (µq +γ(N ))︸ ︷︷ ︸
>0
(1−PNorm)︸ ︷︷ ︸
≥0
≤µq (1−PNorm)+
(
γ0−PNormγ(N )
)
, (4.63)
which implies that for any parameters k, N0, N∞, µq and PNorm the Gyllenberg-Webb models for Ver-
hulstian, logistic and Gompertzian growth are defined and the functions for P (t ) and Q(t ) are given
by eq. 4.45, 4.47 and 4.48. However, for exponential growth γE (N ) = γ0,E = k applies, thus eq. 4.61 is
always fulfilled, hence the model is defined for any t .
On the other hand, the extrapolation to negative times is not always possible. This fact can be
easily understood when looking at PV (N (t ))NV (t ) for Verhulstian growth. The quotient is a strictly decreasing
function for N > 0:
d
dN
(
PV (N )
NV
)
=−N
(x−1)
N x∞
PNormkx
k
(
1−
(
N0
N∞
)x)+µq x < 0. (4.64)
In the extreme case we set PNorm = 1 and N0 > 1. This corresponds with γV (0) = β−µp , for any
N < N0, eq. 4.39 is not valid anymore and at the same time PN > 1, which is not defined. In other
words, as long as
PNorm ≤
k
(
1−
(
N0
N∞
)x)+µq x
k
(
1−
(
1
N∞
)x)+µq x , (4.65)
the functions PV (t ) and QV (t ) are defined for any N (t ) ² [1, N∞].
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Similarly we find for logarithmic and Gompertzian growth that it must be
P LNorm ≤
k
(
1− N0N∞
)
+µq
k
(
1− 1N∞
)
+µq
and (4.66)
PGNorm ≤
µq −k ln
[
N0
N∞
]
µq −k ln
[
1
N∞
] . (4.67)
Fig 4.6 displays the dependence of the fraction P (t )N (t ) on different PNorm and µq .
The cell loss factor µq from the quiescent cell population has an impact on the growth fraction
P (t )/N (t ). This is examined with the help of eq. 4.45:
PNorm(N )= P (N )
N
= PNorm
mq −k ln[N /N∞]
mq −k ln[1/N∞]
(4.68)
For high cell loss rates (µq →∞) the growth fraction will stay almost constant, P (t )/N (t )∼ PNorm.
For vanishing cell loss rates from the quiescent population
(
P (t )
N (t )
)
µq→0
= PNorm ln[N (t )]− ln[N∞]
ln[N0]− ln[N∞]
, (4.69)
the growth fraction increases ∼ ln[N ].
4.4 Modelling Radiotherapy
4.4.1 The 6 Rs of Radiobiology
The effect of radiotherapy fractionation on treatment efficiency can be explained with the six R’s of
radiobiology which influence tumour and normal tissue responses [199, 200, 201]:
1. Repair: When splitting radiation doses to small parts, cells are allowed to repair sublethal dam-
age. For this the cell needs to be able to recognise and activate repair pathways and cell cycle
rest. Because tumour cells often suppress this pathways, efficient repair is not possible. Normal
tissue however is able to repair the sublethal damage until the next fractionation of radiation is
given.
2. Redistribution: Cells throughout the cell cycle have different radiosensitivities. Radiation will
kill more of the radiosensitive cells and less of the radioresistant cells. The surviving cells will
keep on cycling, so some cells will have left the resistant phase and will be more sensitive when
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giving the next fraction.
3. Reoxygenation: Acute hypoxic tumour cells occur when there is a transient closure of capillar-
ies or arterioles supplying parts of the tumour. When splitting the dose there is a chance that
during the next fractionation this part of the tumour is oxygenated again. Chronic hypoxic tu-
mour cells occur due to the poor vascularity of tumours and lie in distance to the blood vessels.
Radiotherapy kill the more oxic cells in the vicinity of blood supply more effectively and enable
hypoxic tumour cells to move closer to the vessels and become more oxic. The next fraction will
be able to kill those cells more easily.
4. Repopulation: It is the increase in cell division of normal and tumour cells after radiation is
given. For early responding normal tissue the begin of repopulation starts at about 2-4 weeks
after radiation start (early toxicity can be reduced by prolonging the treatment). Some tumours
also show an increase in their growth fraction and very short cell cycling times after radiation
which can lead to 15-20 times faster growing cell populations [202]. This is seen in squamous
cell carcinoma and needs to be encountered by accelerated (to shorten treatment time) and
hyperfractionated treatment (to minimise late effects).
5. Radiosensitivity: Apart from cell cycle, oxygen status, repair pathways and repopulation, there
is an intrinsic radiosensitivity in each cell type.
6. (Suggested recently) Reactivation of anti-tumour immune response: Radiotherapy is able to in-
duce a local and systemic immune response by altering the tumour micro-environment. At
the same time radiation can increase immunosuppressive barriers, which can lead to tumour
radioresistance. Pre-clinical findings showed that high fraction doses with photons around 10-
13 Gy maximise anti-tumour immunity [203].
4.4.2 Cancer Stem Cells
Cancer stem cells (CSCs) are defined as cells within a tumour that can selfrenew and generate hetero-
geneous lineages of cancer cells that a tumour consists of [204]. The CSC hypothesis has proposed
that CSCs as a small subpopulation of tumour cells are responsible for tumour heterogeneity, stim-
ulate tumour growth, therapy resistance and even initiate metastasis [205]. They have been found
in multiple cancer types (partly with ongoing controversy) including glioblastoma, breast cancer,
colon cancer, and, with ongoing controversy, in many additional solid cancers such as ovarian can-
cer, melanoma, pancreatic cancer, liver cancer, and others[206, 207, 208, 209, 210, 211, 212]. CSCs are
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believed to exist in the quiescent state of the cell cycle considered to be responsible for therapeutic
(chemotherapy, radiation) resistance [213, 214] because they probably have an enhanced DNA repair
capacity and contain reduced reactive oxygen species levels [215].
Also, accelerated repopulation presumably leads back to CSCs [216]. All this implies that a suc-
cessfull anti cancer therapy needs to kill all CSCs to cure a tumour.
4.4.3 Radiosensitivity
In radiotherapy, a major influence on local tumour control probability is the number of clonogenic
cells before treatment and the cell radiosensitivity [217, 218]. Radiosensitivity of tumour cells are
mainly dependent on ([219], pg: 15)
◦ Hypoxia (oxygen status)
◦ Proportion of clonogenic cells
◦ Intrinsic radiosensitivity
◦ Repair of radiation damage (genetic repair pathways)
◦ Type of DNA lesions that are caused and their persistence.
Even within the same histological group and same stage of development tumours show a broad range
of radiosensitivity [220] (see tab. 8).
Cells have a differing sensitivity to radiation throughout the cell cycle. It has been shown that non-
proliferating tumour cells in vitro and in vivo are generally more radio-resistant than proliferating
cells [221, 222]. This is partly due to a higher ability of quiescent cells to repair damage resulting from
both, chemotherapy and radiotherapy, and also in-vivo due to a larger hypoxic fraction [223, 224].
It is believed that through fractionated radiation therapy the quiescent cell population in vivo
greatly decreases because of a favoured death of proliferating cells and a change of quiescent cells
to the proliferating cells [193]. This points to the fact that the control of quiescent cells has a great
impact on the outcome of radiotherapy [222].
However, particle radiation like carbon ion beams, especially with high LET values, have a signi-
ficant stronger effect on (tumour) cells than conventional radiotherapy in [24]:
- efficiently suppressing the repair of both, total and quiescent cell populations
- damaging hypoxic cells
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Lymphoma,
Neuroblastoma,
Myeloma, SCLC
0.2 (0.08-0.37)
Breast Ca,
SCC,
Colorectal Ca
0.43 (0.14-0.75)
Melanoma,
Osteosarcoma,
Glioblastoma
0.52 (0.2-0.86)
Table 8: Cell survival fractions after
2 Gy radiation in vitro of various cell
types with different histologies. Huge
variation in intrinsic radiosensitivity,
the number of DNA lesions are the
same.
- killing cells because they show less variation in radi-
ation sensitivity relative to the cell cycle
All this leads to less variation in overall radiosensitivity.
4.4.4 Treatment Model Assumptions
Based on the points above, we will describe the heterogen-
eous radiosensitivity throughout the tumour in our model
with two cell pools, proliferating and quiescent cells. Both
cell pools will be assigned an own, ”overall” radiosensitivity,
which precisely is the mean of all cell radiosensitivities of the
respective compartment. The radiosensitivities for the pro-
liferating and quiescent cells within a tumour then are indir-
ectly expressed by the survival fraction Sp and Sq , both of
them are valid for a fraction of radiotherapy and depend on
the dose and type of radiation. The more radiosensitive cells
are, the smaller will be the survival fraction after treatment.
It is assumed that the mean radiosensitivities of both cell compartments do not change over time,
therefore Sp and Sq are constants during the treatment. The general radiosensitivity of a tumour then
is simply governed by the initial growth fraction, the radiosensitivity of proliferating cells and radio-
sensitivity of quiescent cells (and is not a constant). Tumours with a higher fraction of proliferating
cells will be faster growing, but also show a higher radiosensitivity.
If a tumour is treated with a fraction of radiotherapy at t = tRT , the second assumption made is
that the fraction of cells which will be killed by irradiating the tumour are lost immediately after a frac-
tion. Following the assumption that tumour growth is governed by the available nutrition and oxy-
gen and that these factors will not change through radiotherapy, the constants in the growth model
for a tumour, N∞ and k, will not change through the course of radiotherapy. This means that the
total number of tumour cells will therefore follow the same growth curve before and after treatment.
Hence, if no local control is achieved the tumour will grow back to the original size.
The treatment model assumptions are in good agreement with five of the 6 Rs of section 4.4.1
and can also model the impact of high LET radiation: The variable radiosensitivity around the cell
cycle and the variable intrinsic radiosensitivity and repair (all dependant on the treatment modal-
ity and tumour type) is contained in the distribution of survival fractions Sp and Sq . Redistribution
leads to an approximate constant mean survival fraction, a measure for the overall radiosensitivity
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Sp . For treatment with high LET particles the intrinsic and the cell cycle dependant radiosensitiv-
ity will assimilate and show less variation due to the more potent cell kill. Reoxygenation as well
as repopulation is modelled by the fact that quiescent cells will transition into the proliferating cell
compartment. Reactivation of anti-tumour immune response is non neglectable in photon radiation
therapy with doses around 10-12 Gy which corresponds to a radiosurgery treatment. High LET activ-
ates an anti-tumour response also at low fraction doses [201]. Altogether this effect is modelled by
a higher radiosensitivity within the radiotherapy model, however this effect is less pronounced and
only mentioned for the sake of completeness.
As discussed in section 4.4.2 radioresistant, quiescent CSCs might be the reason for treatment
failure. These cells are contained within the tail of the distribution of survival fractions of the qui-
escent cell compartment towards the more radioresistant end (greater value) and a higher fraction
of CSCs will then also shift the mean Sq to higher, resp. more radioresistant value. High LET radi-
ation however can overcome the radioresistance of quiescent CSC due to their complex and oxygen
independent damage to the DNA [225]. Thus, the probability distribution of the survival fraction of
quiescent cells has less variation. However, radiation ”activated”, fast proliferating CSCs also account
for accelerated repopulation which is not covered by the model proposed assuming a constant growth
rate in the underlying growth model. This is especially important to keep in mind when describing
fast growing tumours which receive hyperfractionated treatment.
After a fraction of radiotherapy at t = tRT + ² the quiescent and proliferating cells are diminished
to PRT = P (tRT + ²) = P (tRT )Sp and QRT = Q(tRT + ²) = Q(tRT )Sq . The total number of cells after
irradiation is then NRT = PRT +QRT . Utilising that N∞ and k are constants, NRT corresponds to an
earlier point in time of the undisturbed tumour growth NRT =N (Tx ).
The number of tumour cells after RT can be thus calculated with
N (t > tRT )=N (t − tRT +Tx ) . (4.70)
Tx describes the time, which is equivalent to the number of cells at t = tRT + ² if following the
initial growth curve.
It is assumed that the cell loss rates from the two different cell compartments and the proliferating
rate do not change after radiotherapy. Then, the equations for proliferating and quiescent cells will
stay the same. A change in the total number of cells leads at the same time to a different fraction of
proliferating cells:
P (t > tRT )= P (t − tRT +Tx ) and Q(t > tRT )=Q(t − tRT +Tx ). (4.71)
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We illustrate this with the following example. Assume that with a fraction of RT no quiescent
cells are killed but 40% of proliferating cells. The total number of cells will decrease by 0.4 times the
momentarily fraction P (tRT )/N (tRT ) of proliferating cells. This corresponds to an earlier time Tx <
tRT on the growth function for N (t ). The cells in the proliferating and quiescent cell compartments
will balance out to match the corresponding growth functions for P (Tx ) and Q(Tx ). This will lead to a
change of quiescent cells into the proliferating compartment. It is assumed that this change will take
place immediately without any delay.
4.4.5 Exact Solutions for N Fractions of Radiotherapy
For the generalised Verhulstian model we find for the total number of cells after one irradiation
NV (tRT +²)=NV (tRT )
[
Sq −PNorm(Sq −Sp )
γV (NV (tRT ))+µq
γ0+µq
]
. (4.72)
Note that the above equation is valid also for logistic, exponential and Gompertzian growth.
Using eq. 4.10, the corresponding point in time for the undisturbed growth function of NV (t ) from
which onwards the cells will grow again is
T (NV (tRT +²))=− 1
k
ln
[
k
xγ0
([
NV (tRT )
N∞
(
Sq −PNorm(Sq −Sp )
γV (NV (tRT ))+µq
γ0+µq
)]−x
−1
)]
. (4.73)
For n fractions eq. 4.70 and 4.71 are repeated. Using eq. 4.72 and 4.73 the following recursion
expression for the growth of all cells can be found. A constant dose and constant survival fractions
Sq ,Sp for quiescent and proliferating cells are assumed:
NV ,nRT (t
∗)=N∞
[
1−e−kt∗
(
1−
[ wn
N∞
(
Sq −PNorm(Sq −Sp )
γV (wn)+µq
γV ,0+µq
)]−x)]−1/x
, (4.74)
with wn =N∞
[
1−e−ktn
(
1−
[wn−1
N∞
(
Sq −PNorm(Sq −Sp )
γV (wn−1)+µq
γV ,0+µq
)]−x)]−1/x
,
and w1 =NV (t1).
Here, t∗ denotes the time after the last fraction,tn is the time between fraction n−1 and n, and t1
is the time from diagnosis until the start of the therapy. Thewn give the number of cells shortly before
the nth fraction of radiotherapy.
The solutions for logistic growth again can be found by setting x = 1
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NL,nRT (t
∗)=N∞
[
1−e−kt∗
(
1−
[ wn
N∞
(
Sq −PNorm(Sq −Sp )
k(1−wn/N∞)+µq
k (1−N0/N∞)+µq
)]−1)]−1
, (4.75)
with wn =N∞
[
1−e−ktn
(
1−
[wn−1
N∞
(
Sq −PNorm(Sq −Sp ) ·
k(1−wn−1/N∞)+µq
k (1−N0/N∞)+µq
)]−1)]−1
,
and w1 =N∞
[
1+e−kt1
(
N∞
N0
−1
)]−1
.
The solutions for Gompertzian growth again can be found by taking the limit x → 0
NG ,nRT (t
∗)=N∞
[
wn
N∞
(
Sq −PNorm(Sq −Sp )
µq +k ln(N∞/wn)
µq +k ln(N∞/N0)
)]e−kt∗
, (4.76)
wn =N∞
[
wn−1
N∞
(
Sq −PNorm(Sq −Sp )
µq +k ln(N∞/wn−1)
µq +k ln(N∞/N0)
)]e−ktn
,
with w1 =N∞
[
N0
N∞
]e−kt1
.
4.4.6 Change of Overall Survival Fraction
The survival fraction (SF) here is defined as the number of cells before irradiation divided by the num-
ber of surviving cells after irradiation. Although the survival fractions for proliferating and quiescent
cells are here assumed to be constant for the same doses, the total survival fraction will change for
each fraction. For the nth fraction of radiotherapy the SF is
SFnRT = NnRT (0)
N(n−1)RT (tn)
, (4.77)
where tn is the time between the (n-1)th and nth fraction. Eq. 4.74 is used to calculate
NnRT (0)=wn
(
Sq −PNorm(Sq −Sp )
γ(wn)+µq
γ0+µq
)
, (4.78)
while this equation is valid for any growth, Verhulstian, logistic, exponential or Gompertzian.
With N(n−1)RT (tn)=wn , eq. 4.77 can be simplified to
SFnRT = NnRT (0)
wn
= Sq −PNorm(Sq −Sp )
γ(wn)+µq
γ0+µq
. (4.79)
Because wn denotes the number of all cells right before the (n+1)th fraction), the above equations
can be rewritten in terms of number of total cells, independent of the number of fractions:
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Figure 4.7: Change of the survival fraction depending on the total number of cells. Note that the
biggest change happens for small cell numbers. It is N∞ = 1010, k = .1, µq = .6 and PNorm = 1. The
time scale is given in arbitrary units.
SF (N )= Sq −PNorm(Sq −Sp )
γ(N )+µq
γ0+µq
. (4.80)
SF (N ) is strictly increasing or decreasing:
d
dN
SF (N )=−Sp −Sq
N
kPNorm(γ0+µq )
(
N
N∞
)x
. (4.81)
If Sp < Sq it applies for all wn >wn+1 that SFnRT > SF(n+1)RT and if Sp > Sq it is for all wn >wn+1
that SFnRT < SF(n+1)RT (example is given in fig 4.7). Thus, hoping each fraction will lead to a reduction
of the number of cells, SF will decrease throughout the course of radiation assuming the quiescent
cells are less radiosensitive than proliferating cells. This is in agreement with the finding that larger
tumours are more difficult to control [226, 227, 228].
4.5 In-Silico Modelling
4.5.1 Population Model
The preceding growth and treatment model enables to describe the reaction of a single tumour within
a single patient to fractions of radiotherapy depending on a number of parameters. An individual can
be turned into a cohort of patients assuming the parameters follow certain probability distributions.
Monte Carlo simulation then generates a set of in silico clinical trial data which not only depends
critically on the distribution variables itself but also on the choice of the underlying probability dis-
tribution. In the following the used parameters are examined closely:
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1. Number of tumour cells at diagnosis ND, critical size of recurrence NRec and maximum number
of tumour cells N∞.
2. Initial growth fraction PNorm = P (t=0)N (t=0)
3. Growth rate k
4. Survival fractions Sq and Sp
5. Cell loss rate for quiescent cells µq .
ND is not set to be N0 because then not all combinations of ND and PNorm can be extrapolated back
to a single cell (see eq. 4.65). This has an impact when fitting the model to clinical data. Without
limitation N0 is set 1 and ND corresponds to a general Verhulstian tumour age of
tV,Age = 1
k
ln
[
N x∞−1
(N∞/ND)x −1
]
, (4.82)
and in particular assuming Gompertzian growth the tumour age becomes
tAge = 1
k
ln
[
ln[N∞]
ln[N∞/ND]
]
. (4.83)
Figure 4.8: Growth Rates for different Tu-
mours. The detection level is about 108− 109
and lethal burden and maximum number of
tumour cells around 1012−1013 . From [229].
The distribution of ND is directly given by the
distribution of the patients’ tumour volumes [ml].
Most tumour cells have a diameter of d = 20µm, we
presume they have a spherical shape (V = 43Π
(
d
2
)3
)
and are densely packed [229] (∗0.75). Then the
volume of 1 ml contains approximately 1.8∗108 cells
and needs to be adjusted for different tumour entit-
ies. The limit of detection is about NRec = 108 tu-
mour cells [230] in an MRI. This cell number here
is used to declare a tumour has grown back and re-
lapsed. Usual tumour sizes are around 2-5 cm. If it is
assumed that the tumour has a globular shape, then
this would correspond to approx. 109 − 1010 cells. We assume the maximum size corresponds to
N∞ = 1012 tumour cells (see. figure 4.8). With the number of tumour cells after the last fraction of
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irradiation, NRT, the time of disease-free survival tRec for each patient can be calculated by
tV,Rec = 1
k
ln
[
γV (NRT)
γV (NRec)
(
NRec
NRT
)x]
, (4.84)
and for Gompertzian tumour growth it becomes
tRec = 1
k
log
[
ln[N∞/NRT]
ln[N∞/NRec]
]
. (4.85)
The growth fraction PNorm lies in the interval ]0,1] and therefore it is assumed that the parameter
follows a beta distribution:
Px (α,β)= 1
B(α,β)
xα−1(1−x)β−1 (4.86)
with the Beta functionB(α,β)= Γ(α)Γ(β)
Γ(α+β) ,
Γ denotes the Gamma function Γ(z)=
∫ ∞
0
t z−1 exp−t dt ∀Re(z)> 0.
Because a continuous (non-discrete) function for the cell numbers was chosen, the inital conditions
are somewhat difficult to translate into biological meaning: the model starts with fractions of pro-
liferating and quiescent cells, which depends on PNorm, summing up an overall cell number of 1.
During tumour growth the growth fraction PNorm(N ) will always decrease (see. figure(4.6)) and can
be calculated depending on the total cell number (see eq.4.68).
The tumour growth rate k is positive as the growth function is monotonously increasing. Studies
have shown that the distribution of tumour doubling times (however, taking exponential growth as a
base) is usually asymmetrical in regard to its mean value [232] having a lognormal distribution [233],
see figure 4.9. This means that there are tumours with very long doubling time values compared to
the mean (histogram is positively skewed). Therefore the growth rate for exponential growth (defined
in eq. 4.15) will also follow a lognormal distribution. Consequently, the probability function for the
Gompertzian growth rate k will also follow a lognormal distribution:
Px (µ,σ)= 1p
2piσx
e−
(ln x−µ)2
2σ2 , (4.87)
with µ, σ2 the mean and variance of the associated normal distribution. There is a discrepancy
between measured and in-vivo tumour doubling times which is addressed in section 4.5.2.
The survival fractions Sq and Sp lie in the interval [0,1]. It is assumed this parameter follows a beta
distribution (see eq. 4.86). Again, in-vitro and in-vivo radiosensitivities differ significantly, discussed
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in section 4.5.2.
Figure 4.9: Distribution of tumour doubling
times in patients on a log scale (from [231]).
The cell loss rate of a tumour is the sum from cell
loss from the proliferating and quiescent cell com-
partment µp +µq (both parameters being positive).
In the 2-compartment model however, only µq ap-
pears. Slowly growing tumours like sarcomas tend to
have low cell loss rates (< 30%), fast growing tumours
like carcinomas have high cell loss rates (> 70%). The
model assumes a lognormal probability distribution
(see 4.87) for the cell loss factor µq .
4.5.2 Cell Parameter Differences in-Vivo and in-
Vitro
In many tumours in-vivo only a small proportion of
cells are dividing while other viable cells are in a qui-
escent state [191]. E.g. a mean growth fraction of
less than 3% has been found [234] in slowly growing
tumours. However, in-vitro the cycling reproduct-
ive fraction varies and can reach almost 100% [235].
Experiments comparing growth characteristics in-vitro and in-vivo hint that different tumour cell
growth in cultures can be attributed to the different cellular micro environment like the uniform con-
centration of oxygen and nutrients around the cells [236]. This lead to a decrease in cell cycle time,
an increase in growth fraction and a profound decrease in cell loss [237, 238]. The differences in cell
loss factor in-vivo to in-vitro can vary by the factor 10.
Radiosensitivities in-vitro show a broad distribution of survival fractions. For head-nose-throat
tumours independent of the localisation a variation of survival fraction by 2 Gy photon fraction doses
(SF2) could be found lying in the range of 0.1 to 1 [239]. Again, the differing SF2 distributions in-vitro
and in-vivo can be lead back to different oxygenation and distribution of proliferating and quiescent
cells.
[240] found that for several human tumour cells also from various histologies the radiosensitivity
in-vivo was 1.9 times weaker than in-vitro. This could be explained by the fact that tumour cells in-
vitro are mostly proliferating and therefore are more radiosensitive than a tumour which contains
also quiescent, less radiosensitive cells.
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The fact that there are differences between parameters in-vitro and in-vivo should keep one in
mind when choosing or checking data for model parameters.
4.5.3 Modelling Radiotherapy for Different Beam Qualities
Photons have a different effect on tumour cells than particles. The radiation damage to the DNA
by ionising radiation includes base loss/change, single strang breaks (SSB) and double strang breaks
(DSB): Low-LET radiation (protons, photons) leads to more isolated lesions, high-LET radiation to
more complex and clustered DNA damage [241] . With photons, there is a significant difference in
radiosensitivity between proliferating and quiescent cells. This difference is notable reduced when
the tumour is irradiated with higher LET [222, 242]. The heterogeneity of radiosensitivity within a
tumour is therefore reduced for carbon ions.
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Figure 4.10: Display of the probability distributions
used for the simulation parameters to generate a
reference patient pool (see section 4.5.1). For each
parameter the defining probability distribution type
(beta, lognormal, or Weibull distribution) and their
shape parameters (α and β) are given.
In the model this could be modelled
through a less distinct separation of Sp and
Sq . Likewise the Gaussian distribution of S
could be narrower due to less dependence of
the radiosensitivity of a cell to genetic path-
ways/repair pathways (the amount of poten-
tially not repairable damage is much higher).
An estimated effect on the local tumour con-
trol is shown in figure 4.13b. The impact of dif-
ferent beam qualities on the distribution of ra-
diosensitivities is examined with clinical data
in section 6.
4.5.4 Monte Carlo Simulation of In Silico
Clinical Trials
The model is now tested with arbitrary para-
meters. A patient pool of 2000 individuals
is generated which is treated with 30 fraction
and a fraction dose of 2 Gy. It was found, that
a population of 2000 patients left the resulting
patient population local control curve independent of any further increase in the number of patients
simulated. In the case of local control or survival curves the significance is negligible as long as the
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Figure 4.11: Plot of the tumour age and the growth fraction at diagnosis for the reference tumour
distribution (see figure 4.10).
reproducibility is given.
The radiation course is modelled in the following way: the patient is treated daily (tn = 1[day]),
time from diagnosis is set to tx = 10[days]. For each patient the disease-free survival time tRec (see
eq. 4.85) is calculated and collectively plotted in a Kaplan-Meier curve for a certain follow-up time.
The underlying growth model used follows a Gompertzian growth function. In the following the ef-
fect of varying the parameter distributions on the local control curve is examined. For this a set of
reference parameter distributions was chosen (shown in figure 4.10) that comply with realistic biolo-
gical data but still are arbitrarily chosen. The associated reference local control curve, depicted in the
following plots (figures 4.12, 4.13, 4.14 and 4.15) in black, is compared to local control curves where
single parameter distributions (coloured) are varied.
The distribution of tumour size at diagnosis, which indirectly also translates into the stage of the
tumour, relates in correspondence with the distribution of growth rates to a tumour age distribution
(eq. 4.83). Also, to translate the inital growth fraction PNorm into a more understandable variable,
the growth fraction distribution is calculated at diagnosis, which is depending on growth rate and
quiescent cell loss factor. This is comparable with data which can be found in the literature. Both
graphs are shown in figure 4.11.
The plots in figure 4.12 model the effect of the tumour stage and growth rate on the outcome of
local control after irradiation. Figure 4.12a shows a patient pool divided into a group with small tu-
mour volume with a narrow distribution with a median of 2.1 ml and a group with a wide distribution
ranging up to 400 ml with a median of 80 ml. All other parameters are kept equal for both groups.
The local control rates after 80 months differ by a factor of 5, showing that half of the tumours for
small volumes are still controlled, while for the cohort with larger volumes only 10% are controlled.
The simulation indicates that tumour size is a strong prognostic factor for the outcome of radiother-
apy. Figure 4.12b examines the effect of a faster growing tumour with the same radiosensitivities: the
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(a) Comparison of the effect of patients with a smaller
volume than the reference volume on local control. A
smaller volume indirectly translates into a more favour-
able tumour stage at diagnosis.
(b) Comparison of patients with faster growing tumours
than the reference growth distribution and their effect on
local control.
Figure 4.12: Monte Carlo simulation of local control rates of a patient cohort after irradiation of 30
fractions with 2 Gy. The black curves in both graphs represent the local control reference curve for
a patient pool with reference parameter distributions as shown in figure 4.10. The coloured curves
represent the outcome for a patient pool which share the same parameter distributions as the refer-
ence curve except the parameter distribution depicted with the same colour in the inset with their
respective shape parameters.
growth rate has an impact on the slope of the local control curve and the percentage of tumours that
can be controlled over time. Also, it should be noted that follow-up times do not need to be as long as
in slower growing tumours.
Figure 4.13 examines the impact of the distributions of survival fractions of tumour cells (Sq , Sp )
on local control. Smaller survival fractions lead naturally to better local control. The separate exam-
ination of radiosensitivities of proliferating and quiescent cells on the impact on local control (see
figure (4.13a)) however shows when changing the survival fractions for both cell compartments inde-
pendently to the same distribution, the radiosensitivity of the quiescent cells effect the outcome of
local control much stronger. This is coherent with the literature which finds that the radiosensitiv-
ity of quiescent cells govern the success of radiotherapy [243, 182]. Figure (4.13b) simulates different
beam qualities which are modelled only through the variation in the distribution of survival fractions
for quiescent and proliferating cells. It is assumed that the mean of the intra-tumoural variation of
radiosensitivity is the highest for photons and there is a distinct difference between both, quiescent
and proliferating cells. Protons have a slightly higher radiobiological effectiveness, which was mod-
elled in a shift of both distributions, Sq and Sp , however having a stronger impact on proliferating
cells, as the damage to the DNA of the tumour cells is similar to photons. Finally, the extreme case
of high-LET irradiation is modelled which is thought to lead to an assimilation of the radiosensitiv-
ities of both compartments and the diminution of the variability due to the more complex damage
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(a) Simulation of the impact of variation in survival frac-
tion distribution of both, proliferating and quiescent cells.
For this a patient pool is generated using the reference
parameter distributions as shown in figure 4.10 except for
the survival fraction of the proliferating cells, Sp which is
drawn out of the same probability distribution as the sur-
vival fraction of the quiescent cells, both depicted in grey
in the insets with their respective shape parameters. The
corresponding local control curve is grey. The variation of
the distribution of survival fractions for both cell compart-
ments to the same probability function separately is de-
picted in the coloured curves: the variation to more radio-
sensitive proliferating cells is shown in red in both graphs,
the local control curve and the corresponding inset, the
variation to more radiosensitive quiescent cells is shown
in blue.
(b) Simulation of photon irradiation with different beam
qualities. The black curve represents the local control ref-
erence curve for a patient pool with reference parameter
distributions as shown in figure 4.10. The coloured curves
represent the outcome for patient pools which share the
same parameter distributions as the reference curve ex-
cept the parameter distributions depicted with the same
colour in the insets with their respective shape paramet-
ers. Both radiosensitivity probability distributions, Sq and
Sp , are varied at the same time to emulate the impact
of different beams. The black curve describes conven-
tional radiotherapy with photons, the blue curve emulates
low-LET particles (protons) and the red curve high-LET
particles (carbon ions).
Figure 4.13: Examination of the influence of radiosensitivities for proliferating and quiescent cells on
local control. Monte Carlo simulation of local control rates of a patient cohort after irradiation of 30
fractions with 2 Gy.
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(a) Influence of the distribution of initial growth fraction
and cell loss factor of quiescent cells on the treatment
outcome. Monte Carlo simulation of local control rates
of a patient cohort after irradiation of 30 fractions with
2 Gy. The black curve represents the local control reference
curve for a patient pool with reference parameter distribu-
tions as shown in figure 4.10. The coloured curves repres-
ent the outcome for a patient pool which share the same
parameter distributions as the reference curve except the
parameter distribution depicted with the same colour in
the inset with their respective shape parameters: the red
local control curve describes the impact of the variation of
the inital growth fraction, the blue curve the consequence
of changing the cell loss factor.
(b) Dose escalation study: Monte Carlo simulation of local
control rates of a patient cohort with reference parameter
distributions as shown in figure 4.10. The black curve il-
lustrates treatment outcome of a patient cohort after irra-
diation of 30 fractions with 2 Gy. The blue curve depicts the
outcome after treating the patients with 4 more fractions.
The overall dose of 60 Gy was escalated to 68 Gy.
Figure 4.14: Impact of variation of the parameters growth fraction, cell loss and the radiation dose on
local control.
to the DNA which is (almost) independent of cell cycle [7, 222, 242]. However, included within the
probability distributions of the survival fractions of proliferating and quiescent cells are directly the
effects of fractionation (see section (4.4.1)) which is discussed in section (4.4.4). The difference in the
distributions of Sq and Sp and the a smaller mean of Sp generates the fractionation effects. The other
way round the assimilation of both distributions implies that the inter-relationship between fraction-
ation response and LET becomes negligible. Because the radiosensitivity of the quiescent cells have
a major impact on treatment outcome it is clear that carbon ions lead to a superior effect and in the
model case to local control of the tumour.
Tumours usually have a small growth fraction (quotient of proliferating cells to total cell number)
of proliferating cells. In the growth model both, the initial growth fraction PNorm and the quiescent
cell loss rate µq , have an impact on the number of proliferating and quiescent cells (see eq. 4.45).
Thus, if the radiosensitivities of both cell compartments differ, both variables will have an effect on
local control. Fig 4.14a shows that a proportional change in PNorm has a stronger impact on the tu-
mour than µq : lower growth fraction leads to a lower tumour control (because it is assumed that pro-
liferating cells are stronger effected by radiation). Out of the same considerations a higher quiescent
cell loss rate leads to improved local control.
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(a) Best fit for varying the survival fractions of proliferating
and quiescent cells. The best fit to the reference local tu-
mour control of a patient cohort at follow up times 5 years
and greater is given by the blue curve. The correspond-
ing parameter distribution in the inset is depicted with the
same colour.
(b) Best fit for varying the parameter distributions for
growth fraction PNorm and tumour growth rates kG . The
red local control curve illustrates the impact of a different
probability distribution of the initial growth fraction (dis-
played within the inset PNorm in red) while keeping the
reference growth rate (depicted within the inset of kG in
black). The lilac and blue local control curves demonstrate
the effort to find a best fit to the reference curve for the red
initial growth fraction and varying the probability distri-
butions of the growth rate. It is either possible to fit the
shoulder of the control curve (time period first two years
of follow-up) depicted in blue or the long-time outcome
in lilac. Both corresponding growth rate probability dis-
tributions are displayed in the inset kG for the respective
colour.
Figure 4.15: Monte Carlo simulation of local control rates of a patient cohort after irradiation of 30
fractions with 2 Gy. The black curves in both graphs represent the local control reference curve for
a patient pool with reference parameter distributions as shown in figure 4.10. The coloured curves
represent the outcome for a patient pool which share the same parameter distributions as the refer-
ence curve except the parameter distribution depicted with the same colour in the inset with their
respective shape parameters. ”Best fit” describes the effort to produce a similar local control curve as
the reference black local control curve by varying different parameter distributions.
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Phase I/II radiation dose escalation studies evaluate besides toxicities also efficacy e.g. how local
control or survival rates will improve compared to historical controls. Figure 4.14b compares two
patient cohorts with 60 and 68 Gy (30 vs. 34 fractions). The endpoints differ by almost 20 %. Knowing
the parameter distributions of certain tumour entities supports the evaluation of the benefit of higher
doses in silico.
Within the model evaluation it is not only important to determine the effects of singular para-
meters on the outcome graph but also to determine how unequivocal the curves are related to the
parameter distributions. This helps to interpret and validate results of a curve fitting to real data. Fig-
ure 4.15 depicts the effort to find a second fit to the reference curve with different parameter distribu-
tions. In figure 4.15a the best fit to the reference local control curve only manages to find distributions
for quiescent and proliferating cell survival rates (Sq and Sp ) for the same results in the endpoint local
control (slope and value for t > 50 months), simultaneously it is not possible to to bring the shoulder
of the curves into accordance. Figure 4.15b varies the distributions for growth fractions and tumour
growth rates. The change to smaller initial growth fractions while the other parameter probability dis-
tributions of the reference local control curve remain the same, leads to an expected lowering of local
control (red curve). In a second step the probability distribution of the growth rate is changed to fit
the local control curve to the original reference curve. It is either possible to assimilate the shoulder
of the curve with a different parameter distribution for the growth fraction or find a similar endpoint
which however leads to a drop in local control immediately after the end of radiotherapy. In this case,
it is not possible to reproduce the outcome of radiotherapy of the reference parameter distributions
with new probability distributions of growth fraction and growth rates.
In conclusion it can be said that all parameters of the model have a non-negligible effect on the
treatment outcome and need to be considered. Besides the parameters Sq and Sp , parameters which
have a direct influence on the growth function like e.g. tumour cell number at diagnosis ND or the
growth rate k will most likely have the strongest effect on local control. If the radiosensitivities of
proliferating and quiescent cells do not differ much, the cell compartment model gets negligible and
parameters like the initial growth fraction PNorm and the quiescent cell loss factor can be neglected.
4.6 Conclusion and outlook
The model presented here manages to model basic processes when a solid tumour is irradiated. It is
capable of simulating important characteristics of tumour behaviour like sigmoid growth, cell quies-
cence, cell death and response to radiation therapy with different beam qualities. Main basic prin-
ciples of fractionation (see section 4.4.1) like repair, redistribution, repopulation, reoxygenation and
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radiosensitivity are contained naturally within the model.
However, accelerated repopulation occurs in some tumours treated by radiotherapy which can
not be modelled at this stage. The discovery of cancer stem cells (CSC) have shown that tumours
being radioresistant to low-LET radiation include a subset of slowly proliferating/quiescent and ra-
dioresistant stem cells [212, 209]. CSCs are partially incorporated in the model as a non-proliferating
cells and are responsible for the far right radio-resistant part of the survival fraction spectrum Sq . Low
dose photons increase the proportion of radioresistant, cycling stem cells [244] which might drive ac-
celerated population [245, 246]. The introduction of a third, proliferating cell compartment in the
future could aid in tackling to describe accelerated repopulation for prolonged radiation therapy and
needs to be looked into in detail.
Incorporating strictly analytical and one-dimensional functions in the model there is little com-
putational effort needed to fit simulated data to a real-world situation and makes an extraction of
relevant biological parameters yet possible. It is a novel approach to model outcome differences in
low- and high-LET beams through the differences in the distribution of radiosensitivity of proliferat-
ing and quiescent cells within a patient. In-vitro tests have shown that high-LET reduces the variation
of radiosensitivity. Especially the radiosensitivity of quiescent cells and the tumour volume are a cru-
cial prognostic factor for the outcome of radiotherapy. The model relates both to each other and
manages to describe the most important reactions in a simple yet effective way.
The underlying ideas transcribed here are universally applicable and thus the model can be used
for any solid tumour. Despite the simplifying assumptions the qualitative behaviour of this model
agrees very well with clinical experience. Since the model is built in a modular way, it is easily possible
to specify or improve any sub-model individually. Even the inclusion of other treatment modalities
such as chemotherapy or surgery is possible.
The parameters included in the model have a reference to real data which makes it possible to
directly interpret and compare them to clinical and biological data. It is possible to design in silico
clinical trials and to determine e.g. prognostic factors or indications hadron therapy in particular rare
tumours where mostly enough data for sufficient statistics are missing.
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5 Application I: Implementation of a Database for Side Effects and Sup-
port of Treatment Decision
5.1 Hadron Therapy Information Sharing Prototype
Figure 5.1: Conceptual overview of HISP (from [247]).
The knowledge of treatment outcome as-
sociated with various cancer management
strategies is necessary to find useful ther-
apies. However, at the same time it is es-
sential to know and understand toxicities
associated with certain treatment regimes
to ensure patient safety and guarantee less
aggressive but effective therapies. Had-
ron therapy is a novel treatment method in
Europe and expected to be equal or super-
ior in both, treatment outcome and side ef-
fects. There is a clear need for data shar-
ing in cancer care and research [248, 249]
to emphasise and demonstrate advantages
of this treatment, give indications and sup-
port treatment planning. There are only few centres across Europe and patients are referred cross-
border for treatment. In the frame of the EU Training Network PARTNER, our research group has
set up a the idea of a Hadron Therapy Information Sharing Platform (HISP) [250] as a prototype in-
frastructure for transnational exchange of scientific and clinical information. In a common effort
HISP was designed with an architecture that could manage data access, integration and retrieval for
different user groups ensuring data protection of clinical data [251]. One the one hand, in the clin-
ical scenario, confidential patient data such as diagnosis and treatment information would be made
accessible to doctors distributed across several hospitals. One the other hand, researchers would
be able to work with anonymised data. Grid technology was identified to provide an environment
for working with distributed sources and being most suitable for meeting the ICT challenges of the
health care sector since it ”offers rapid computation, large data storage and flexible collaboration by
harnessing together the power of large numbers of computers, from end-users’ desktops to powerful
workstations and clusters of more powerful machines" [51].
Clinical patient’s information usually is located in various databases, even paper records within a
86
Figure 5.2: Follow-up data model
single hospital and, if more hospitals are involved also across several institutions. Like the sources the
HISP users will be distributed across Europe. The platform is designed in such a way that it supports
multi-centre, trans-national collaboration for a variety of different user domains (medical doctors,
patients, epidemiologists, economists, biologists, physicists...) as a gateway to patient information
held in multiple hospital databases. An overview of the functionality of the platform is given in fig-
ure 5.1. The database model from section 3 was implemented as a rare tumour database (RTDB). A
detailed technical description of HISP can be found in the literature [250].
5.1.1 Use Case: Follow Up
Knowledge about the toxicities associated with various cancer management strategies is essential for
guaranteeing patient safety and for scientific progress towards less aggressive but effective therapies.
In a situation where several types of treatments show comparable treatment success, superiority of
one over the other is determined by their (lack of) toxicities. Which therapy will be more viable in
health economics terms will not only depend on the immediate cost of therapy but also on indirect
cost to the health system. ’Mild’ toxicities which hamper the patients’ daily life and curb their pro-
ductivity but do not require clinical follow-up are as important in these considerations as ’severe’
toxicities which require the patient to return to regular medical treatment.
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Figure 5.3: Follow-up scenario.
To demonstrate the functionality of the sys-
tem, we focus on an adverse-event-reporting
scenario - a key component of comprehensive
patient follow-up. The reporting of adverse,
treatment-related events is part of the patient
management process, beginning with the ini-
tial visit where a baseline is assessed, continuing
during treatment with each clinical review, and
then at intervals during follow-up. An overview
how the follow-up of patients treated at an Eu-
ropean particle centerand followed up from various doctors in multi-centric clinical studies is de-
picted in figure 5.3. The underlying database model is a simplified extract from the database model
of section 3 and can be found in figure 5.2. It contains detailed data about the tumour, the treatment
parameters, the patient and the course of the disease including acute and late toxicities.
Figure 5.4: Real-time evaluation of adverse events
displayed by Google Charts [252].
This demonstration covers the main aspects
of system functionality: patients and doctors re-
port an adverse event as structured, coded infor-
mation; this information is integrated into med-
ical records at treatment centres, and is then
available, across a distributed architecture, un-
der role-based access control [253]. Data is
ubiquitously available for the user with appro-
priate rights and can be evaluated as ”snap shot
picture” for example as database search for the
common side effects regarding a certain treat-
ment modality (see figure 5.4).
5.2 Modelling of Medical Prognosis
In the past there have been many approaches to model the prognosis of medical applications and to
support medical treatment decisions. A doctor will decide on a specific treatment depending on the
patient’s health, on his sought treatment results and needs to assess this against consequences in the
future. However, there are many uncertainties involved which will govern the course of the disease
(or side effects) like the individually varying treatment response (or radiosensitivity).
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Figure 5.5: A Markov model is built from a set
of (mutually exclusive) health states s. There
are three different types of states - temporary:
probability of staying in the state for consec-
utive cycles =0, transient: probability of be-
ing in the state approaches zero when t goes
to infinity, absorbing state (death). The set
of transition probabilities p among the health
states are constant or time-varying with a
given cycle length (year, month etc.). To each
health state a utility value and/or cost can be
assigned. The future path only depends on
the actual health state, not the history how it
came there (Markovian property).
In practise, those treatment decisions are made
using heuristic findings and with the help of the sub-
jective judgement by the treating physician. These
are usually based on simple statistical evaluation of
endpoints of a patient cohort66, for example survival.
The above mentioned models aim at a deeper insight
over the course of the disease or during the medical
decision process and can help to define an optimal
solution for an individual patient.
Common mathematical tools used to develop
those models are Markov chains and Markov decision
processes. This method was introduced by Markov,
a Russian mathematician, in 1906. His method de-
scribes stochastic processes and has applications in
many different fields, the most popular might be eco-
nomics.
5.2.1 Medical Markov Models
Markov models were introduced into clinical trials a
long time ago [254] and, in 1983 a Markov model for medical prognosis was introduced [255]. Mean-
while much research exists on this field and Markov chains have been used to evaluate a big variety
of endpoints. The simulations allow evaluation of the effects of model parameters on outcome, such
as care procedures on the quality of life of a patient group in a real time setting, without the need
for customised experiments. Markov models are frequently used if interactions between individuals
are not important and individuals are considered as independent, and when repetitive events have
to be described. Thus, Markov models can be used to compare different treatment modalities. Data
from clinical trials have been exploited such as quality-adjusted life expectancy [256], cost efficiency
of treatments or screenings [257, 258, 259] and more.
The model includes reasonable treatment choices and its possible effects within a conceptual
framework to predict the outcome: in a simple picture it can be described by a patient who is always
in one of a finite number of discrete and mutually exclusive health states. His disease course can be
modelled through transitions between these states in discrete time steps corresponding to clinically
66 Group of people who share a common characteristic.
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significant events [260, 261]. The states may be traversed repeatedly and it is also possible to remain
in a state for a long time. The likelihood for a patient to change from one state to the other is expressed
by the transition probabilities (see figure 5.5). Measures for cost and outcome can be associated with
transitions and stated to account for treatment costs and gain or loss of quality of life. As a path for
a simulated patient pool is iterated through the model, all utilities and costs for each transition and
state are accumulated (a detailed example can be found in [261]). With the help of this formalism, a
prognosis or treatment decision can be made depending on the initial situation (e.g. comorbidites,
treatment type).
However, the Markov chain formalism has some limitations. For example the Markov property [262]
must be fulfilled, which means that the model has to be set up in a way that the conditional probab-
ility distribution of future states of the process, given the present state and the past states, depends
only upon the present state.
5.2.2 Generic Markov Model for Side Effects
Adverse events are an important factor for the evaluation of radiotherapy. Treatment decisions are
not only based on the prognosis of treatment outcome such as local tumour control or survival but
on other, life altering effects on the patient. Acute side effects can compel to stop the treatment and in
the worst case lead to death of the patient. Late effects can severely limit functions of adjacent organs
and tissue to the tumour and have an irreversible impact on the quality of life of the patient.
Figure5.6 introduces a generic Markov model which describes the course of the treatment-related
side effects after radiation therapy. The model is divided in two sub-models with separate time hori-
zons. The ”acute adverse events model” covers acute symptoms (denoted by a1, a2, a3...) during
the treatment and until six weeks after treatment. The ”chronic adverse events model” describes late
effects (denoted by c1, c2, c3...) starting six weeks after treatment end or later. Since it is planned
to use data from various tumour volumes and treatment doses the health states are grouped in all
possible combinations of severe side effects and no or mild side effects. Here, severe means toxicity
grade 3 or higher (according to CTCAE v.4). Patients start in the initial state and progress to either one
of the health states in the acute model. If they survive treatment they will proceed to the ”no/mild
adverse event” state within the chronic model. Over time, patients may develop further chronic side
effects and progress into health states with higher number of chronic adverse events or death”. Pa-
tients that die due to treatment will transit ”treatment related death” and transverse to the absorbing
state ”death”.
The cycle length is a year, however this depends on the existing data. Each health state and/or
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Figure 5.6: State transition diagram for a general Markov model describing adverse events after ra-
diotherapy. Generalisation from [257]. The model comprises an ”acute adverse events model” (top)
and a ”chronic adverse events model” (bottom). In both sub-models the side effects are grouped into
no or mild adverse events and in any combination of severe side effects: possible combinations of
acute side effects (a1; a2; a1„a2; etc.) and treatment-related death. The late-effects model includes
possible combinations of late effects (c1; c2; c1,c2; etc.) and death. Possible health state transitions
are denoted by arrows.
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state transition can be combined with a cost function such as cost of treatment or quality of life.
If integrating the effects of treatment over time one gets e.g. a probability distribution for quality
adjusted life expectancy which allows to compare different treatments. When examining treatments
that differ in outcome, the health states after treatment need to be paired with the characteristics of
either having ”tumour control” or having ”no tumour control”.
Markov models are usually individually built. They incorporate varying design assumptions for
the same type of problem. A generalisation of Markov models for a family of analyses assumes certain
common characteristics. This could be for example different grades of side effects which occur with
radiotherapy. The model presented here is a standardised analysis model for a range of parameters
and can be applied e.g. for different tumor entities and beam qualities. Each model is individualised
by the existing data. This Ansatz facilitates complex analysis and prediction procedures with the help
of e.g. clinical trial data which are usually under-used because they are only acquired for answering a
trial hypothesis.
5.2.3 Model Specification Through Data from HISP
The generic adverse events Markov model can be automatically populated by data from a database.
This can be illustrated by the procedure of defining the generic model (figure 5.6) with the help of
data from HISP. The SQL code for harvesting information out of the data model of the protoype HISP
(see figure 5.2) can be found in appendix A.4.
A further concept of the automated process of specification of generic Markov models, a templat-
ing language, was developed by a collaborator and thus is not part of this thesis. This language allows
to specify a generic Markov model by defining relations between state-placeholders. The placehold-
ers can be populated by existing data. The application of the generic Markov model to existing data
refines the abstract Markov model into a specific Markov model by defining the states and transition
parameters. The whole scope of this common research project can be found in the literature [263].
5.3 Conclusion
Although a (working) solution for clinical data management exists for hadron therapy: a common
particle database within the European ULICE (Union of Light Ions Centers in Europe) framework [264],
the prototype presented here introduce a variability of possible uses how data can be processed and
utilised in a clinical and scientific environment.
The ULICE database is aiming at integrating and saving data from clinical studies in hadron ther-
apy in one common database through a web-based interface. The database is set up as a collection
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of digital patient’s files which are split up into different modules: containing the treatment overview,
the case management (health insurance data), RT images and study modules (Screening, study treat-
ment, last examination, follow up, adverse events) [264]. However, the data needs to be uploaded and
are saved physically on a server and therefore the absolute data sovereignty is lost. Also, ”each client
or rather clinical trial is stored in a separate database, thus having different maintenance and user
management possibilities” which does not enable to evaluate data across all trials [265]. No concept
of automated analysis exists.
In contrary to this, the HISP prototype offers some remarkable aspects: HISP uses data federation
and provides and integrated view over distributed data sources. All functionalities of the platform
(patient data integration, presentation, reporting and analysis) are accessible via a secure web portal:
patients and doctors can report medical information in a structured manner, doctors can view their
patients’ information across multiple hospitals in a virtually integrated view and researchers can re-
quest statistic information from the federated data sources.
Side effects collected in the use case scenario can be extracted for the proposed generic Markov
model. It enables the analysis of the impact of a specific therapy or treatment technique on side
effects for various tumor entities in a standardised way. This model combined with a cost model of
treatment costs and quality of life could for example be used to assess the benefit of new radiotherapy
technologies, such as CyberKnife and proton beam therapy or carbon ion therapy. With the help of a
framework to express such generic models this approach lowers burden to design and deployment of
data-driven decision making framework and proposes a standard for description/exchange of general
Markov models. The Markov model enables to evaluate and predict clinical outcome.
HISP’s purpose is to demonstrate technical feasibility, therefore its implemented capabilities are
limited and may need to be extended for real-life usage: additional investment will be required to de-
ploy and support the HISP platform, for example for the integration into real hospital systems includ-
ing a complete recording of tumour and treatment related data. Still, this prototype is an interesting
and viable alternative to other in-house developments.
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6 Application II: Modelling of Radiotherapy of Patients with Chordoma
6.1 Introduction
6.1.1 Chordoma
Chordomas are very rare tumours which make up 1-4% of all primary bone tumours with incidence
rate 0.1/100000/year [266]. The median age at presentation is between 46 and 58 years of age. Chor-
domas are slow but steady growing malignant tumours arising from cellular remnants of the noto-
chord. Therefore usual presentations are bones in the skull base and anywhere along the spine. Most
commonly, chordomas grow in the clivus (32%), sacrum and coccyx (29%), but can also appear in the
cervical, thoracic and lumbar vertebrae of the spine. Very rare cases have been reported in the ribs,
legs and feet [267]. The cancer rarely metastasises when sited in the skull base, however, along the
spine there is a 20-40% possibility of metastases [268, 269]. Chordomas are staged like sarcomas [270].
In contrary to rapidly growing tumours, which have high cell loss factors (e.g. carcinomas tend to have
cell loss factors >70%), sarcomas have low cell loss factors (<30%) . Chordomas are comprised of mor-
phologically very inhomogeneous cells [271]. Thus, cell proliferation throughout the tumour is not
homogeneous. The proliferative index67 can vary by a factor 8 within the same tumour [272]. Interest-
ingly, white males are more often affected (57%) than white females (40%), whereas black individuals
are less likely to develop chordoma (3%). Also age has an impact on the prognosis (younger age gives
a better prognosis) [273]. Skull base chordoma tend to be more common in younger patients, whereas
spinal chordomas occur more frequently in elderly patients [274].
Although Chordomas are classified as low-grade tumours, they are difficult to treat. Treatment op-
tions include either surgery and/or radiotherapy and no chemotherapy. For most histologies neurosur-
gical resection is considered the primary treatment modality. However, complete surgical resection
in the skull base is often not possible because it contains deep drilling in the bones which is not pos-
sible near sensitive adjacent normal tissue structures [275]. Chordoma are relatively radio-resistant
and need high doses to be controlled [276]. Very often organs at risk such as the brain stem, chiasm,
and optic nerves, as well as the spinal cord near the tumour area limit the radiation dose from con-
ventional radiotherapy and thus local tumour control [277]. After resection and/or radiotherapy they
tend to recur tenaciously [267]. This and the locally invasive growth pattern makes their prognosis
similar to malignant lesions. Without treatment the median survival is less than 2.5 years and some-
times even less than 1 year [278]. Although advances in microsurgical techniques made it possible
to perform total resections in some cases, a study on 74 patients with skull base chordoma aimed
67 Defined through the number of cells proliferating. It is a measure how fast the tumour is growing.
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at macroscopic total resection of which 53 patients received a gross total removal resulted in a 10-
year recurrence-free survival of only 31% [279]. After conservative treatment all tumours recur over
time, sometimes longer that 10 years after initial treatment indicating the need for additional treat-
ment [280].
6.1.2 Skull Base Chordoma Treated by Radiotherapy
Formerly skull base chordomas were treated by conventional radiotherapy to achieve local control.
Doses of 45-60 Gy were not associated with high progession-free and overall survival rates [269, 276].
Treatment is often accompanied by severe side effects like temporal lobe damage [281]. A study from
1988 treating 25 patients with conventional radiotherapy with a dose range of 45 to 65 Gy and a me-
dian of 55 Gy with fraction doses between 1.5 and 1.7 Gy found a median progression-free survival of
32 months. Assuming an α/β ratio68 for chordoma of 2.45 Gy [282], 55 Gy corresponds to an EQD269
of 50 Gy. There was no cure but above 55 Gy improved local control [283]. It reflects the main problem
that local control is obviously the overwhelming problem of treatment failure and the only chance of
cure and survival is permanent local control [284]. Escalated doses (in the range of 70 Gy using con-
ventional fractionation of 1.8-2.0 Gy per fraction) led to modestly improved results indicating that
chordoma are radioresistant. However, these high doses are limited by nearby critical structures like
spinal cord, brainstem and optic elements [285, 286]. One should note that older studies looking at
long-term results mostly consider cases which employ techniques which use simple ways to shape
and modulate the beam that do not represent the state of art. However, new techniques might enable
a slightly higher dose but mostly have an effect on acute and long-term adverse events.
Out of radiobiological considerations the low α/β ratio for chordoma, indicating a higher sensit-
ivity for the probability of late toxicity by increasing the fraction dose, seems to support higher single
doses without increasing the risk for adverse events. When using stereotactic radiosurgery (SRS) with
photons, delivery of the dose in one fraction, a much steeper dose fall-off allows to deliver higher
doses to the tumour [287]. However, again critical structures nearby and a tumour volume greater
than about 10 ml are limiting factors for SRS. The alternative approach would be to use hypofrac-
tionated stereotactic radiotherapy (SRT), which delivers the dose in a few fractions, with high single
dose per fraction[288]. A case study from 2001 looked at 10 patients who underwent post-surgical
68 Cell survival curves can be described by the linear-quadratic equation (LQ-model): Log[survival] = −(αD +βD2). D
denotes the Dose and α/β describes the bendiness of the Log[survival] curve. Late responding tissues have low α/β ratio,
the curve is more ”bendy” and they are more sensitive to change in fraction size. 69 The Equivalent total dose in 2-Gy
fractions EQD2 denotes the total dose in 2 Gy fractions which equals the same log cell kill as a given schedule. It can be
calculated for any Biological Effective Dose BED=nd
(
1+ d
α/β
)
by EQD2 = BED
1+ 2
α/β
.
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radiosurgery in 1-3 fractions with a median dose of 19.4 Gy and a maximum intratumoral dose av-
erage of 27 Gy [289]. This corresponds to about a mean EQD2 of 53 Gy. The tumour volume was
small, 1.1-25.1 ml, and after a median follow-up time of 48 months 8 patients were still progression-
free and no new neurological deficits and necrosis caused by the radiation treatment was noted. In
2017, another case study of 16 patients looked at small volumes in the skull base with a median PTV
of 14.75 ml (range: 7.1-37 ml) and a median overall dose of 37.5 Gy (range 25-40 Gy) delivered in 5
fractions (mean EQD2 84 Gy) with stereotactic radiotherapy after initial surgery. They found a 28-
month recurrence-free-survival of 90%. 45% of the patients showed acute grade 1-3 toxicity and only
2 patients (10%) experienced grade 4 or 5 late toxicity70 [290]. Although the follow-up time was rather
short, the study indicates that SRT seems to be a valuable option of treating skull base chordoma
of small volumes with ”tolerable” side effects. A recent study from 2015 [291] using photons with
image-guided, intensity-modulated radiotherapy showed that with modern techniques it is possible
to deliver high doses with favourable dose distributions similar to protons. Although tumour volumes
were located near critical structures, a high total dose of 76 Gy with conventional fractionation of 2 Gy
doses could be applied resulting in a 5-year actuarial71 local control rate of 65.3% . The median tu-
mour volume was 21.6 ml (range 14-85 ml).
The radioresistance of chordomas, inadequate radiation doses within the tumour and problems
with severe side effects of treatment accounts for a particular challenge and has led to investigate
other forms of radiotherapy: Hadron therapy using charged particles like protons and carbon ions
offer advantageous physical and ballistic properties allowing a steeper dose gradient and thus im-
proved dose localisation. This is due to the Bragg peak which distinguishes itself by a sudden rise in
dose deposition and subsequently a sharp dose fall off at the end of the range (see figure 1.1). Charged
particles allow higher doses of radiation to be delivered to the target volume and also reduced the ra-
diation injury.
Historically low-LET72 therapy became available before new technologies for photons were de-
veloped. High tumour target volume doses were only achievable with protons with acceptable severe
side effects at that time. Since the seventies skull base chordoma were treated with fractionated
proton beam radiotherapy. A study from 1989 [292] investigated 68 patients which were treated by
70 Grade 5 toxicity means death related to treatment. 71 An actuarial analysis is performed when the actual date of a
survival event is unknown. The known information is that the event occurred between time tn and time tn+1. The actuarial
analysis is carried out at specific time intervals. Kaplan-Meier analysis is used when the actual date of the endpoint is
known. 72 Linear energy transfer (LET) is the amount of energy that an ionising particle transfers to the material traversed
per unit distance. It describes the strength of action of radiation with matter.
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protons with a median overall dose of 69 CGE73 (RBE for protons is set to 1.1), delivered with conven-
tional fraction doses of 1.8-2.1 CGE. They found an increased 5 year actuarial local control of 82% and
a disease free survival rate of 76% with ”acceptable side effects”. However, there was no resolution of
chordoma. Similar but not as good results were found from a study with 49 patients between 1995
and 2000 in d’Orsay, France [294] combining high-energy photons and protons. A median dose of
67 CGE was delivered with 3 years local control rates of 71%. The volume and diameter of the GTV74
had a significant impact on local control, and almost all tumours relapsed within the CTV75 or GTV.
In the early days of low-LET irradiation also helium was used for treating skull base tumours.
Between 1977 and 1992, 126 patients were treated with charged particles with a total mean dose of
68 CGE (range 60-80 CGE) and 2.0 Gy fraction dose using a RBE value of 1.6 for helium[295]. The
Kaplan-Meier-5-year local control was 63%, while the follow-up median was 51 months.
Newer studies at the Paul Scherrer Institute (PSI) using spot-scanning technique76 to deliver the
proton dose showed encouraging results for high tumour doses: 64 patients were treated with a me-
dian total dose of 73 Gy(RBE)77 while the median GTV was 16.4 ml (range 1.8-48.1 ml) [296]. The
median follow-up time was rather short, but the actuarial 3-year local control rates were 87.5% and
no severe toxicity, assessed according to CTCAE, was detected. This was confirmed by long term res-
ults with 5- and 7-year local control rates above 75% and 70% [297]. A study from 2009 examining 64
patients with skull base chordoma found actuarial 5-year local control rates were 81% with a mean
total dose of 73.5 Gy(RBE), 1.8-2 Gy/fraction. A residual tumour volume greater 25 ml was correlated
with lower tumour control [298].
High-LET particle beams like carbon ion particles possess advantageous physical and radiobio-
logical properties : less scattering in tissue, less broadening with depth and a greater biological ef-
fectiveness per unit dose because they cause more complex damage to tumour cells than those of
low LET [299]. Beams of ions heavier than helium show a strong increase of linear energy transfer
passing through tissue, especially the LET of carbon ion beams increase along their path through
tissue, reaching a maximum in the Bragg peak region [9]. Likewise the RBE increases with LET and
carbon ions offer a higher biological effectiveness in the Bragg peak caused by more cell-cycle and
73 Cobalt Gray equivalent. 1 CGE represents the dose with similar biological effect on the treated volume as 1 Gy of photon
dose. For this the physical dose is multiplied by an radiobiological factor for e.g. protons (RBE=1.1) [293]. 74 Gross
tumour volume: Extent of the tumour which has been seen, palpated or imaged. 75 Clinical tumour volume: Volume,
which includes the GTV and a margin for sub-clinical disease spread. 76 Newer technique which uses magnets to seer
and deflect the proton beam. The depth of the Bragg peak is adjusted by varying the energy of the beam before entering the
gantry. Scanning makes intensity modulated proton therapy (IMPT) possible. The integral dose to the patient is reduced
because scanning produces fewer neutron as passive scattered protons. 77 “RBE-weighted absorbed dose” = RBE(x,y,z)
× dose(x,y,z)
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oxygenation-independent, irreversible cell damage. All this is favourable in the case of skull base
chordoma: Hug et al. [300] confirmed an increased risk for local relapse when the tumour compresses
the brain stem. Local failure will occur in low-dose regions in the target volume due to dose restric-
tion by the brain stem tolerance. Therefore improved technical ability to deliver high doses precisely
in the neighbourhood of organs at risk will lead to better local control.
However, high-LET particles produce lower-LET particles via fragmentation. Those particles have
greater ranges than the primary ions and therefore deposit energy beyond the distal edge of the Bragg
peak which complicates treatment planning.
At the National Institute of Radiological Sciences, (NIRS) in Japan 29 patients with skull base
chordoma were treated with carbon ion particles [301]. The dose was escalated from 48 to 60.8 GyE
over 4 weeks with 16 fractions. To calculate the biological weighted dose they used a constant RBE
factor arguing that independent of the length of the spread out Bragg peak (SOBP) the RBE is 3 at
the distal part. For high doses of 60.8 GyE the 5-year local control was 91%, whereas lower doses
of 48.0–57.6 GyE led to local control rates of only 60%. At the Gesellschaft für Schwerionenforschung
(GSI) in Germany 96 patients with skull base chordoma were treated by hypofractionation with a dose
of 60-70 CGE delivered with 20 fractions within 3 weeks. All patients had a gross residual tumour and
local control rates were 80.6% and 70.0% at 3 and 5 years, respectively, with acceptable toxicity [302].
According to the systematic review of Matloob et al. [303], ”proton therapy improves long-term
local control and survival in skull base chordoma”. However, there is a strong limitation due to the
lack of documentation of the tumour size, extent of primary surgery and outcome measures. There is
a need of further studies to ”directly compare proton therapy to other treatment modalities”, to decide
which therapy to prefer in selected patients. Similar results have been found in a meta-analysis clin-
ical study comparing the effectiveness of radiotherapy for chordoma [304]. The results tend to prefer
particle therapy after surgery for chordoma to SRT, although no clear conclusion between carbon
ion and proton irradiation could be drawn. There were no differences in the 3- year overall survival
among SRT, proton therapy and carbon ion therapy but the 10-year survival was clearly in favour of
particle irradiation. The survey was marked with problems like insufficient data in regard to patient
numbers, missing resection status, volume data, scarce reporting of toxicities and the report of mixed
tumour entities like chondrosarcoma and chordoma. Another nagging question is if the treatment
with carbon ions offer a an advantage over protons. [305] calls for ”randomised studies comparing
the outcome after carbon ion RT with proton RT are especially needed to evaluate the role of particle
beams in the treatment of skull base tumours in children and young adults”. In this regard, carbon
ion radiotherapy may have a possibility of further improving the long-term result but more clinical
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trials are needed [301, 304]. The easiest way to achieve this are randomised trials assessing these new
treatment modalities for skull base chordoma but so far no published data exist [306]. The little data
that is available despite the promising outcome of particle therapy treating chordoma is due to fact
that centers of expertise are needed for the technical complexity and size of the treatment facilities
and that the therapy is very expensive [24]. As radiotherapy is a useful treatment tool in the combat
of chordoma, ”information on cellular radiosensitivity to photon and/or charged particles is urgently
needed” [307].
6.2 Extraction of Radiobiological Parameters from Clinical Data with In Silico Modelling
Against this background so-called in silico trials that could be used to evaluate new treatment strategies
to predict patient-specific response to dose schedules are becoming an invaluable tool. They allow to
investigate situations that would otherwise be impossible to perform [55]. Mathematical modelling
might also help with finding prognosis factors and predict the outcome of dose escalation studies.
To simulate the reaction of chordoma to radiotherapy with different beam qualities the analytical
model from chapter 4 is applied here. It is based on a local tumour growth model and a radiation
therapy treatment model. As chordoma have low vascularity [308] a model considering only the tu-
mour parenchyma and neglecting the interplay between tumour stroma and cancer cells for both, the
effect of RT and the growth process, is sufficient. Stromal cells have an effect on tumour cells playing
a role in tumour progression, metastasis, recurrence and drug resistance [309].
Chordomas are resistant to low-LET radiation due to hypoxia and cancer stem cells which are
radioresistant [310]. However, chordomas are slowly growing and no accelerated repopulation effects
after radiation could be found in the literature.
6.2.1 Model Assumptions and Simulation Procedure
The tumour shows sigmoidal growth and describes two compartments in which the cells can be situ-
ated: quiescent or proliferating. Both cell types will show different radiosensitivities when irradiated.
Besides cell loss due to radiation treatment cell loss within the growing tumour from both cell groups
exist and dead cells are cleared out of the system immediately. The parameters used in the model are
directly related to biological and radiobiological measures.
A single patient’s tumour’s reaction to radiotherapy can be modelled in the following way: The
tumour grows, receives radiotherapy (shrinking of the tumour) and after the end of treatment if there
are still remaining tumour cells will keep on growing. If the tumour regrows to a detectable tumour
size within the follow up time period, it is noted as a relapse.
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To receive a local control curve a patient cohort and its reaction to radiotherapy is Monte Carlo
simulated by variation of the model’s parameters according to certain probability distributions - de-
noted here as patient model. The effect of varying beam qualities will follow from varying radiosensit-
ivity parameters. The simulation generated a number of 3000 patients to ensure that the resulting
local control curve was independent of any further increase in the population number78.
Within the model fixed parameters exists which are approximated (see section 4.5.1). They need
to be adjusted to each tumour entity and location:
◦ Approximation of conversion tumour volume - cell number: 1.8×108 chordoma cells corres-
pond to 1 mm3. This is needed to convert the measured volume data or even tumour stage into
cell numbers. It should be noted that for the model the actual malignant cells are important.
This is for example the total tumour bulk or residual tumour after surgery, denoted as gross tu-
mour volume (GTV). The clinical target volume (CTV) often includes besides the GTV potential
residual tumour detected by MRI, CT and intraoperative findings. Finally, the CTV plus a safety
margin79 is called the planning target volume (PTV) which is the volume irradiated in clinical
practise. This is important as the tumour can regrow from a single tumour cell, however the
number of cells in the area of suspected disease can be neglected for the model simulations as
they are contributing a vanishing amount of tumour cells to the total tumour cell number.
◦ The maximum number of tumour cells which could be reached due to the lack of nutrition and
space was set to N∞ = 1012 cells.
◦ Definition of Recurrence: As soon as the tumour is detectable again with radiological (MRI, CT)
measures. For the simulation NRez = 108.
◦ Time from detection to treatment start is arbitrarily set to t1 = 10 days. In the case of slowly
growing tumours like chordoma, t1 has no impact on the outcome.
By fitting the simulated local control curve to real clinical local control curves the distribution of the
following parameters from the mathematical model can be determined:
◦ Growth rate k ² [0,∞[
◦ Cell loss factor from quiescent cells µq ² [0,∞[
78 Reproducibility of the simulation is quantified in a qualitative manner (”stays the same for each simulation with the
same probability distribution parameters”). This should be sufficient as we are dealing with a very qualitative interpretation
of our results and also a very imprecise curve the data needs to be fitted to. 79 Size depends on the treatment option.
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◦ Inital growth fraction PNorm ² [0,1]
◦ Survival fraction after radiation for quiescent cells Sq ² [0,1]
◦ Survival fraction after radiation for proliferating cells Sp ² [0,1]
Parameters in the range of [0,∞[ are modelled through a lognormal distribution, for [0,1] a beta distri-
bution is used. A patient pool (n=2000) is generated with Monte Carlo simulated data of the paramet-
ers αSq , βSq , αSp , βSp , αPNorm , βPNorm , µk , σk , µµq and σµk with an initial tumour volume distribution
according to the clinical data and a given treatment regime (fraction dose, fractions/week, total dose).
For each generated patient the tumour regression time is calculated with eq. 4.76 NRez = N (tRez ).
Simulated annealing is used to fit the patient cohort to the clinical local control curve.
6.2.2 Skull base Chordoma Treated With X-Rays
Patient characteristics. The data used to examine the effect of X-rays on chordomas of the skull base
was published by Debus et al. in 2000 [288]. 37 patients were investigated between 1990 and 1997 of
which thirty three had undergone subtotal or gross total tumour resection. 3 of the patients had at
least 2 surgeries or more.
Treatment planning and delivery. Patients had stereotactic radiation therapy after surgery with
potential and visible residual tumour and none received chemotherapy. The clinical target volume
included the visible tumour and potential residual tumour detected by MRI, CT and intraoperative
findings. The planning tumour volume used a 2 mm safety margin. The median target volume was
56 ml with a range from 17 to 215 ml. The treatment dose was delivered by three or four non-coplanar
fields with an energy of 15 MV from a linear accelerator. The median prescribed treatment dose was 66
Gy at the isocenter with a median daily fraction of 1.84 Gy which corresponds to approx. 36 fractions.
The target border was covered by the 90 % isodose line of the prescribed dose with a steep dose fall off
to the surrounding tissue. Maximum doses for brain stem, optic nerve and optic chiasm were 54 Gy.
Follow up. Check-ups were performed with MRI to evaluate local relapse. The examinations were
scheduled 6 weeks and 3 months after therapy and after every 6 months. The mean follow-up time
was 27 months, ranging up to 95 months. At 2 years, the local control rate for chordomas was 82%
and 50% at 5 years. After the maximum follow-up time of 8 years, only 40% local control could be
achieved. Of the 11 patients developing tumour relapse, 7 occurred within the treatment volume, 3 at
the margin and one out of field. No clinically significant acute adverse events occurred and only one
patient developed a severe late toxicity, a right-sided hemiparesis.
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Figure 6.1: Skull base chordoma treated by conventional stereotactic radiotherapy with a median
total dose of 66 Gy. The plot shows local control against time in months after the end of radiation.
Fit of simulated data (red, smooth curve) to the clinical recurrence curve (black, step-like function
from [288]) with the parameters from figure 6.2.
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Figure 6.2: Fitted model parameters extracted from a clinical trial of patients treated with SRS X-rays:
distributions of the planning target volumes V olG , initial proliferation factor PNorm, growth rate kG
with underlying Gompertzian growth rate and quiescent cell loss factor µq , which are independent
of radiotherapy. As a marker of radiosensitivity the distribution of survival fractions are given for
proliferating and quiescent cells Sp /Sq at median doses of 1.84 Gy.
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Simulation and results. The information on the treated volumes given by the article is not very
detailed. Therefore a probability distribution had to be picked at random which fulfilled the scarce
information on the present tumour volumes. A Weibull distribution seemed to be reasonable and
simple enough producing positive values for the volume (contrary to a normal distribution) and pre-
venting larger volumes than the observed maximum (contrary to a lognormal distribution). The para-
meters of the Weibull distribution was determined to match with the given maximum and mean val-
ues (see figure 6.2). According to section 4.5 the mathematical model was fitted to the clinical data
shown in figure 6.1. The extracted probability distributions of the fitted parameters of the model
show that proliferating tumour cells are on average more radiosensitive and the quiescent cell popu-
lation show a broader distribution of radiosensitivity. The survival fractions can be approximated by
a Gaussian function with the results
X-rays: Sp = 0.45±0.19 < Sq = 0.61±0.24 1.8Gy/frac. (6.1)
An overview of all fitted probability distributions of all model parameters is presented in figure 6.2.
It should be noted that there was no specification how big the actual gross tumour volumes were.
The volume data used in the simulation were indicating the planning tumour volumes which include
preoperative findings and a safety margin leading to a higher tumour cell count in the simulation.
Having this in mind the results for the survival fractions will give an optimal minimal result, whereas
in reality the radiosensitivities will be shifted to the right. There is not enough information to quantify
the error because the actual tumour volumes can not be reconstructed.
6.2.3 Skull base Chordoma Treated With Protons
Patient characteristics. The response of skull base chordoma to proton therapy was examined with
clinical data extracted from local control curves published by Ares, Hug et. al in 2009 [298]. In the
time period between 1998 and 2005, 42 patients with skull base chordoma were treated with protons
using the spot-scanning technique at Paul Scherrer Institute, Switzerland. 33 patients had a primary
tumour and underwent proton radiotherapy after one surgery, 9 patients were treated for recurrent
disease after one or several operations.
Treatment planning and delivery. The macroscopic tumour was identified by CT and MRI and
was included in the clinical target volume along with the preoperative tumour extension plus suspec-
ted microscopic cancer spread. The planning tumour volume was created with a mean 5 mm safety
margin. 24 patients had a gross tumour volume that was smaller and 18 patients that was greater
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Figure 6.3: Skull base chordoma treated by spot-scanning-based proton therapy. The mean total dose
was 73.5 Gy(RBE). The plot shows local control against time in months after the end of radiation.
Fit of simulated data (red, smooth curve) to the clinical local control curve (black, step-like function
from [298]) with the parameters from figure 6.4.
than 25 ml post-surgery and before radiation therapy. 4 patients were treated with mixed beams, pro-
tons plus photons, which will be neglected in the simulation. Mean dose was 73.5 Gy(RBE) (range
67-74) with a single dose of 1.8-2 Gy(RBE) per fraction and 4 fractions per week, using an constant
RBE of 1.1 for protons. Treatment plans consisted of three to four fields, maximising the dose cover-
age of the gross tumour volume and respecting dose constraints of the organs at risk. Maximum dose
constraints to the brainstem center and surface were 54 Gy(RBE) and 60 Gy(RBE), respectively, and
60 Gy(RBE) to the optic chiasm ans optic nerves. 18 patients had brainstem compression or abutment
from the tumour.
Follow up. Check-ups were performed with MRI and CT to evaluate local relapse. Within the first
2-3 years, the examinations were scheduled in intervals of 3-6 months and after than once a year.
The mean follow-up period was 38 months, in the range of 14-92 months. 5 patients developed local
recurrence within 3 years. The actuarial 5-year local control rate were 81%. 4 patients died during
follow-up, related to their disease. The trial was performed altogether for 64 patients with chordoma
and chondrosarcoma. Late adverse events defined as side effects observed after 90 days following the
completion of radiotherapy were only given for the total patient group without distinction between
the tumour entities and classified according to the CTCAE v.3.0 grading system (see section 2.4.2):
Overall, 4 patients developed severe side effects including Grade 3 and 4 unilateral optic neuropathy
and 2 cases of Grade 3 symptomatic temporal lobe parenchyma damage. No patient developed brain-
stem toxicity. No treatment-related secondary malignancies were observed.
Simulation and results. Little is known about the distribution of tumour volumes. Using the same
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Figure 6.4: Fitted model parameters extracted from a clinical trial of patients treated with protons:
distributions of the gross tumour volumes V olG , radiosensitivities of proliferating and quiescent cells
Sp /Sq , initial proliferation factor PNorm, growth rate kG and quiescent cell loss factor µq . The under-
lying growth function is Gompertzian.
arguments as in section 6.2.2 and especially stressing the fact that the distribution of tumour volumes
in a clinical trial have a sharp maximum limit, a Weibull distribution was used which redeemed the
gross tumour volume data (see figure 6.4). The fitted simulation local control curve is shown in fig-
ure 6.3. The probability distributions of the fitted parameters of the analytical model show that pro-
liferating tumour cells are on average more radiosensitive and the quiescent cell population show a
similar width of distribution of the radiosensitivity. Both survival fractions can be approximated by a
normal distribution (depicted here by mean±standard deviation) with the following result:
Protons: Sp = 0.38±0.20 < Sq = 0.55±0.22 1.8−2Gy(RBE)/frac (6.2)
An overview of the probability distribution of all biological data is presented in figure 6.4.
6.2.4 Skull base Chordoma Treated With Carbon Ions
Patient characteristics. The effectiveness of carbon ion therapy in the treatment of skull base chor-
doma was examined with the help of clinical data extracted from local control curves published by
Schulz-Ertner, Karger et al. in 2007 [302]. Between 1998 and 2005 a total number of 96 patients with
post-surgical residual or inoperable skull-base chordomas were treated with carbon ion therapy at
GSI, Germany. 59 patients were treated for primary, 37 patients for recurrent tumours, all of them
had undergone at least once surgery. Only patients with either inoperable recurrent tumours or mac-
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Figure 6.5: Skull base chordoma treated by treated by raster-scanning-based carbon ion therapy with
a median total dose of 60 CGE. The plot shows local control against time in months after the end of
radiation. Fit of simulated data (red, smooth curve) to the clinical recurrence curve (black, step-like
function from [302]) with the parameters from figure 6.6.
roscopic tumour after surgery were accepted for treatment with carbon ion therapy.
Treatment planning and delivery. Biologic plan optimisation was performed taking into account
a varying RBE across the irradiated volume. The mean RBE was around 3 within the planning tar-
get volume. It was ensured that a homogeneous biologically effective dose was reached throughout
the target volume (opposed to a physical homogeneous dose) calculated by the TRiP software [311].
For the initial planning target volume, the gross tumour volume and suspected sub-clinical disease
established from histologies, surgical reports and MRI findings were included. A boost planning
target volume was defined which only included the tumour gross volume detected by MRI plus a
2 mm safety margin. The median boost planning target volume was 80.3 ml within the range of 13.9-
594.2 ml. The technique used was raster scanning. The initial planning target volume was treated to
target doses between 45 and 52.5 CGE (median 45 CGE) in 15 fraction. After this, the boost planning
target received a dose of 15 to 17.5 CGE, the total dose within the boost planning target volume accu-
mulated to 60 to 70 CGE (median 60 CGE). The fractionation of 7 times 3.0 to 3.5 CGE per week was
applied. Converting the dose to a conventional fractionation scheme of 2 CGE/day using and α/β
ratio of 2 Gy for both, late toxicity to the brain and chordoma cells, then biological equivalent doses
between 75 and 96.25 CGE were reached in the boost volume. The target border was covered by the
90% isodose line of the prescribed dose, avoiding underdosage within the target volume. Maximum
doses allowed to the optic nerves and optic chiasm was 54 CGE, 50 CGE at the center of the brainstem
allowing small volumes of 1 ml at the surface to receive up to 60 CGE and finally the dose to the spinal
chord was restricted to 45 CGE.
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Figure 6.6: Fitted model parameters extracted from a clinical trial of patients treated with carbon ions:
distributions of target volumes and the estimated gross tumour volumes V olG (red), radiosensitivit-
ies of proliferating and quiescent cells Sp /Sq , initial proliferation factor PNorm, growth rate kG and
quiescent cell loss factor µq . The underlying growth function is Gompertzian.
Follow up. The patients were followed up clinically and with MRI scans of the brain. The first
follow-up examination was 6 weeks after radiotherapy, later within the first 2-3 years follow-up ap-
pointments every 3 to 6 months were scheduled, thereafter yearly. Mean follow-up time was 31
months, in the range of 3-91 months. 15 patients developed recurrences of which 11 occurred within
the boost volume, 4 on the margin. After 3 years the actuarial local control rates were 80.6%, after 5
years 70%. Acute adverse events were classified according to CTCAE v.3, late effects were graded ac-
cording to RTOG/EORTC scores (see section 2.4.2). 2 patients with large tumours extending into the
oropharynx developed severe acute mucositis Grade 3. Severe late adverse events included 4 patients
with Grade 3 optic nerve neuropathy. However, three of the patients had preexisting unilateral visual
field deficits because of tumour involvement before radiotherapy and developed unilateral blindness
after carbon ion irradiation, one woman developed bilateral blindness. One case of Grade 3 soft tissue
necrosis occurred. No treatment-related secondary malignancies were observed.
Simulation and results. The distribution of tumour volumes used in the simulation relate only
to the data given by the boost volume and were fitted to a Weibull distribution (using the same ar-
guments as in section 6.2.2). This is supported by the assumption that the major bulk of tumour
resides within the boost planning target volume and the tumour cells within the additional area of
the inital planning target volume can be neglected containing only suspected sub-clinical disease.
However, these regions need to be included in the radiation treatment to rule out possible recurrence
from singe cells but are irrelevant for the simulation. The tumour gross volumes is approximated by a
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sphere which simplifies the subtraction of the 2 mm safety margin. The fitted local recurrence curve
is displayed in figure 6.5. The probability distributions of the fitted parameters of the model show
that the radiosensitivity of the quiescent tumour cells assimilate to the proliferating cell population
and show more narrow width of distribution of the survival fraction:
Carbon ions: Sp = 0.25±0.17 < Sq = 0.31±0.19 3−3.5CGE/fraction (6.3)
An overview of all probability distributions is presented in figure 6.6. However, it should be noted that
the parameters of the inital growth fraction and the quiescent cell loss rate are very insensitive to the
fit which can be reduced to the assimilation of radiosensitivities of both cell compartments.
6.3 Results
6.3.1 Clinical Fit
The model was successfully fitted to all clinical local control curves as shown in figure 6.1, 6.3 and
6.5. Unfortunately the data to refer to was very scarce, especially tumour volume information which
had to be estimated. The attention was directed to the a close fit at early times and a good fit at later
times, mainly determined by the tumour growth rate if the follow-up time was sufficient long enough.
Because the objective function to minimise the sum of squares between both curves is expressed
within a multi-dimensional parameter space, it is not possible to guarantee that the best possible fit
has been found.
Tumour specific data like the growth fraction PNorm, growth rate k and cell loss factor of quiescent
cells µq are treatment independent and should only vary slightly between different trials. Thus it is
very encouraging that the results of these parameters are very similar for each clinical trial.
6.3.2 Chordoma Growth Rates and Tumour Doubling Times
The model describes tumour growth with a growth rate k which cannot be compared directly with
the term tumour doubling time (DT) given in the literature. DT assumes exponential growth which
can only approximate unrestricted growth of cells in a laboratory setting well but not in-vivo. Tumour
cell lines are used in a laboratory setting for developing new cancer treatments which then can be
transferred into a clinical setting. So far only few chordoma cell lines have been established which
all show extremely long doubling times in comparison to other cancer cell lines. The cell lines from
sacral tumours show cell doubling times around a few days, in particular U-CH1 about 7 days [313],
its sub-population, U-CH1-N approximately 3 days [307], Chor-IN-1 around 7 days [314] and JHC7
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(a) Measured in-vivo DT of skull base chordoma [312]
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(c) An exponential function (pink) with each chosen expo-
nential growth rate is fitted to a Gompertzian growth curve
(blue) within the area of cell numbers where the tumour is
detectable.
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(d) The determined Gompertzian growth rates are rep-
resented by the dots in the plot. A Lognormal distri-
bution for the corresponding Gompertzian growth rate
kGomp (blue curve) fitted to the dots was found with the
parameters µ=−5.19 and σ= 0.63.
Figure 6.7: Method to convert a distribution of clinical tumour doubling times of skull base chordoma
into Gompertzian growth rates.
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about 5 days [315]. The only chordoma cell line available from the clivus up to date, MUG-CC1, has
a slightly longer doubling time of about 10 days [316]. Comparing those cell doubling times with
tumour growth in-vivo it is apparent that the latter is much slower. Data from a laboratory setting
therefore should be used in a clinical setting with the utmost caution (see 4.5.2).
In a clinical study, tumour growth in-vivo in skull base chordoma was examined by means of MRI
scans. The patients had an age range of 8-63 years with a mean of 39.4 years. The cell growth was
monitored after surgery assuming exponential tumour growth. Tumour doubling times in months
for all 19 cases were 7, 13, 14, 16, 17, 17, 18, 20, 21, 24, 24, 25, 28, 36, 36, 37, 46, 84, 100 [312], showing
a huge variety.
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Figure 6.8: Comparison of Gompertzian
growth rates: converted from clinical DT
(red) vs. parameter estimation from simu-
lation (black).
In order to compare the data with our biological
parameters extracted from our model it is necessary
to establish a relationship between exponential tumour
doubling times and Gompertzian growth rates. For this
we fit the tumour doubling times to a lognormal dis-
tribution and use the relation 4.15 to obtain the cor-
responding transformed distribution of growth rates k.
Then we align various exponential growth curves with
different growth rates to the Gompertzian growth curves
in the detectable, visible region of tumour growth at dia-
gnosis which is around 107 − 108 tumour cells (see fig-
ure 4.8) to obtain the corresponding growth rates for Gompertzian growth. Finally, the determined
Gompertzian growth rates are fitted to a lognormal distribution (see figure 6.7). The comparison this
calculated distribution with the growth rates determined by fitting the model to local control curves
shows a difference by the factor 2-2.3 which is still quite a good fit regarding the inaccuracy of the fit
in regard to the granular data, in particular volume distributions.
6.3.3 Tumour Age
5 10 15 20 25
years
Figure 6.9: Distribution of estimated tumour
age at diagnosis for the patient group treated
with protons.
Figure 6.9 shows the prediction of the age distribution
at diagnosis using the parameters from figure 6.4. Ac-
cording to eq. 4.83 it was calculated assuming a es-
timated volume reduction after surgery of 50%. The
mean age is approximately 6 years for the corrected
volumes at diagnosis. The distributions are skewed
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which results from the skewness of tumour growth
rates and skewed volume distributions and is strongly
correlated with the growth rate.
6.3.4 Radiosensitivities
The radiosensitivities modelled for each beam quality represent the survival fraction for a given single
dose and in the used cases only proton and photon irradiation can be compared as their fraction
doses are almost equal, patients treated with photons receive a fraction dose of 1.8 Gy, patients
treated with protons had fractions doses within the range of 1.8-2.0 Gy(RBE) which corresponds to
1.6-1.8 Gy using RBE=1.1. Proliferating cells seem to be similar radiosensitive to both beam qualit-
ies, their distributions for Sp are almost the same. There is a prominent difference in radiosensit-
ivity between proliferating and quiescent cells. This can be understood considering that protons
and photons are both low LET radiation leading to less complicated DNA damage. A difference can
be found for the radiosensitivity of quiescent cells, their distribution is less broad for proton irradi-
ation and the mean is smaller. Protons offer the advantage of a much more conformal dose distri-
bution than photons which is more favourable if sensitive organs at risk are adjacent. This might
lead to higher doses which can be given e.g. in the brain and thus to a better local tumour control.
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Figure 6.10: Comparison of volume distribu-
tions used in the simulation.
Carbon ion therapy was treated hypofractionated
with a single dose of 3-2.5 CGE. Obviously both sur-
vival fractions, for the quiescent and proliferating
cells are smaller than for protons and photons. The
difference of radiosensitivity between proliferating
and quiescent cells was markly reduced. Also, the
heterogeneity of radiosensitivity was suppressed res-
ulting in narrower distributions. This is in accordance
with a paper by Masunaga et.al. [222] who found that
in-vivo irradiation of squamous cell carcinomas in mice with carbon ions efficiently inhibited repair
in quiescent cells and suppressed the heterogeneity of the tumour cell-killing effect within solid tu-
mours in comparison to X-ray radiation.
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(a) Small tumour volume, mean[vol]=21 ml. (b) Big tumour volume, mean[vol]=121 ml.
Figure 6.11: Local control curves for the same tumour volumes treated with photons (red), protons
(blue) and carbon ions (black) using the same treatment parameters (total dose and fractionation) as
in the clinical trials.
6.3.5 Comparison of Different Beam Qualities treating Skull Base Chordoma
The comparison of data from clinical trials for photons, protons and carbon ions treating skull-base
chordoma is not easy and can be misleading (see section 6.2.3). Our three cases stand exemplary
for reviews and discussions which have tried to answer the question of superiority of one treatment
modality over the other. The advantage of in silico modelling is that outcomes can be compared more
easily using the same conditions or endpoints.
Although the local control rates for proton therapy look more promising than for carbon ion ther-
apy, it should be noted that the tumour volume range that was examined differ massively (see fig-
ure 6.10). In this study, the volumes treated by SRT are obviously larger than the volume proton ther-
apy treated. However, it must be remembered that the volumes for the photon treatment include also
areas of suspected disease and tumour volume which was resected prior to radiation therapy. There-
fore, the volumes examined here are probably too large and the survival fractions estimated too low
(see section 6.2.2).
In a first in silico trial a patient population is generated using the same tumour volume and bio-
logical parameters and is treated by photons, protons and carbon ions. Fractionation and total doses
are used from each study described in section 6.2.3. The results can be found in figure 6.11. It is obvi-
ous when comparing small volumes with a mean of approximately 18 ml to larger volumes to a mean
of 121 ml that the size of the tumour has a major impact on outcome. 10-year local control for SRT for
small volumes are only 20%, but for bigger volumes even less than 10%. Tumour control for proton
and carbon ion therapy look more promising with around 55% control for large volumes and for small
volumes around 85% at follow-up after 10 years. It is not surprising that the 10-year local control of
photon treatment ”scores so badly”, at only 20% local control for small tumour volumes and less than
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(a) Small tumour volume, mean[vol]=26 ml. (b) Big tumour volume, mean[vol]=121 ml.
Figure 6.12: Dose escalation study: comparing local control curves for equal tumour volumes treated
with protons (blue) and carbon ions (black) while increasing the total dose of the carbon ion treat-
ment dose with an additional fraction (solid line) in comparison to the unescalated dose (grey).
10% for large tumour volumes. The EQ2D2 of the photon treatment is much lower at about 63 Gy
compared to the EQ2D2 of proton and carbon ions of approximately 75 CGE in this setting. The sim-
ilar biological effective overall dose is the reason the results of both particle treatment modalities are
so similar.
The maximum dose which can be delivered to the tumour is restricted by the dose which the sur-
rounding tissue can tolerate. The physical nature of photon absorption in matter sets a constraint to
the dose maximum if critical structures are bordering the tumour. Steeper dose gradients are possible
for smaller target volumes, however in comparison to the simulation results particles have a clear ad-
vantage. The comparison of protons to carbon ions might be more difficult. We suspect that higher
equivalent total doses in carbon ion treatment can be given to the tumour: this is due to the steeper
lateral dose fall of carbon ions compared to protons with energies used in a clinical setting[20]. In
addition, the RBE of tumours increases faster than the RBE of normal tissue when increasing fraction
doses [26] and the RBE is much higher is in the Bragg peak (inside the tumour) which guarantees to
spare critical structures and allows for dose escalation.
Figure 6.12 shows the impact of an additional fraction which corresponds to an increase of the
total dose of approximately 3.8 Gy EQ2D2 in the treatment with carbon ions. The additional fraction
leads to an increase of local control having the strongest effect on larger tumour volumes. Escalating
the dose in the study with small volumes results in the success of almost no tumour recurrence and
an increase of 12% in local control. With larger tumour volumes the additional fraction leads to an
improvement of the 10-year local control rate of 20%.
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6.4 Discussion and Conclusion
Skull base chordoma rarely metastasise and represent a rare tumour within the brain that are challen-
ging to treat because of their radioresistance and their frequent vicinity to delicate structures in the
brain. Survival is strongly dependent upon local control which in return is strongly correlated with
high doses administered to the tumour. Clinical trials show similar results for new photon treatment
techniques like radiosurgery or stereotactic radiotherapy in comparison to particle therapy, protons
and carbon ions. However, with only few centers available for proton therapy and even fewer for
carbon ion therapy there still needs to be evaluated which treatment modality is favourable. A math-
ematical model could substitute clinical trials to investigate parameters of treatment on the patient’s
outcome and find a suitable indication for the respective therapy. The model from chapter 4 was
applied to clinical trials using three different beam qualities for treating skull base chordoma:
The strength of this model presented here is that it can explain fundamental biological and ra-
diobiological processes. The mapping of the two-compartment model of proliferating and quiescent
cells onto a sigmoidal growth curve and assigning each compartment of cells a specific distribution of
survival fractions depending on beam type and fraction dose makes it possible to describe radiation
therapy in a plausible way:
◦ The six R’s of fractionation are contained naturally in the model (see chapter 4). Radiosurgery
approaches can also be compared to conventional and particle therapy. The radiosensitivities
for proliferating and quiescent cells depend on the fraction dose (and dose rate) and therefore
should be determined out of a patient pool receiving the same fraction dose. The mean of the
distribution of the survival fractions of the radiosurgery (single fraction) will be much smaller
than expected due to calculations with the LQ model [317] because the large fraction doses
induce an additional anti-tumour-immune response effect (see section 4.4.1).
◦ No accelerated repopulation in chordomas has been mentioned in the literature. However,
severe radioresistance has been found due to quiescent cancer stem cells. The stem cells are
included in the quiescent cell compartment and account for the radioresistant tail of the sur-
vival fraction Sq (see section 4.4.2).
◦ The expected impact of high-LET on quiescent and proliferating cells (see section 4.4.3) lead-
ing to assimilation and narrowing of the distribution of radiosensitivities of both cell compart-
ments was proven true as a result of fitting the local control curves to clinical trial data of pa-
tients treated with photon, proton and carbon ions.
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Until now no mathematical model was used to investigate patients with chordoma treated by radio-
therapy. However, some work has been published on modelling the effect of radiotherapy on tumours.
There are applicable models for clinical practise which include a patient pool oriented strategy to ex-
tract radiobiological information from clinical data [154, 155, 318].
A comparison of the model presented here with the inital radiation model, the ”BJJK-model” [55]
(decribed in section 2.5.2) demonstrates how much more powerful it is. Although both models use
the same three modelling scales (tumour growth at patient level, treatment on a cellular level and a
study cohort at population level), they differ very much from each other. The BJJK-model describes
the tumour with only one compartment of equal tumour cells. The underlying growth curve is expo-
nential and all fractions are given at the same time with a constant survival fraction SF. The overall
survival fraction for a specific treatment is given by SF n , where n denotes the number of fractions
given. This set up prohibits the possibility to describe fractionation effects, in particular repair, re-
population, reoxygenation and radiosensitivity. As different beam qualities have a varying effect on
those fractionation effects, the BJJK-model can not distinguish between them and moreover can not
model the dependence of radiosensitivity of quiescent cells on local tumour control. Since the model
has been fitted to only one patient group, no consistency in the fitted results of biological parameters
like growth rates could be demonstrated.
The model does not account for aggressive treatment recurrences. Relapsed tumours often grow
more aggressively and are more difficult to control. This could be due to activated cancer stem
cells [319]. Patient age was not included as a specific parameter in the model although it is known
to be highly prognostic of local control. It was shown that an increased patient age was associated
with faster growing tumours [312]. In the current model both facts are contained within the distri-
bution of tumour growth rates, however depicts a weakness of the model and is an area for future
work. A small percentage of chordoma metastasise. This is not included in the tumour description
and could be looked into more in detail when using this model for other solid tumours. Nonetheless
local control is the most important factor for long-time survival in patients with chordoma and thus
metastases are negligible. The dose distribution within the tumour is assumed to be homogeneous
which is not realistic. There is no way to account for tumour recurrence that occurred outside the
GTV and in margin areas which received less dose.
The age distribution of the tumours at presentation is directly correlated with the tumour growth
rate. The growth model used has a sigmoid growth characteristic which is realistic. As the growth
rate is estimated too high in comparison to in-vivo data the tumour age will also be underestimated.
The reason for this might be traced back to improper mapping of tumour volume to the number of
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tumour cells and the incomplete reporting of tumour volume before treatment which needs to be
looked into closer in the future.
The in silico trial examining the effect of volume contribution to the prognosis of skull base chor-
doma found that larger postoperative residual GTVs significantly worsens long-term local control
which is in accordance with the literature [320, 321, 322, 323]. To study the effect of dose escalation
the model was used to perform a treatment schedule with an additional fraction for carbon ion ther-
apy (additional 3.8 CGE EQD2). Again, treatment outcome was strongly correlated with delivered
dose, and had an stronger impact for larger volumes [321].
Long-term local control in skull base chordoma is correlated with long-term survival. The fit of
the model to clinical data for long follow-up times are therefore of great importance. Unfortunately
the data used here was very thinly represented, so it was easy to fit the model to the tail of the local
control curve as well as to the bulk of the patients. We are convinced, however, that there also will
be very good agreement to a more detailed local control curve. Section 4.5.4 has proven the versat-
ility of the model and how the different parameters influence the local control curve. The biological
parameters that were extracted describing the tumour were very similar for each clinical trial. Radi-
osensitivities for proton, carbon and photon irradiation of proliferating cells are consistent with data
from in vitro studies of various chordoma cell lines [307], confirming the higher radiosensitivities in
regard to particle therapy and the assimilation of radiosensitivities of proliferating and quiescent cells
due to more complex radiation damage. The estimated RBE of 3 for carbon ions in combination with
the calculation for BED used to compare different treatment modalities and dose schedules is in good
agreement with the results of the in silico trials with approximately the same biological effective total
dose (EQ2D2) treating the same volume with protons and carbon ions. As a result a α/β ratio of 2 for
chordoma treated by carbon ions seems to be valid[302].
The difficulty in performing meta-analysis on clinical trials in radiotherapy is very often the lack
of consistent assessment of treatment effects (tumour and normal tissue), different endpoints (dose,
follow-up times) and heterogeneity of the patient pool (tumour volume). In silico modelling enables
to use the same patient pool for photon, proton and carbon therapy confirming the superiority of
particle therapy to photons. The difference in 10-year local control was a significant 50% for mean
tumour volumes greater than 20 ml. This result aligns with a recent meta-analysis study [304].
Following the results of the in-silico clinical trial, these indications for treating chordomas are
proposed: Since the 5-and 10-year local control rates of skull base chordoma are very discouraging
for photon therapy even for small volumes with the mean of 21ml, it seems safe to say that skull
base chordoma in any case should be treated with particles. The reason for this is partly that in the
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brain very radiosensitive organs at risk lie in the vicinity of the treated volume which determine the
maximum dose which can be given to the tumour. This dose is smaller for photons than for particle
therapy due to their favourable dose deposition. Proton and carbon ion therapy show equally good
local control curves for the same overall dose of 75 CGE. For small volumes (21 ml), 5 and 10 year local
control rates are above 80%. However, for larger volumes (mean 121 ml) local control rates diminish
to less than 60% ten years after treatment. Carbon ion have an increased RBE within the Bragg peak
and a steeper lateral dose gradient which spares normal tissue and allows to escalate the dose. The
result from examining skull base tumours with this model is that protons seem to be the right choice
for tumours with smaller volumes and that larger volumes need to be treated with carbon ions and
dose escalation. When setting a treatment goal like ”a 10-year local control rate of 90% needs to be
achieved” the indication for carbon ion therapy then can be simulated by varying the tumour volume
and accepting or rejecting the outcome.
With the help of this model the design of clinical trials can be supported in particular by estimat-
ing expected differences between treatment arms and by calculating the number of patients needed
for the necessary statistical power. This is especially important for the treatment of rare tumours.
Although designed to describe or predict the reaction to treatment of a patient cohort by assign-
ing each parameter a probability distribution, the model can even be applied for individualised pa-
tient’s care. For this a maximum number of parameters are determined. The simulation will then
show a more individualised prognosis of the patient depending on how personal the input was. As
an example the residual tumour volume can be narrowed down up to a number and the tumour cell
proliferation can be evaluated using Ki67 immunostaining [312]. In connection with the evaluation
of structures at risk a dose adaptive radiation protocol [323] can be established and examined which
treatment modality and sufficient dose is needed for a satisfactory therapy.
The model described in this thesis offers an simple analytical approach to describe patients with
skull base chordoma which are treated by radiotherapy. It is built in a generic way, so that it could be
applied to other solid tumours. Even other treatment modalities, such as chemotherapy or surgery,
could be easily included. In the future, some new developments will be examined.
Although several highly complicated and realistic models of the effects of radiotherapy on cellular
and tumour level exist [153, 324, 325] none of them are at the stage to be employed in the clinic
and can be used to extract information radiobiological/biological information of a patient cohort.
The development of multi-scale models, using cellular, structural and population information may
deepen our understanding of current treatment protocols and potential future treatment modalities.
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7 Conclusions and Recommendations
In Europe, many particle centers have been built over the last years with more centers on the way.
Among the European hadron therapy community, in particular among the existing and future cen-
ters, there is a strong need for collaboration [34]. This thesis examined the data capturing and eval-
uation of tumour data for different approaches. An extensive list of data fields was compiled for the
documentation of rare tumours and exemplary used for the development of a data model for the
documentation of side effects.
This model was implemented as a use case in a prototype Hadron Therapy Information Sharing
Platform (HISP) for the follow-up of patients after particle therapy. Although solutions for clinical data
management exist such as a common particle database within the European ULICE framework [326],
the HISP prototype offers some remarkable aspects: HISP uses data federation and provides and in-
tegrated view over distributed data sources. All functionalities of the platform (patient data integra-
tion, presentation, reporting and analysis) are accessible via a secure web portal: patients and doctors
can report medical information in a structured manner, doctors can view their patients’ information
across multiple hospitals in a virtually integrated view and researchers can request statistic informa-
tion from the federated data sources.
Since both, the treatment outcome as well as the effects of therapy on normal tissue are important
factors in evaluating a new treatment modality, both characteristics were looked at separately:
Side effects collected in the use case scenario can be automatically extracted for a proposed gen-
eric Markov model for the evaluation of treatment related toxicities. It enables the analysis of the
impact of therapy on side effects and respective cost functions (e.g. quality of life) for various tu-
mor entities in a standardised way. With the help of a framework to express such generic models this
approach lowers burden to design and deployment of data-driven decision making framework and
proposes a standard for description/exchange of general Markov models.
Another application for the possible usage of the data recorded in the tumour database was the
development of a mathematical model which could model basic processes for cancers in patients
treated by radiotherapy with the help of clinical data. It is capable of simulating important charac-
teristics of tumour behaviour like sigmoidal growth, cell quiescence, cell death, incorporates the ef-
fects of fractionation and the response to radiation therapy with different beam qualities. The use of
strictly analytical and one-dimensional functions in the model requires only very little computational
effort to fit simulated data to a real-world situation and makes an extraction of relevant biological
parameters possible. This is a novel approach to model outcome differences in low- and high-LET
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beams through the differences in the distribution of radiosensitivity of proliferating and quiescent
cells within a patient. The parameters included in the model have a reference to real data which
makes it possible to directly interpret and compare them to clinical and biological data. It is possible
to design in silico clinical trials and to determine e.g. prognostic factors or indications hadron therapy
in particular rare tumours where mostly enough data for sufficient statistics are missing.
With the help of this model the design of clinical trials can be supported in particular by estimat-
ing expected differences between treatment arms and by calculating the number of patients needed
for the necessary statistical power. This is especially important for the treatment of rare tumours.
Finally, the model was applied to real clinical data of patients with skull base chordoma treated by
photon, proton and carbon ion therapy. With only rare data available with mostly differing endpoints
and tumour volumes the model was able to compare treatment modalities by using the extracted
biological and radiobiological data for in silico trials. As a result it was found that carbon ions are
favourable for large volumes but for small volumes around 20ml, the efficacy of proton therapy is
sufficient.
The underlying ideas transcribed here are universally applicable and thus the model can be used
for any solid tumour. Despite the simplifying assumptions the qualitative behaviour of this model
agrees very well with clinical experience. Since the model is built in a modular way, it is easily possible
to specify or improve any sub-model individually. Even the inclusion of other treatment modalities
such as chemotherapy or surgery is possible. A number of other improvements are suggested by the
results so far, which will be examined in the future.
The parameters included in the model have a reference to real data which makes it possible to
directly interpret and compare them to clinical and biological data. The model enables to design
in-silico clinical trials and to determine e.g. prognostic factors or indications hadron therapy in par-
ticular rare tumours where mostly enough data for sufficient statistics are missing.
Until now no mathematical model was used to investigate patients with chordoma treated by
radiotherapy. However, some work has been published on modelling the effect of radiotherapy on
tumours. There are applicable models for clinical practise which include a patient pool oriented
strategy to extract radiobiological information from clinical data [154, 155, 318]. The model described
in this thesis offers an complementary approach including the endeavour to model the effect of cell-
cycle dependent radiosensitivity. Although several highly complicated and realistic models of the
effects of radiotherapy on cellular and tumour level exist [153, 324, 325] none of them are at the stage
to be employed in the clinic. The development of multi-scale models, using cellular, structural and
population information may deepen our understanding of current treatment protocols and potential
119
future treatment modalities.
The next step is to populate the HISP with real data and to feed the data automatically into the
analysis models. For this further work needs to look into the translation of different systems for re-
cording adverse events following treatment that all data can be combined. The application of the
local control model needs to be tested with other cancers to prove its versatility. However, for many
fast growing tumour accelerated repopulation is non negligible and needs to be included into the
model if hyperfractionated treatment schedules are used. Finally, simulated local control rates could
be implemented as cost functions into the Markov model of side effects.
To sum up, both analysis, side effects and local control, combined potentially provide a very
powerful tool to evaluate indications and outcome for hadron therapy and can be applied to exist-
ing patients’ data across many clinic trials.
120
References
[1] E Niederlaender. Causes of death in Europe. Eurostat, KS-08-02-001-EN-C, 2006.
[2] William B Coleman and Tara C Rubinas. Molecular Pathology : The Molecular Basis of Human
Disease, volume 4. Elsevier Academic Press, 2009.
[3] G Gatta, J M van der Zwan, P G Casali, S Siesling, A P Dei Tos, I Kunkler, R Otter, L Licitra,
S Mallone, A Tavilla, A Trama, R Capocaccia, and RARECARE working group. Rare cancers are
not so rare: the rare cancer burden in europe. Eur J Cancer, 47(17):2493–511, 2011.
[4] G Delaney, S Jacob, C Featherstone, and M Barton. The role of radiotherapy in cancer treat-
ment: estimating optimal utilization from a review of evidence-based clinical guidelines. Can-
cer, 104(6):1129–37, 2005.
[5] RARECARE. Technical report with basic indicators for rare cancers and health care related
macro indicators [online]. February 2010. Available from: http://www.rarecare.eu/rare_ind
icators/WP5_Technical_Report.pdf [cited 11/2018].
[6] National Bureau of Standards. Radiation quantities and units: International commission on
radiological units and measurements (icru) report 10a, 1962.
[7] Eric J Hall. Radiobiology for the Radiologist. J.B. Lippincott Company Philadelphia, USA, 5th
edition edition, 2000.
[8] Daniela Schulz-Ertner and Hirohiko Tsujii. Particle radiation therapy using proton and heavier
ion beams. J Clin Oncol, 25(8):953–964, 2007.
[9] Daniela Schulz-Ertner, Oliver Jäckel, and Wolfgang Schlegel. Radiation therapy with charged
particles. Semin Radiat Oncol, 16:249–259, 2006.
[10] M Krämer and G Kraft. Calculations of heavy-ion track structure. Radiat Environ Biophys,
33:91–109, 1999.
[11] Robert R Wilson. Radiological use of fast protons. Radiology, 47(5):487–491, 1946.
[12] A Wambersie and H G Menzel. Present status, trends and needs in fast neutron therapy. Bull
Cancer Radiother, 83 Suppl:68s–77s, 1996.
[13] Martin Jermann. Hadron therapy patient statistics. Technical report, PTCOG, 2009. Available
from: http://ptcog.web.psi.ch/Archive/Patientstatistics-update02Mar2009.pdf.
121
[14] ICRU. Report 78: Prescribing, recording and reporting proton-beam therapy. J Int Comm Radiat
Units Meas, 7(2), 2007.
[15] T Elsässer, M Kramer, and M Scholz. Accuracy of the local effect model for the prediction of
biologic effects of carbon ion beams in vitro and in vivo. Int J Radiat Oncol Biol Phys, 71(866–
72), 2008.
[16] Oliver Jäckel. Heavy ion radiotherapy. In W Schlegel, T Bortfeld, and Anca-Ligia Grosu, editors,
New Technologies in Radiation Oncology, volume 365–377. Springer Verlag Berlin Heidelberg
New York, 2006.
[17] M Durante. Heavy ion therapy at GSI. https://three.jsc.nasa.gov/articles/GSI0923101.pdf, (ac-
cessed 09/2019).
[18] H Paganetti. Relative biological effectiveness (RBE) values for proton beam therapy. variations
as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol, 59:R419–
72, 2014.
[19] T Elsässer, W K Weyrather, T Friedrich, M Durante, G Iancu, M Krämer, G Kragl, Brons S,
M Winter, K J Weber, and M Scholz. Quantification of the relative biological effectiveness for
ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and
a novel approach for treatment planning. Int J Radiat Oncol Biol Phys, 78(4):1177–83, 2010.
[20] Hirohiko Tsujii. Overview of carbon-ion radiotherapy. J Phys Conf Ser, 777, 2017.
[21] T Kamada, H Tsujii, and H Tsuji. Efficacy and safety of carbon ion radiotherapy in bone and
soft tissue sarcomas. J Clin Oncol, 20:4466—4471, 2002.
[22] H Tsujii, J E Mizoe, T Kamada, M Baba, S Kato, H Kato, H Tsuji, S Yamada, S Yasuda, T Ohno,
T Yanagi, A Hasegawa, T Sugawara, H Erzawa, S Kandatsu, K Yoshikawa, R Kishimoto, and
T Miyamoto. Overview of clinical experiences on carbon ion therapy at NIRS. Radiother Oncol,
73(Suppl 2):S41—S49, 2004.
[23] D Schulz-Ertner, A Nikoghosyan, C Thilmann, T Haberer, O Jakel, C Karger, G Kraft, M Wannen-
macher, and J Debus. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol
Phys, 58:631–640, 2004.
[24] Marco Durante and Jay S Loeffler. Charged particles in radiation oncology. Nat Rev Clin Oncol,
7:37–43, 2009.
122
[25] C P Karger. Biological models in treatment planning. In W Schlegel, T Bortfeld, and Anca-
Ligia Grosu, editors, New Technologies in Radiation Oncology, volume 221–235. Springer Verlag
Berlin Heidelberg New York, 2006.
[26] K Ando, S Koike, A Uzawa, N Takai, T Fukawa, Y Furusawa, M Aoki, and Y Miyato. Biological
gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early
response of skin reaction in mice. J Radiat Res, 46(1):51–57, 2005.
[27] G H Fletcher. Textbook of radiotherapy. Philadelphia, Pa: Lea and Febiger, 3rd edition edition,
1980.
[28] Silvia Scoccianti, Beatrice Detti, Davide Gadda, Daniela Greto, Ilaria Furfaro, Fiammetta Fiam-
metta Meacci, Gabriele Simontacchi, Lucia Di Brina, Pierluigi Bonomo, Irene Giacomelli, Icro
Meattini, Monica Mangoni, Sabrina Cappelli, Sara Cassani, Cinzia Talamonti, Lorenzo Bordi,
and Lorenzo Livi. Organs at risk in the brain and their dose-constraints in adults and in chil-
dren: A radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol,
114(2):230–238, 2015.
[29] Eleanor A Blakely and Polly Y Chang. Late effects from hadron therapy. Radiat Onc, 73(Supp 2),
2004.
[30] Jacques Balosso. Radiation tolerance of healthy tissues, high-LET beam particularities. Radiat
Onc, 73(supp 2):S141–3, 2004.
[31] Uwe Schneider. Review: Modeling the risk of secondary malignancies after radiotherapy. Genes,
2:1033–1049, 2011.
[32] Myonggeun Yoon, Sung Hwan Ahn, Jinsung Kim, Dong Ho Shin, Sung Yong Park, Se Byeong Lee,
Kyung Hwan Shin, and Kwan Ho Cho. Radiation-induced cancers from modern radiotherapy
techniques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol
Phys, 77(5):1477–1485, 2010.
[33] Bleddyn Jones. Modelling carcinogenesis after radiotherapy using Poisson statistics: implica-
tions for IMRT, protons and ions. J Radiol Prot, 29(2A):A143–57, 2009.
[34] Manjit Dosanjh and ENLIGHT. Talk, 2018.
[35] PTCOG. Particle therapy facilities in operation. (accessed 12/2018). Available from: https:
//www.ptcog.ch/index.php/facilities-in-operation.
123
[36] M Dosanjh, B Jones, J Pawelke, M Pruschy, and B S Sørensen. Overview of research and therapy
facilities for radiobiological experimental work in particle therapy. report from the European
Particle Therapy Network radiobiology group. Radiother Oncol, 128(1):14–18, 2018.
[37] Teruhiko Terasawa, Tomas Dvorak, Stanley Ip, Gowri Raman, Joseph Lau, and Thomas A Trikali-
nos. Systematic review: Charged-particle radiation therapy for cancer. Ann Intern Med,
151(8):556–565, 2009.
[38] Mark Lodge, Madelon Pijls-Johannesma, Lisa Stirk, Alastair J Munro, Dirk De Ruysscher, and
Tom Jefferson. A systematic literature review of the clinical and cost-effectiveness of hadron
therapy in cancers. Radiother Oncol, 83(2):110–122, 2007.
[39] A A Lazar, R Schulte, B Faddegon, E A Blakely, and M Roach. Clinical trials involving carbon-ion
radiation therapy and the path forward. Cancer, 124(23):4467–4476, 2018.
[40] Marco Durante. Proton beam therapy in Europe: more centres need more research. Br J Cancer,
2018.
[41] O Mohamad, S Yamaday, and M Durante. Clinical indications for carbon ion radiotherapy. Clin
Oncol, 30:317–329, 2018.
[42] Hirohiko Tsujii and Tadashi Kamada. A review of update clinical results of carbon ion radio-
therapy. Jpn J Clin Oncol, 42(8):670–685, 2012.
[43] P Coorevits, M Sundgren, G O Klein, A Bahr, B Claerhout, C Daniel, M Dugas, D Dupont,
A Schmidt, P Singleton, G De Moor, and D J Kalra. Electronic health records: new opportunities
for clinical research. Intern Med, 274(6):547–60, 2013.
[44] C Tudur Smith, P R Williamson, and A G Marson. Investigating heterogeneity in an individual
patient data meta-analysis of time to event outcomes. Stat Med, 24(9):1307–1319, 2005.
[45] H Xu, Z Fu, A Shah, Y Chen, N B Peterson, Q Chen, S Mani, M A Levy, Q Dai, and J C Denny.
Extracting and integrating data from entire electronic health records for detecting colorectal
cancer cases. Annu Symp Proc, 2011:1564–72, 2011.
[46] Alfio Quarteron. Mathematical models in science and engineering. Notices Amer Math Soc,
56(1), 2009.
[47] Lewis J Kleinsmith. Principles of Cancer Biology. Cummings, Benjamin, 2005.
124
[48] J D Murray FRS, editor. Mathematical Biology. An Introduction, volume 17 of Interdisciplinary
Applied Mathematics. Springer New York, 2002.
[49] Loredana G Marcu and Wendy M Harriss-Phillips. In silico modelling of treatment-induced
tumour cell kill: Developments and advances. Comput Math Method M, 2012.
[50] Ian T Foster, Carl Kesselman, and Steven Tuecke. The anatomy of the grid: enabling scalable
virtual organizations. Int J Supercomput Appl, 15(3), 2001.
[51] I Andoulsi, I Blanquer, V Breton, A Dobrev, C Van Doosselaere, V Hernandez, J Herveg, N Jacq,
Y Legre, M Olive, H Rahmouni, T Solomonides, K Stroetmann, V Stroetmann, and P Wilson.
Share the journey - a european healthgrid roadmap. Technical report, European Commission:
Information Society and Media, 2008.
[52] Lena Griebel, Hans-Ulrich Prokosch, Felix Köpcke, Dennis Toddenroth, Jan Christoph, Ines
Leb, Igor Engel, and Martin Sedlmayr. A scoping review of cloud computing in healthcare.
BMC Med Inform Decis Mak, 15(17), 2015.
[53] Robert C Miller. Problems in rare tumor study: a call for papers. Rare Tumors, 2(1), 2010.
[54] Norman F Kirkby. Modelling and simulation of radiotherapy. Nucl Instrum Methods: Phys Res
B, 255:13–17, 2007.
[55] N G Burnett, R Jena, S J Jefferies, S P Stenning, and N F Kirkby. Mathematical modelling of
survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts
poorer outcome after delay to start treatment. Clin Oncol, 18:93–103, 2006.
[56] Usama Fayyad, Gregory Piatetsky-Shapiro, and Padhraic Smyth. Knowledge discovery and data
mining: Towards a unifying framework. In Proceedings of the Second International Conference
on Knowledge Discovery and Data Mining, Portland. AAAI Press, 1996.
[57] Krzysztof J Cios and William Moore. Uniqueness of medical data mining. Artif Intell Med, 26:1–
24, 2002.
[58] NHS. National Cancer Data Set with site specific cancers. (accessed 12/2018). Available
from: https://www.datadictionary.nhs.uk/version2/data_dictionary/messages/national_canc
er_data_set/national_cancer_data_set_definition_fr.asp?shownav=1.
[59] DKG. Homepage OTD-3: Basic and Organ-specific Tumour Documentation. (accessed
12/2018). Available from: https://eliph.klinikum.uni-heidelberg.de/pdf/OTD_P1.pdf.
125
[60] Cancer Institute NSW. NSW Clinical Cancer Registry. (accessed 05/2018). Avail-
able from: https://canceraustralia.gov.au/system/tdf/publications/framework_specialist1_
504af022c1d40.pdf?file=1&type=node&id=2815.
[61] SEER. SEER limited-use record description, 2009. (accessed 12/2018). Available
from: https://seer.cancer.gov/data-software/documentation/seerstat/nov2011/TextData.File
Description.pdf.
[62] CoC. Facility Oncology Registry Data Standards revised 2010, 2010. (accessed 12/2018). Avail-
able from: http://www.facs.org/cancer/coc/fords/FORDS_for_2010d_05012010.pdf.
[63] NHS. Cancer registration data set. (accessed 12/2018). Available from: https:
//www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&cad=rja&uact=8&ved=
2ahUKEwjSvKbEyvXfAhXFb1AKHQ2CCuoQFjADegQIBRAC&url=https%3A%2F%2Fassets.pu
blishing.service.gov.uk%2Fgovernment%2Fuploads%2Fsystem%2Fuploads%2Fattachment_
data%2Ffile%2F764506%2FDICTIONARY_-_1.17_NCRAS_data_dictionary_v3.7__LIVE_.xlsx&
usg=AOvVaw2fTuA8FKvA8l5SyS9vAuUO.
[64] European Network of Cancer Registries. Guidelines on confidentiality in population-based
cancer registries in the European Union. (accessed 12/2018). Available from: https://www.
encr.eu/sites/default/files/pdf/ENCR_Eurocouse_GuidelinesConfidentialityEthics.pdf.
[65] Vandenbergh. Description of the software ODSeasy. (accessed 12/2018). Available from: http:
//www.med.uni-giessen.de/akkk/info/15/abstracts/vandenbergh.html.
[66] Altmann, Katz, and Dudeck. The Giessen tumor documentation system (GTDS)–review and
perspectives. Methods Inf Med, 45(1):108–115, 2006.
[67] Altmann, Katz, and Dudeck. A reference model for clinical tumour documentation. Stud Health
Technol Inform, 124:139–44, 2006.
[68] GTDS. Homepage. (accessed 12/2018). Available from: http://www.med.uni-giessen.de/akkk
/gtds/.
[69] IARC. Homepage of TP53 Mutation Database. (accessed 12/2018). Available from: http://ww
w-p53.iarc.fr/.
[70] Institute Curie. Homepage Human Tumour DataBase. (accessed 12/2018). Available from:
http://bioinfo-out.curie.fr/projects/hutudb/index.html.
126
[71] Grampian University Hospitals NHS Trust. Colorectal initiative tumour database. (accessed
12/2018). Available from: www.abdn.ac.uk/iahs/uploads/files/CIT.pdf.
[72] Grampian University Hospitals NHS Trust. Scottish urology cancer database.
[73] Grampian University Hospitals NHS Trust. Lung cancer database. (accessed 12/2018). Avail-
able from: https://docplayer.net/43156773-Institute-of-applied-health-sciences-university-o
f-aberdeen-database-review-medicine-assessment-research-unit.html.
[74] Grampian University Hospitals NHS Trust. Aberdeen breast cancer database. (accessed
12/2018). Available from: https://www.abdn.ac.uk/iahs/uploads/files/ABC.pdf.
[75] E Ferrante, M Ferraroni, Castrignanò T, L Menicatti, M Anagni, G Reimondo, P Del Monte,
D Bernasconi, P Loli, M Faustini-Fustini, G Borretta, M Terzolo, M Losa, A Morabito, A Spada,
P Beck-Peccoz, and A G Lania. Non-functioning pituitary adenoma database: a useful resource
to improve the clinical management of pituitary tumors. Eur J Endocrinol, 155:823–829, 2006.
[76] Babel, Faessler, Garamani, Keckeisen, and Vartziotis. Interdisciplinary medical database net-
work for the research of novel therapies and pharmaceuticals. In Proceedings Itap 2006 in Ioan-
nina, 2006.
[77] Raffael Kurek, Robin Babel, Susan Clare, Andrea Endress, Victor Faessler, Olaf Fischbach, Mi-
chael Keckeisen, Harald Loeffler, Hans Neubauer, Erich Solomayer, Diethelm Wallwiener, and
Tanja Fehm. TumorAGENT - an interdisciplinary tumor database for translational research in
breast cancer. In Proceedings of World Congress Medical Physics and Biomedical Engineering,
2006.
[78] Naoki Nakaya, Koichi Goto, Kumi Saito-Nakaya, Masatoshi Inagaki, Tetsuya Otani, Tatsuo Ake-
chi, Kanji Nagai, Fumihiko Hojo, Yosuke Uchitomi, Shoichiro Tsugane, and Yutaka Nishiwaki.
The lung cancer database project at the national cancer center, japan: Study design, corres-
ponding rate and profiles of cohort. Jpn J Clin Oncol, 36(5):280–284, 2006. doi:10.1093/jjco
/hyl015.
[79] Eastern Cancer Registration and Information Centre (ECRIC). Personal visit, 23.4.2010.
[80] National Brain Tumour Registry. Homepage. (accessed 12/2018). Available from: www.ncin.o
rg.uk/view?rid=598.
127
[81] NHS. Background information on the RTDS project. (accessed 12/2018). Available
from: https://webarchive.nationalarchives.gov.uk/20130124040245/http://www.dh.gov.uk/pr
od_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_076955.pdf.
[82] NATCANSAT. Homepage of NATCANSAT about RTDS. (accessed 12/2018). Available from:
http://www.natcansat.nhs.uk.
[83] Faith G Davis, Bridget J McCarthy, and Mitchel S Berger. Centralized databases available for de-
scribing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry
of the United States; Surveillance, Epidemiology and End Results; and National Cancer Data
Base. Neuro-oncol, 1:205–211, 1999.
[84] CBTRUS. Homepage. (accessed 12/2018). Available from: http://www.cbtrus.org.
[85] James B Yu. NCI SEER public-use data: Applications and limitations in oncology research.
Oncology, 23(3):288–95, March 2009.
[86] SEER. Homepage. (accessed 12/2018). Available from: http://seer.cancer.gov/.
[87] CoC. National Cancer Database. (accessed 12/2018). Available from: http://www.facs.org/can
cer/ncdb/index.html.
[88] IMPAC. National Oncology DataBase (NODB). (accessed 12/2018). Available from: https://ww
w.elekta.com/dam/jcr:e80c415c-d935-43f1-9fc4-dc4e1ffeda3f/NODA_Leaflet.pdf.
[89] GENEPI Entb1. Project description. (accessed 05/2010). Available from: http://www.ist-world
.org/ProjectDetails.aspx?ProjectId=4e08539ae75e47c48698715be3e7f2a1.
[90] GENEPI Entb2. Project description. (accessed 05/2010). Available from: http://www.estro.org/
projects/Pages/GENEPIEntb2.aspx.
[91] GENEPI. Database policy and protocol of clinical documentation. (accessed 05/2010). Avail-
able from: http://www.estro.org/projects/Documents/Genepi%20%20policy.doc.
[92] GENEPI. Informed consent procedure. (accessed 05/2010). Available from: http://www.estro.
org/projects/Documents/Genepi%20-%20informed%20consent%20procedure.doc.
[93] GENEPI. Protocols for processing and storing tissue samples. (accessed 05/2010). Available
from: http://www.estro.org/projects/Documents/GENEPI%20tissue%20collection.doc.
128
[94] Conticabase. European sarcoma database and tumour bank. (accessed 12/2018). Available
from: https://conticabase.sarcomabcb.org.
[95] Conticagist. European sarcoma database and tumour bank, homepage. (accessed 12/2018).
Available from: https://conticagist.sarcomabcb.org/.
[96] EUROCARE. Homepage of the EUROpean CAncer REgistry-based study on survival and CARE
of cancer patients. (accessed 12/2018). Available from: http://www.eurocare.it/.
[97] NCI. Homepage CaBIG. (accessed 05/2010). Available from: https://cabig.nci.nih.gov/.
[98] Scott Oster, Stephen Langella, Shannon Hastings, David Ervin, Ravi Madduri, Tahsin Kurc,
Frank Siebenlist, Peter Covitz, Krishnakant Shanbhag, Ian Foster, and Joel Saltz. caGrid 1.0:
A Grid enterprise architecture for cancer research. In AMIA Annu Symp Proc, pages 573—577,
2007.
[99] CaGrid Community. Homepage. (accessed 05/2010). Available from: http://cagrid.org/.
[100] NCI. caCORE SDK. (accessed 05/2010). Available from: https://cabig.nci.nih.gov/tools/ca
CORE_SDK.
[101] Peter A Covitz, Frank Hartel, Carl Schaefer, Sherri De Coronado, Gilberto Fragoso, Himanso
Sahni, Scott Gustafson, and Kenneth H Buetow. caCORE: A common infrastructure for can-
cer informatics. Bioinformatics, 19(18):2404–2412, 2003. doi:10.1093/bioinformatics/btg
335.
[102] EyecancerBig. The ophthalmic oncology intranet. (accessed 05/2010). Available from: http:
//www.eyecancerbig.com.
[103] Taoying Huang, Pareen J Shenoy, Rajni Ainha, Michael Graiser, Kevin W Bumpers, and Chris-
topher R Flowers. Development of the Lymphoma Enterprise Architecture Database: A caBIG
silver level compliant system. Cancer Inform, 8:45–64, 2009.
[104] BioGrid Australia. Homepage. (accessed 12/2018). Available from: http://www.biogrid.org.au.
[105] VPAC. ACCORD: Cancer patient database. (accessed 12/2018). Available from: https://www.bi
ogrid.org.au/page/26/data-collection-software-cancer.
[106] BioGrid Australia. Data dictionaries and data collection forms of various tumour entities for
download. (accessed 12/2018). Available from: http://biogrid.blob.core.windows.net/assets/u
ploads/files/ACCORD-User-Manual-2.2.9-Sept-2011.pdf.
129
[107] S P Naber. Continuing role of a frozen-tissue bank in molecular pathology. Diagn Mol Pathol,
5:253–259, 1996.
[108] S P Naber, L L Smith, and H J Wolfe. Role of the frozen tissue bank in molecular pathology.
Diagn Mol Pathol, 1:73–79, 1992.
[109] Wikipedia. Database models. Available from: http://en.wikipedia.org/wiki/Database_model
[cited 12/2018].
[110] Edgar F Codd. A relational model of data for large shared data banks. Commun ACM, 13(6):377–
87, June 1970.
[111] International Organization for Standardization (ISO). ISO/IEC 9075-1:2016 information tech-
nology – database languages - SQL - part 1: Framework (SQL/framework) [online]. Available
from: https://www.iso.org/standard/63555.html [cited 12/2018].
[112] Michael Joiner and Albert van der Kogel, editors. Basic Clinical Radiobiology. Hodder Arnold,
4th edition edition, 2009.
[113] JR William Small and Gayle E Woloschak, editors. Radiation toxicity: A practical guide. Cancer
Treatment and Research. Springer, 2008.
[114] J Bentzen and S M Overgaard. Patient-to-patient variability in the expression of radiation-
induced normal tissue injury. Semin Radiat Oncol, 4(2):68–80, 1994.
[115] Julianne M Pollard and Richard A Gatti. Clinical radiosensitivity with DNA repair disorders: An
overview. Int J Radiat Oncol Biol Phys, 74(5):1323–1331, 2009.
[116] N G Burnet, J Johansen, I Turesson, J Nyman, and J H Peacock. Describing patients’ normal
tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions
based on potential predictive assay of normal tissue radiosensitivity. steering committee of
the BioMed2 European Union Concerted Action Programme on the development of predict-
ive tests of normal tissue response to radiation therapy. Int J Cancer, 79(6):606–613, 1998.
[117] Christian Nicola Andreassen and Jan Alsner. Genetic variants and normal tissue toxicity after
radiotherapy: A systematic review. Radiother Oncol, 92(3):299–309, September 2009.
[118] Gillian C Barnett, Catherine M L West, Alison M Dunning, Rebecca M Elliot, Charlotte E Coles,
Paul D P Pharoah, and Neil G Burnet. Normal tissue reactions to radiotherapy: towards tailoring
treatment dose by genotype. Nat Rev Cancer, 9(2):124–142, February 2009.
130
[119] World Health Organization. WHO handbook for reporting results of cancer treatment. Offset
Publication Geneva, 1979.
[120] J D Cox, J Stetz, and T F Pajak. Toxicity criteria of the Radiation Therapy Oncology group (RTOG)
and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat
Oncol Biol Phys, 31(5):1341–6, March 1995.
[121] F Mornex, J J Pavy, J Denekamp, and M Bolla. Scoring system of late effects of radiations on
normal tissues: the SOMA-LENT scale. Cancer Radiother, 1(6):622–68, 1997.
[122] Philip Rubin, Louis S Constine, Luis F Fajardo, Theodore L Phillips, and Todd H Wasserman.
Overview: Late effects of normal tissue (LENT) scoring system. Int J Radiat Oncol Biol Phys,
31(5):1041–1042, 1995.
[123] J-J Pavy, J Denekamp, J J Letschert, B Littbrand, F Mornex, J Bernier, D Gonzales-Gonzales, J-C
Horiot, M Bolla, and H Bartelink. Late effects toxicity scoring: The SOMA scale. Int J Radiation
Oncology Biol Phys, 31(5):1043–1047, 1995.
[124] Cancer Therapy Evaluation Program. Common Toxicity Criteria v2.0, March 1998. (accessed
08/2010). Available from: http://ctep.info.nih.gov/protocolDevelopment/electronic_applicati
ons/docs/ctcv20_4-30-992.pdf.
[125] Andy Trotti, Roger Byhardt, Joanne Stetz, Clement Gwede, Benjamin Corn, Karen Fu, Leonard
Gunderson, Beryl McCormick, Mitchell Morris, Tyvin Rich, William Shipley, Walter Curran, and
Radiation Therapy Oncology Group. Common Toxicity Criteria: version 2.0. an improved ref-
erence for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat
Oncol Biol Phys, 47(1):13–47, April 2000.
[126] Cancer Therapy Evaluation Program. Common Toxicity Criteria v3.0, August 2006. (accessed
12/2018). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applicati
ons/docs/ctcaev3.pdf.
[127] NCI. Common Terminology Criteria for Adverse Events (ctcae) v.4 and v.5 data files and related
documents, 2010. accessed 08/2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Abou
t.html.
[128] Ute Heilman, editor. Strahlentherapie. Springer Verlag Berlin Heidelberg, 2006.
131
[129] W Parulekar, R Mackenzie, G Bjarnason, and R C Jordan. Scoring oral mucositis. Oral Oncol,
34(1):63–71, 1998.
[130] Deborah Watkins Bruner. Should Patient-Reported Outcomes be Mandatory for Toxicity Re-
porting in Cancer Clinical Trials? Clin Oncol, 25(34):5345–5347, 2007.
[131] The Christie NHS Foundation Trust. Clinical Oncology - scoring treatment effects : LENT
SOMA. (accessed 11/2010). Available from: http://www.christie.nhs.uk/pro/depts/clinonc/
lent_soma/questionnaires.aspx.
[132] The Christie NHS Foundation Trust. Clinical oncology - scoring treatment effects: CTCAE.
(accessed 11/2010). Available from: http://www.christie.nhs.uk/pro/depts/clinonc/lent_som
a/CTCAEv3.aspx.
[133] NCI. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE). (accessed 10/2010). Available from: http://outcomes.cancer.gov/tools/
pro-ctcae.html.
[134] D A Power. Late effects of radiotherapy: how to assess and improve outcomes. Br J Radiol,
78:150–152, 2005.
[135] S M Bentzen, W Dörr, M S Anscher, J W Denham, M Hauer-Jensen, L B Marks, and Williams J.
Normal tissue effects: Reporting and analysis. Semin Radiat Oncol, 13(3):189–203, July 2003.
[136] G O Griffiths, M K B Parmar, and A J on behalf of the CHART Steering Committee Bailey. Physical
and psychological symptoms of quality of life in the CHART randomized trial in head and neck
cancer: short-term and long-term patient reported symptoms. Br J Cancer, 81(7):1196–1205,
1999.
[137] Kenneth Jensen, Anders Bonde Jensen, and Cai Grau. The relationship between observer-based
toxicity scoring and patient assessed symptom severity after treatment for head and neck can-
cer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC
quality of life questionnaires. Radiother Oncol, 78(3):298–305, 2006.
[138] Cancer Therapy Evaluation Program. Common Toxicity Criteria v4.0, May 2009. (accessed
10/2010). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quic
kReference_8.5x11.pdf.
132
[139] Acute Radiation Morbidity Scoring Criteria. (accessed 04/2011). Available from:
http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidit
yScoringCriteria.aspx.
[140] RTOG/EORTC Late Radiation Morbidity Scoring Schema. (accessed 04/2011). Available
from: http://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRa
diationMorbidityScoringSchema.aspx.
[141] RTOG. SOMA late effects. PDF file. (accesssed 11/2018). Available from: http://www.rtog.org
/LinkClick.aspx?fileticket=_rSiZbdkeXs%3d&tabid=140.
[142] Vinay G Vaidya and Frank J Alexandro Jr. Evaluation of some mathematical models for tumour
growth. Int J Bio-Medical Computing, 13:19–35, 1982.
[143] Michael Olinick. Mathematical Models in the Social and Life Sciences. Addison-Wesley, 1978.
[144] A C Burton. Rate of growth of solid tumours as a problem of diffusion. Growth, 30(2):157–76,
1966.
[145] Anna Kane Laird. Dynamics of tumour growth. Br J Cancer, 18(3):490–502, 1964.
[146] Anna Kane Laird. Dynamics of tumour growth: Comparison of growth rates and extrapolation
of growth curve to one cell. Br J Cancer, 19(2):278–91, 1965.
[147] H M Byrne. The role of growth factors in avascular tumour growth. Math Comput Modelling,
26(4):35–55, 1997.
[148] M Gyllenberg and G F Webb. Quiescence as an explanation of Gompertzian tumor growth.
Growth Develop Aging, 53:24, 1989.
[149] A S Qi, X Zheng, C Y Du, and An B S. A cellular automation model of cancerous growth. J Theor
Biol, 161(1):1–12, 1993.
[150] R Rockne, E C Alvord Jr, J K Rockhill, and K R Swanson. A mathematical model for brain tumor
response to radiation therapy. J Math Biol, 58:561–578, 2007.
[151] D D Dionysiou, G S Stamatakos, D Gintides, N Uzunoglu, and K 1In Kyriaki. Critical parameters
determining standard radiotherapy treatment outcome for glioblastoma multiforme: A com-
puter simulation. Open Biomed Eng J, 2(43–51), 2008.
133
[152] Heiko Enderling, Mark A J Chaplain, Alexander R A Anderson, and Jayant S Vaidya. A math-
ematical model of breast cancer development, local treatment and recurrence. J Theor Biol,
246:245–259, 2007.
[153] Dimitra D Dionysiou, Georgios S Stamatakos, Nikolaos K Uzunolgu, and Konstantina S Nikita. A
computer simulation of in vivo tumour growth and response to radiotherapy: New algorhithms
and parametric results. Comput Biol Med, 36(5):448–464, 2006.
[154] Norman F Kirkby, Sarah J Jefferies, Raj Jena, and Neil G Burnet. A mathematical model of the
treatment and survival of patients with high-grade brain tumours. J Theor Biol, 245:112–124,
2007.
[155] Zhibin Huang, Nina A Mayr, William T C Yuh, Simon S Lo, Joseph F Montebello, John C Grecula,
Lu Lanchun, Kaile Li, Hualin Zhang, Nilendu Gupta, and Jian Z Wang. Predicting outcomes in
cervical cancer: A kinetic model of tumor regression during radiation therapy. Cancer Res,
70:463–470, 2010.
[156] Henry C Pitot. Fundamentals of Oncology. Dekker, Marcel, 4th edition edition, 2002.
[157] Jules J Berman. Tumor classification: molecular analysis meets Aristotle. BMC Cancer, 4(10),
March 2004. Available from: http://www.biomedcentral.com/1471-2407/4/10.
[158] Martin D Abeloff, James O Armitage, John E Niederhuber, Michael B Kastan, and W Gillies McK-
enna. Clinical Oncology. CHURCHILL LIVINGSTONE ELSEVIER, Fourth Edition edition, 2008.
[159] Raymond W Ruddon. Cancer Biology. Oxford University Press, 4th edition edition, 2007.
[160] P H McKee, C N Chinyama, W F Whimster, W V Bogomoletz, G S Delides, and C J M de Wolf,
editors. Comprehensive Tumour Terminology Handbook. John Wiley & Sons, 2001.
[161] Urs-Nikolaus Riede. Color Atlas of Pathology. Thieme, 2004.
[162] NCI. Cancer classification. Available from: http://training.seer.cancer.gov/disease/categories/
classification.html [cited 7/2015].
[163] J Treuner and I B Brecht. Weichteilsarkom. In Kompendium Internistische Onkologie. Springer,
2006.
[164] Felix Berlth, Elfriede Bollschweiler, Uta Drebber, Arnulf H Hoelscher, and Stefan Moenig. Patho-
histological classification systems in gastric cancer: Diagnostic relevance and prognostic value.
World J Gastroenterol, 20(19):5679–5684, 2014.
134
[165] M B Amin, S Edge, F Greene, D R Byrd, R K Brookland, M K Washington, J E Gershenwald, C C
Compton, K R Hess, D C Sullivan, J M Jessup, J D Brierley, L E Gaspar, R L Schilsky, C M Balch,
D P Winchester, E A Asare, M Madera, D M Gress, and L R Meyer, editors. AJCC Cancer Staging
Manual. American College of Surgeons, 8th edition edition, 2018.
[166] Gleason Grading System. (accessed 08/2010). Available from: http://en.wikipedia.org/wiki/Gl
eason_score.
[167] Bloom-Richardson grading system. accessed 08/2010. Available from: http://en.wikipedia.org
/wiki/Bloom-Richardson_grading_system.
[168] David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-
Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, and David W
Ellison. The 2016 World Health Organization classification of tumors of the central nervous
system: a summary. Acta Neuropathol, 2016.
[169] Min Yang, Chun-Lu Tan, Yi Zhang, Neng-Wen Ke, Lin Zeng, Ang Li, Hao Zhang, Jun-Jie Xiong,
Zi-Heng Guo, Bo-Le Tian, and Xu-Bao Liu. Applications of a novel tumor-grading-metastasis
staging system for pancreatic neuroendocrine tumors. Medicine (Baltimore), 95(28), 2016.
[170] Ivan Damjanov and Fang Fan, editors. Cancer Grading Manual. Springer, 2007.
[171] David N Louis, Hiroko Ohgaki, Otmar D Wiestler, and Webster K Cavenee, editors. WHO Classi-
fication of Tumours of the Central Nervous System. International Agency for Research on Cancer
(IARC), 2007.
[172] International Classification of Diseases for Oncology. World Health Organization, 3rd edition
edition, 2013.
[173] WHO. International classification of diseases (ICD). Available from: http://www.who.int/clas
sifications/icd/en/.
[174] SEER. SEER site recode ICD-O-3, January 2003. Available from: http://seer.cancer.gov/sitereco
de/icdo3_d01272003/.
[175] [online]Available from: http://www.who.int/classications/icd/updates/icd03update [cited July
2015].
[176] NCI. Staging: Questions and answers. (accessed 06/2010). Available from: http://www.cancer
.gov/cancertopics/factsheet/Detection/staging.
135
[177] UICC. The TNM Classification of Malignant Tumours. Wiley-Blackwell, 7th edition edition,
2009.
[178] C Witteking and I Tischoff. Tumorklassifikationen: Aktuelle aspekte und probleme der an-
wendung. Pathologe, 25(6):481–491, 2004.
[179] Leslie H Sobin and Carolyn C Compton. TNM seventh edition: What’s new, what’s changed:
communication from the International Union Against Cancer and the American Joint Com-
mittee on Cancer. Cancer, 116(22):5336–9, November 2010.
[180] S M Bentzen and H D Thames. Tumor volume and local control probability: clinical data and
radiobiological interpretations. Int J Radiat Oncol Biol Phys, 36:247–251, 1996.
[181] H R Mellor, D J P Ferguson, and R Callaghan. A model of quiescent tumour microregions
for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer, 93(3):302–309,
2005.
[182] Wanyin Chen, Jihu Dong, Jacques Haiech, Marie-Claude Kilhoffer, and Maria Zeniou. Cancer
stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int, 2016.
[183] Frank Kozusko and Zeljko Bajzer. Combining Gompertzian growth and cell population dynam-
ics. Math Biosci, 185:153–167, 2003.
[184] Narendra S Goel and Nira Richter-Dyn. Stochastic Models in Biology. Academic Press, Inc, 1974.
[185] Warren K Sinclair. Cyclic X-ray responses in mammalian cells in vitro. Radiat Res, 33(3):620–
643, 1968.
[186] J Y Lee, M S Kim, E H Kim, N Chung, and Y K Jeong. Retrospective growth kinetics and radio-
sensitivity analysis of various human xenograft models. Lab Anim Res, 32(4):187–193, 2016.
[187] The Biology Project. The cell cycle and mitosis tutorial. Available from: http://www.biology.ar
izona.edu/cell_bio/tutorials/cell_cycle/cells2.html [cited July 2018].
[188] Geoffrey M Cooper and Robert E Hausman. The cell: a molecular approach. Sinauer Associates,
Inc., 6nd edition edition, 2013.
[189] C A Wallen, D N Ridinger, and L A Dethlefsen. Heterogeneity of x-ray cytotoxicity in proliferat-
ing and quiescent murine mammary carcinoma cells. Cancer Res, 45(7):3064–3069, 1985.
136
[190] L B Gardner, Q Li, M S Park, W M Flanagan, G L Semenza, and C V Dang. Hypoxia inhibits G1/S
transition through regulation of p27 expression. J Biol Chem, 276:7919–7926, 2001.
[191] R C Jackson. The problem of the quiescent cancer cell. Enzyme Regul, 29:27–46, 1989.
[192] D W Siemann. The tumor microenvironment: a double-edged sword. Int J Radiat Oncol Biol
Phys, 42(4):697–699, 1998.
[193] S Masunaga, K Ono, M Mitsumori, and M Abe. The alteration of radiosensitivity of quiescent
cell populations in murine solid tumors irradiated twice at various intervals with x-rays. Jpn J
Cancer Res, 84:1130–5, 1993.
[194] J M Brown and A J Giaccia. The unique physiology of solid tumors: opportunities (and prob-
lems) for cancer therapy. Cancer Res, 58(7):1408–16, 1998.
[195] M J Gonzàlez and F L Herrera. Cell loss and tumor growth revisited. Med Hypotheses, 42(1):39–
42, 1994.
[196] G G Steel. Cell loss as a factor in the growth rate of human tumours. Eur J Cancer, 3(4):381–387,
1967.
[197] S B Refsum and P Berdal. Cell loss in malignant tumours in man. Europ J Cancer, 3:235–236,
1967.
[198] Robert A Meek, Marylou Ingram, Jeanne Monroy Meek, Jerry L McCullough, Ming-Chi Wu, and
Adel A Yunis. Establishment and cell cycle kinetics of a human squamous cell carcinoma in
nude mice and in vitro. Cancer Res, 41:1076–1085, 1981.
[199] H Rodney Withers. The four R’s of radiotherapy. Adv Radiat Oncol, 5:241–271, 1975.
[200] G Gordon Steel, T J McMillan, and J H Peacock. The 5Rs of radiobiology. Int J Radiat Biol,
56(6):1045–1048, 1989.
[201] Jihane Boustani, Mathieu Grapin, Pierre-Antoine Laurent, Lionel Apetoh, and Céline Mirjolet.
The 6th R of radiobiology: Reactivation of anti-tumor immune response. Cancers, 11(6), 2019.
[202] H R Withers, J M Taylor, and B Maciejewski. The hazard of accelerated tumor clonogen repop-
ulation during radiotherapy. Acta Oncol, 27(2):131–146, 1988.
[203] Jan Poleszczuk and Heiko Enderling. The optimal radiation dose to induce robust systemic
anti-tumor immunity. Int J Mol Sci, 19(11), 2018.
137
[204] M F Clarke, J E Dick, P B Dirks, C J Eaves, C H Jamieson, D L Jones, J Visvader, I L Weissman,
and G M Wahl. Cancer stem cells–perspectives on current status and future directions: AACR
Workshop on cancer stem cells. Cancer Res, 66(19):9339–44, 2006.
[205] T Reya, S J Morrison, M F Clarke, and I L Weissman. Stem cells, cancer, and cancer stem cells.
Nature, 414(105–111), 2001.
[206] M Al-Hajj, M S Wicha, A Benito-Hernandez, S J Morrison, and M F Clarke. Prospective identi-
fication of tumorigenic breast cancer cells. Proc Natl Acad Sci, 100(3983–3988), 2003.
[207] S A Bapat, A M Mali, C B Koppikar, and N K Kurrey. Stem and pro- genitor-like cells contribute
to the aggressive behavior of human epithelial ovarian cancer. Cancer Res, 65(3025–3029), 2005.
[208] D Fang, T K Nguyen, K Leishear, R Finko, A N Kulp, S Hotz, P A Van Belle, X Xu, D E Elder, and
M Herlyn. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res,
65:9328–9337, 2005.
[209] Ca Li, D G Heidt, P Dalerba, C F Burant, L Zhang, V Adsay, M S Wicha, M F Clarke, , and D M
Simeone. Identification of pancreatic cancer stem cells. Cancer Res, 67(1030–1037), 2007.
[210] S Ma, K W Chan, L Hu, T K Lee, J Y Wo, I O Ng, B J Zheng, and X Y Guan. Identification and
characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 132:2542–
2556, 2007.
[211] L Ricci-Vitiani, D G Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle, and R De Maria. Iden-
tification and expansion of human colon-cancer-initiating cells. Nature, 445:111–115, 2007.
[212] S K Singh, I D Clarke, M Terasaki, V E Bonn, C Hawkins, J Squire, and P B Dirks. Identification
of a cancer stem cell in human brain tumors. Cancer Res, 63:5821–5828, 2003.
[213] C G Hubert, M Rivera, L C Spangler, Q Wu, S C Mack, B C Prager, M Couce, R E McLendon,
A E Sloan, and J N Rich. A three- dimensional organoid culture system derived from human
glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors
found in vivo. Cancer Res, 76(2465–2477), 2016.
[214] X S Qi, F Pajonk, S McCloskey, D A Low, P Kupelian, M Steinberg, and K Sheng. Radioresistance
of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication
for breast irradiation. Radiother Oncol, 124(3):455–461, 2017.
138
[215] M Diehn, R W Cho, N A Lobo, T Kalisky, M J Dorie, A N Kulp, D Qian, J S Lam, L E Ailles, M Wong,
and et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells.
Nature, 458:780–783, 2009.
[216] L Marcu and E Bezak. Influence of stem cell cycle time on acceleraated re-population during
radiotherapy in head and neck cancer. cell prolif, 45:404–412, 2012.
[217] Ala Yaromina, Marie Krause, Howard Thames, Andrea Rosner, Mechthild Krause, Franziska
Hessel, Reidar Grenman, Daniel Zips, and Michael Baumann. Pre-treatment number of clono-
genic cells and their radiosensitivity are major determinants of local tumour control after frac-
tionated irradiation. Radiother Oncol, 83:304–310, 2007.
[218] Leo E Gerweck, Shashirekha Vijayappa, Akihiro Kurimasa, Kazuhiko Ogawa, and David J Chen.
Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res,
66(17):8352–5, 2006.
[219] C A Perez and L W Brady. Perez and Brady’s Principles and Practice of Radiation Oncology.
Lippincott Williams & Wilkins, 2007.
[220] Boris Zhivotovsky, Betrand Joseph, and Sten Orrenius. Tumor radiosensitivity and apoptosis.
Exp Cell Res, 248(1):10–17, 1999.
[221] P Vaupel. Tumor microenvironmental physiology and its implications for radiation oncology.
Semin Radiat Oncol, 14(3):197–275, 2004.
[222] Shin-ichiro Masunaga, Koichi Ando, Akiko Uzawa, Ryoichi Hirayama, Yoshiya Furusawa,
Sachiko Koike, and Koji Ono. Responses of total and quiescent cell populations in solid tumors
to carbon ion beam irradiation (290 MeV/u) in vivo. Radiat Med, 26(5):270–277, 2008.
[223] Shin ichiro Masunaga, Hideko Nagasawa, Yong Liu, Yoshinori Sakurai, Hiroki Tanaka, Genro
Kashino, Minoru Suzuki, Yuko Kinashi, and Koji Ono. Evaluation of the radiosensitivity of the
oxygenated tumor cell fractions in quiescent cell populations within solid tumors. Radiat Res,
174(4):459–466, 2010.
[224] S Masunaga and K Ono. Significance of the response of quiescent cell populations within solid
tumors in cancer therapy. J Radiat Res, 43(1):11–25, 2002.
[225] Sung-Jae Baek, Hideshi Ishii, Keisuke Tamari, Kazuhiko Hayashi, Naohiro Nishida, Masam-
itsu Konno, Koichi Kawamoto, Jun Koseki, Takahito Fukusumi, Shinichiro Hasegawa, Hisataka
139
Ogawa, Atsushi Hamabe, Masaaki Miyo, Kozo Noguchi, Yuji Seo, Yuichiro Doki, Masaki Mori,
and Kazuhiko Ogawa. Cancer stem cells: The potential of carbon ion beam radiation and new
radiosensitizers. Oncol Rep, 34(5):2233–2237, 2015.
[226] Daniel Ulrich Boehm, Antje Lebrecht, Theodoros Maltaris, Marcus Schmidt, Wulf Siggelkow,
Susanne Fischer, Eva Kandelhart, and Heinz Koelb. Influence of resection volume on locore-
gional recurrence of breast cancer after breast-conserving surgery. Anticancer Res, 28(2B):1207–
1211, 2008.
[227] F N Kazmi, A Adil, S Ghaffar, and F Ahmed. Association between tumour volume and recurrence
of squamous cell carcinoma of the head and neck. J Pak Med Assoc, 62(11):1129–1133, 2012.
[228] B I Chung, T V Tarin, M Ferrari, and J D Brooks. Comparison of prostate cancer tumor volume
and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol
Oncol, 29(3):314–8, 2011.
[229] Sten Friberg and Stefan Mattson. On the growth rates of human malignant tumors: Implica-
tions for medical decision making. J Surg Oncol, 65:284–297, 1997.
[230] Laszlo Kopper. Tumor cell growth kinetics. Gynecol Oncol, 6(2):141–143, 2001.
[231] Canadian Institutes of Health Research (CIHR). Toward canadian benchmarks for waiting times
for radiotherapy for cancer: Synthesizing the evidence and establishing research priorities. Re-
port 3, Appendix 2.
[232] Esmaeil Mehrara, Eva Forssell-Aronsson, Håkan Ahlman, and Peter Bernhardt. Specific growth
rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res,
67(8), April 2007.
[233] Katsuo Usuda, Yasuki Saito, Motoyasu Sagawa, Masami Sato, Keiji Kanma, Satomi Takahashi,
Chiaki Endo, Yan Chen, Akira Sakurada, and Shigefumi Fujimura. Tumor doubling time and
prognostic assessment of patients with primary lung cancer. Cancer, 74(8):2239–44, October
1994.
[234] M P Gallee, E Visser-de Jong, F J ten Kate, F H Schroeder, and T H Van der Kwast. Monoclonal
antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J
Urol, 142, 1989.
140
[235] F L Baker, L J Sanger, R W Rodgers, K Jabboury, and O R Mangini. Cell proliferation kinetics of
normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive
fraction. cell prolif, 28(1):1–15, 1995.
[236] Gary S Tennyson and Bernard P Lane. In vivo and in vitro growth of a rat tracheal squamous
cell carcinoma. Cancer Research, 41(11 Part 1):4687–4692, 1981.
[237] E K Rofstad, E O Pettersen, T Lindmo, and R Oftebro. The proliferation kinetics of NHIK 1922
cells in vitro and in solid tumors in athymic mice. Cell Tissue Kinet, 13(2):163–171, 1980.
[238] C J Kovacs, M J Evans, and M A Hopkins. Properties of the H-4-II-E tumor cell system. ii. in vitro
characteristics of an experimental tumor cell line. Cell Tissue Kinet, 10:245–254, 1977.
[239] T Bjork-Eriksson, C M L West, E Karisson, N J Slevin, S E Davidson, R D James, and C Mercke.
The in vitro radiosensitivity of human head and neck cancers. Br J Cancer, 77(12):2371–2375,
1998.
[240] E P Malaise, B Fertil, N Chavaudra, and M Guichard. Distribution of radiation sensitivities for
human tumor cells of specific histological types: Comparison of in vitro to in vivo data. Int J
Radiat Oncol, 12(4):612–24, 1986.
[241] A Urushibara, N Shikazono, R Watanabe, K Fujii, P O’Neill, and A Yokoya. Dna damage induced
by the direct effect of he ion particles. Radiat Prot Dosimetry, 122:163–5, 2006.
[242] Shin-ichiro Masunaga, Koichi Ando, Akiko Uzawa, Ryoichi Hirayama, Yoshiya Furusawa,
Sachiko Koike, Yoshinori Sakurai, Kenji Nagata, Minoru Suzuki, Genro Kashino, Yuko Kinashi,
Hiroki Tanaka, Akira Maruhashi, and Koji Ono. Radiobiologic significance of response of intrat-
umor quiescent cells in vivo to accelerated carbon ion beams compared with gamma-rays and
reactor neutron beams. Int J Radiat Oncol Biol Phys, 70(1):221–228, 2008.
[243] Everett J Moding, Michael B Kastan, and David G Kirsch. Strategies for optimizing the response
of cancer and normal tissues to radiation. Nat Rev Drug Discov, 12(7):526–542, 2013.
[244] J Russell, T E Wheldon, and P Stanton. A radioresistant variant derived from a human neur-
oblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res, 55(21):4915–21,
1995.
[245] T M Phillips, W H McBride, and F Pajonk. The response of CD24(-/low)/CD44+ breast cancer-
initiating cells to radiation. J Natl Cancer Inst, 98(24):1777–1785, 2006.
141
[246] S Bao. Glioma stem cells promote radioresistance by preferential activation of the DNA damage
response. Nature, 444:756–760, 2006.
[247] Daniel Abler, Vassiliki Kanellopoulos, and Faustin Roman. Hadrontherapy Information Sharing
Platform. Poster, september 2009.
[248] J Sommer. The delay in sharing research data is costing lives. Nat Med, 16:744, 2010.
[249] E Pisani and C AbouZahr. Sharing health data: good intentions are not enough. Bull World
Health Organ, 88(6):462–66, 2010.
[250] Faustin Laurentiu Roman, Daniel Abler, Vassiliki Kanellopoulos, Gabriel Amoros, Jim Davies,
Manjit Dosanjh, Raj Jena, Norman Kirkby, Ken Peach, and Jose Salt. Hadron therapy informa-
tion sharing prototype. J Radiat Res, 54, 2013.
[251] Daniel Abler and Faustin Laurentiu Roman. Services of the Hadron therapy Information Shar-
ing Platform. Legal and Ethical implications. partner wp22 and 23 deliverable 2. CERN Tech
Rep. (accessed 04/2011). Available from: https://espace.cern.ch/partnersite/workspace/faust
/Shared%20Documents/Deliverables/PARTNER_WP22_23_Deliverable2.pdf.
[252] Google. Google charts.
[253] Daniel Abler, Faustin Laurentiu Roman, and Vassiliki Kanellopoulos. PARTNER platform for
distributed recording and analysis for adverse event. ENLIGHT, conference 2011, 2011.
[254] G H Weiss and M Zelen. A semi-Markov model for clinical trials. J Appl Prob, 2(2):269–85, 1965.
[255] J Robert Beck and Stephen G Pauker. The Markov process in medical prognosis. Med Decis
Making, 3:419–434, 1983.
[256] John W Loewy, Asha S Kapadia, Bart Hsi, and Barry R Davis. Statistical methods that distinguish
between attributes of assessment : Prolongation of life versus quality of life. Med Decis Making,
12:83–92, 1992.
[257] Janneke P C Grutters, Madelon Pijls-Johannesma, Dirk De Ruysscher, Andrea Peeters, Stefan
Reimoser, Johan L Severens, Philippe Lambin, and Manuela A Joore. The cost-effectiveness of
particle therapy in non-small lung cancer: Exploring decision uncertainty and areas for future
research. Cancer Treat Rev, 36:468–476, 2010.
[258] Mark E Cowen, Michael Chartrand, and William F Weitzel. A Markov model of the natural
history of prostate cancer. J Clin Epidemiol, 46:3–21, 1994.
142
[259] Usman Yusuf Abubakar, Sunday A Reju, and Bamidele O Awojoyogbe. Markov decision model
and the application to the cost of treatment of leprosy disease. Leonardo, 6(11):69–78, 2007.
[260] Frank A Sonnenberg and J Robert Beck. Markov models in medical decision making: a practical
guide. Med Decis Making, 13:322–339, 1993.
[261] Andrew Briggs and Mark Sculpher. An introduction to markov modelling for economic evalu-
ation. Pharmacoeconomics, 13(4):397–409, 1998.
[262] Sheldon M Ross. Introduction to Probability Models. Academic Press, 2003.
[263] D Abler, V Kanellopoulos, J Davies, M Dosanjh, R Jena, N Kirkby, and K Peach. Data-driven
Markov models and their application in the evaluation of adverse events in radiotherapy. J
Radiat Res, 54:i49–i55, 2013.
[264] Kerstin A Kessel, Nina Bougatf, Christian Bohn, Daniel Habermehl, Dieter Oetzel, Rolf Bendl,
Uwe Engelmann, Roberto Orecchia, Piero Fossati, Richard Pötter, Manjit Dosanjh, Jürgen De-
bus, and Stephanie E Combs. Connection of European particle therapy centers and generation
of a common particle database system within the European ULICE-framework. Radiat Oncol,
7(115), 2012.
[265] Kerstin A Kessel, Christian Bohn, Uwe Engelmann, Dieter Oetzel, Nina Bougatf, Rolf Bendl,
Jürgen Debus, and Stephanie E Combs. Five-year experience with setup andimplementation
of an integrated database system for clinical documentation and research. Comput Meth Prog
Bio, 114, 2014.
[266] H B Newton. Chordomas. Chichester: John Wiley I& Sons Ltd, 3rd edition edition, 2006.
[267] Chordoma Foundation [online]. 2018. (accessed 07/2018). Available from: http://www.chordo
mafoundation.org/chordoma/.
[268] L Watkins, E S Khudados, M Kaleoglu, T Revesz, P Sacares, and H A Crockard. Skull base chor-
domas: A review of 38 patients, 1958-1988. Br J Neurosurg, 7(3):241—248, 1993.
[269] E L Gay, L N Sekhar, E Rubinstein, D C Wright, Sen C, Janecka I P, and Snyderman C H. Chordo-
mas and chondrosarcomas of the cranial base: Results and follow-up of 60 patients. Neurosur-
gery, 36:887–897, 1995.
[270] Eric K Hansen and Mack Roach III, editors. Handbook of Evidence-Based Radiation Oncology.
Springer, 2nd edition edition, 2010.
143
[271] S Han, C Polizzano, G P Nielsen, F J Hornicek, A E Rosenberg, and V Ramesh. Aberrant hyper-
activation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordo-
mas. Cancer Res, 15(6):1940—1946, 2009.
[272] R Pallini, G Maira, F Pierconti, M L Falchetti, E Alvino, G Cimino-Reale, E Fernandez,
E D’Ambrosio, and L M Larocca. Chordoma of the skull base: predictors of tumor recurrence. J
Neurosurg, 108(6):1256–62, June 2008.
[273] Saad Khairi and Matthew G Ewend. Chordoma. Curr Treat Options Neurol, 4(2):167–173, 2002.
[274] M L McMaster, A M Goldstein, C M Bromley, N Ishibe, and D M Parry. Chordoma: incidence
and survival patterns in the United States, 1973-1995, 2001.
[275] Laligam Sekhar, Ramachandran Pranatartiharan, Amitabha Chanda, and Donald C Wright.
Chordomas and chondrosarcomas of the skull base: results and complications of surgical man-
agement. Neurosurg Focus 10, 3(2), 2001.
[276] Charles Catton, Brian O’Sullivan, Robert Bell, Normand Laperriere, Bernard Cummings, Victor
Fornasier, and Jay Wunder. Chordoma: long-term follow-up after radical photon irradiation.
Radiother Oncol, 41(1):67–72, 2018/10/16 1996.
[277] A Terahara, A Niemierko, M Goitein, D Finkelstein, E Hug, N Liebsch, D O’Farrell, S Lyons, and
J E Munzenrider. Analysis of the relationship between tumor dose inhomogeneity and local
control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys, 1(45):351–358, 1999.
[278] L N Sekhar, E Gay, and D C Wright. Neurosurgery, volume 2, chapter Chordomas and Chondro-
mas of the Cranial Base, pages 1529–1541. New York: McGraw-Hill, 2 edition, 1996.
[279] F Tzortzidis, F Elahi, D Wright, S K Natarajan, and L N Sekhar. Patient outcome at long-term
follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery,
59:230–237, 2006.
[280] T A Rich, A Schiller, H D Suit, and H J Mankin. Clinical and pathologic review of 48 cases of
chordoma. Cancer, 56(1):182–187, 1985.
[281] R Santoni, N Liebsch, D M Finkelstein, E Hug, P Hanssens, M Goitein, AR Smith, D O’Farrell,
J T Efird, B Fullerton, and J E Munzenrider. Temporal lobe (TL) damage following surgery and
high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosar-
comas of the base of the skull. Int J Radiat Oncol Biol Phys, 41(1):59–68, 1998.
144
[282] F C Henderson, K McCool, J Seigle, W Jean, W Harter, and G J Gagnon. Treatment of chor-
domas with cyberKnife: Georgetown University experience and treatment recommendations.
Neurosurgery, 64:44–53, 2009.
[283] DB Fuller and JG Bloom. Radiotherapy for chordoma. Int J Radiat Oncol Biol Phys, 15(2), 1988.
[284] M A Fagundes, E B Hug, N J Liebsch, W Daly, J Efird, and J E Munzenrider. Radiation therapy for
chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse.
Int J Radiat Oncol Biol Phys, 33(3):579–84, 1995.
[285] J P Austin, M M Urie, G Cardenosa, and J E Munzenrider. Probable causes of recurrence in pa-
tients with chordoma and chondrosarcoma of the base of skull and cervical spine. Int J Radiat
Oncol Biol Phys, 25:439–444, 1993.
[286] S Khairi and M G Ewend. Chordoma. Curr Treat Options Neurol, 4:167–173, 2002.
[287] EH Balagamwala. Principles of radiobiology of stereotactic radiosurgery and clinical applica-
tions in the central nervous system. Technol Cancer Res Treat, 11(1):3–13, 2012.
[288] Jürgen Debus, Daniela Schulz-Ertner, Lothar Schad, Marco Essig, Bernhard Rhein, Christoph O
Thillmann, and Michael Wannenmacher. Stereotactic fractionated radiotherapy for chordomas
and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys, 47(3):591–596, 2000.
[289] Steven Chang, David P Martin, Elizabeth Lee, and John R. Adler. Stereotactic radiosurgery and
hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical
chordomas. Neurosurg Focus, 10(3), 2001.
[290] Harish N Vasudevan, David R Raleigh, Julian Johnson, Adam A Garsa, Philip V Theodosopoulos,
Manish K Aghi, Christopher Ames, Michael W McDermott, Igor J Barani, and Steve E Braun-
stein. Management of chordoma and chondrosarcoma with fractionated stereotactic radio-
therapy. Front Surg, 4(35), 2017.
[291] Arjun Sahgal, Michael W. Chan, Eshetu G Atenafu, Laurence Masson-Cote, Gaurav Bahl, Eu-
gene Yu, Barbara-Ann Millar, Caroline Chung, Charles Catton, Brian O’Sullivan, Jonathan C.
Irish, Ralph Gilbert, Gelareh Zadeh, Michael Cusimano, Fred Gentili, and Normand J Laperri-
ere. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma
and chondrosarcoma: preliminary outcomes. Neuro Oncol, 17(6):889–894, 2015.
145
[292] Mary Austin-Seymour, John Munzenrider, Michael Goitein, Lynn Verhey, Marcia Urie, Richard
Gentry, Steven Birnbaum, Donna Ruotolo, Patricia McManus, Steven Skates, Robert G. Oje-
mann, Andrew Rosenberg, Alan Schiller, Andreas Koehler, and Herman D. Suit. Fractionated
proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull.
J Neurosurg, 70(1):13–7, 1989.
[293] W P Levin, H Kooy, J S Loeffler, and DeLaney T F. Proton beam therapy. Br J Cancer, 93(8), 2005.
[294] Georges Noël, Jean-Louis Habrand, Eric Jauffret, Renaud de Crevoisier, Sygon Dederke, Hamid
Mammar, Christine Haie-Méder, Dominique Pontvert, Dominique Hasboun, Régis Ferrand,
Gilbert Boisserie, Anne Beaudré, Geneviève Gaboriaud, Ferran Guedea, Lourdes Petriz, and
Jean-Jacques Mazeron. Radiation therapy for chordoma and chondrosarcoma of the skull base
and the cervical spine. Strahlenther Onkol, 4:241–248, 2003.
[295] J R Castro, D E Linstadt, J P Bahary, P L Petti, I Daftari, J M Collier, P H Gutin, G Gauger, and T L
Phillips. Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J
Radiat Oncol Biol Phys, 29(4), 1994.
[296] Damien C Weber, Hans Peter Rutz, Eros S Pedroni, Alessandra Bolsi, Beate Timmermann, Jorn
Verwey, Antony J Lomax, and Gudrun Goitein. Results of spot-scanning proton radiation ther-
apy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institute experi-
ence. Int J Radiat Oncol Biol Phys, 63(2):401–409, 2005.
[297] D C Weber, R Malyapa, F Albertini, A Bolsi, U Kliebsch, M Walser, A Pica, C Combescure, A J Lo-
max, and R Schneider. Long term outcomes of patients with skull-base low-grade chondrosar-
coma and chordoma patients treated with pencil beam scanning proton therapy. Radiother
Oncol, 120(1):179–74, 2016.
[298] Carmen Ares, Eugen B Hug, Antony J Lomax, Alessandra Bolsi, Beate Timmermann, Hans Peter
Rutz, Jan C Schuller, Eros Pedroni, and Gudrun Goitein. Effectiveness and safety of spot scan-
ning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-
term report. Int J Radiat Oncol Biol Phys, 75(4):1111–1118, 2009.
[299] Eleanor A Blakely, Frank Q H Ngo, Stanley B Curtis, and Cornelius A Tobias. Heavy-ion radiobi-
ology: Cellular studies. In John T Lett, editor, Advances in Radiation Biology, volume 11, pages
295–389, 1984.
146
[300] E B Hug, L N Loredo, J D Slater, A DeVries, R I Grove, R A Schaefer, A E Rosenberg, and J M Slater.
Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg,
91(3):432–9, 1999.
[301] Hirohiko Tsujii, Tadashi Kamada, Masayuki Baba, Hiroshi Tsujii, Hirotoshi Kato, Shingo
Kato, Shigeru Yamada, Shigeo Yasuda, Takeshi Yanagi, Hiroyuki Kato, Ryusuke Hara, Naotaka
Yamamoto, and Junetsu Mizoe. Clinical advantages of carbon-ion radiotherapy. New J Phys, 10,
2008.
[302] Daniela Schulz-Ertner, Christian P Karger, Alexandra Feuerhake, Anna Nikoghosyan, Stephanie
Combs, Oliver Jäckel, Lutz Edler, Michael Scholz, and Jürgen Debus. Effectiveness of carbon ion
radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys, 68(2):449–
457, 2007.
[303] Samir A Matloob, Haleema A Nasir, and David Choi. Proton beam therapy in the manage-
ment of skull base chordomas: systematic review of indications, outcomes, and implications
for neurosurgeons. Brit J Neurosurg, 30(4):382–7, 2016.
[304] Jinpeng Zhou, Bowen Yang, Xin Wang, and Zhitao Jing. Comparison of the effectiveness of
radiotherapy with photons and particles for chordoma after surgery: A meta-analysis. World
Neurosurg, 117:46–53, September 2018.
[305] Stephanie E Combs, Anna Nikoghosyan, Oliver Jaekel, Christian P Karger, Thomas Haberer,
Marc W Münter, Peter E Huber, Jürgen Debus, and Daniela Schulz-Ertner. Carbon ion radio-
therapy for pediatric patients and young adults treated for tumors of the skull base. Cancer,
115(6):1348–55, 2009.
[306] B P Walcott, B V Nahed, A Mohyeldin, J V Coumans, K T Kahle, and M J Ferreira. Chordoma:
current concepts, management, and future directions. Lancet Oncol, 13(2):69–76, 2012.
[307] Takamitsu A Kato, Akihisa Tsuda, Mitsuru Uesaka, Akira Fujimori, Tadashi Kamada, Hirohiko
Tsujii, and Ryuichi Okayasu. In vitro characterization of cells derived from chordoma cell line
U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiation
Oncology, 6(116), 2011.
[308] Michael J Ebersold, Patrick W Hitchon, John M Duff, and Lynn M Quast. Spine Surgery: Tech-
niques, Complications, Avoidance and Management, volume 1, chapter Primary Bony Spinal
Lesions, pages 663–679. Churchill Livingstone, 1999.
147
[309] Sen Guo and Chu-Xia Deng. Effect of stromal cells in tumor microenvironment on metastasis
initiation. Int J Biol Sci, 14(14):2083–2093, 2018.
[310] E Aydemir, O F Bayrak, F Sahin, B Atalay, Kose G T, M Ozen, S Sevli, A B Dalan, M E Yalvac,
T Dogruluk, and U Türe. Characterization of cancer stem-like cells in chordoma. J Neurosurg,
116:810–820, 2012.
[311] M Krämer, W K Weyrather, and Scholz M. The increased biological effectiveness of heavy
charged particles: From radiobiology to treatment planning. Technol Cancer Res Treat, 2:427–
436, 2003.
[312] J L Holton, T. Steel, M Luxsuwong, H A Crockard, and T Revesz. Skull base chordomas: correla-
tion of tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Appl
Neurobiol, 26:497–503, 2000.
[313] S Scheil, S Brüderlein, T Liehr, H Starke, J Herms, M Schulte, and P Möller. Genome-wide
analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the
first human chordoma cell line, uch1. Gene Chromosome Canc, 32(3):203–2011, 2001.
[314] Roberta Bosotti, Paola Magnaghi, Sebastiano Di Bella, Liviana Cozzi, Carlo Cusi, Fabio Bozzi,
Nicola Beltrami, Giovanni Carapezza, Dario Ballinari, Nadia Amboldi, Rosita Lupi, Alessio
Somaschini, Laura Raddrizzani, Barbara Salom, Arturo Galvani, Silvia Stacchiotti, Elena Tam-
borini, and Antonella Isacchi. Establishment and genomic characterization of the new chor-
doma cell line Chor-IN-1. Sci Rep, 7, 2017.
[315] Wesley Hsu, Ahmed Mohyeldin, Sagar R Shah, Colette M ap Rhys, Lakesha F Johnson, Neda I
Sedora-Roman, Thomas A Kosztowski, Ola A Awad, Edward F McCarthy, David M Loeb, Jean-
Paul Wolinsky, Ziya L Gokaslan, and Alfredo Quiñones-Hinojosa. Generation of chordoma cell
line JHC7 and the identification of brachyury as a novel molecular target: Laboratory investig-
ation. J Neurosurg, 115(4):760–769, 2011.
[316] Verena Gellner, Peter Valentin Tomazic, Birgit Lohberger, Katharina Meditz, Ellen Heitzer,
Michael Mokry, Wolfgang Koele, Andreas Leithner, Bernadette Liegl-Atzwanger, and Beate
Rinnera. Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as
a model for potential new treatment strategies. Sci Rep, 6, 2016.
[317] David J Brenner. Point: The linear-quadratic model is an appropriate methodology for determ-
ining iso-effective doses at large doses per fraction. Semin Radiat Oncol, 18(4):234–239, 2008.
148
[318] Lara Barazzuol, Neil G Burnet, Raj Jena, Bleddyn Jones, Sarah J Jefferies, and Norman F Kirkby. A
mathematical model of brain tumour response to radiotherapy and chemotherapy considering
radiobiological aspects. J Theor Biol, 262(3):553–565, 2009.
[319] Ain Zubaidah Ayob and Thamil Selvee Ramasamy. Cancer stem cells as key drivers of tumour
progression. Br J Biomed Sci, 25(20), 2018.
[320] J X O’Connell, A E Rosenberg, L G Renard, N J Liebsch, J T Efird, and J E Munzenrider. Base
of skull chordoma. a correlative study of histologic and clinical features of 62 cases. Cancer,
74:2261–2267, 1994.
[321] E R Gatfield, D J Noble, G C Barnett, N Y Early, A C F Hoole, N F Kirkby, S J Jefferies, and N G Bur-
net. Tumour volume and dose influence outcome after surgery and high-dose photon radio-
therapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol, 30(4):243–
253, April 2018.
[322] S Potluri, S J Jefferies, R Jena, Harris F, K E Burton, A T Prevost, and N G Burnet. Residual
postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma
and chondrosarcoma of the skull base and spine. Clin Oncol, 23:199–208, 2011.
[323] V Fung, V Calugaru, S Bolle, H Mammar, C Alapetite, P Maingon, L De Marzi, S Froelich, J L
Habrand, R Dendale, G Noël, and L Feuvret. Proton beam therapy for skull base chordomas in
106 patients: A dose adaptive radiation protocol. Radiother Oncol, 128(2):198–202, 2018.
[324] Harald Kempf, Haralampos Hatzikirou, Marcus Bleicher, and Michael Meyer-Hermann. In
silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids. PLOS
Comput Biol, 9(11), 2013.
[325] Gibin G Powathil, Douglas J A Adamson, and Mark A J Chaplain. Towards predicting the re-
sponse of a solid tumour to chemotherapy and radiotherapy treatments: Clinical insights from
a computational model. PLOS Comput Biol, 9(7), 2013.
[326] K A Kessel, N Bougat, and Bohn C et al. Connection of european particle therapy centers and
generation of a common particle database system within the european ulice-framework. Ra-
diat Onc, 7(15), 2012.
[327] A B Miller, B Hoogstraten, M Staquet, and A Winkler. Reporting results of cancer treatment.
Cancer, 47(1):207–214, 1981.
149
[328] Arbeitsgemeinschaft Deutscher Tumorzentren e.V. Onkologischer basisdatensatz, 2002. (ac-
cessed 07/2010). Available from: http://www.tumorzentren.de/tl_files/dokumente/adt_basis
.pdf.
[329] NATCANSAT. Radiotherapy database project dataset. (accessed 05/2010). Available
from: http://www.canceruk.net/rtservices/rtds/rtdsdownloads/RTDS%20Dataset%20V3.71%
20with%20codes%20and%20values.doc.
[330] Non-public information on the dataset of a particle therapy database provided by Robert Miller,
august 2010.
[331] RTOG 0529 forms for phase II trial anal cancer [online]. ID:RTOG 0529 Forms. Avail-
able from: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0529&
mode=html&ptid=383 [cited 11/2018].
150
A Database
A.1 Data Fields for a Rare Tumour Database
Overview of data fields needed for tumour documentation. Name, content and description can be
found in the first three columns. All data fields are compared to existing tumour documentation sys-
tems for comparison. A marked data field in these columns only has the meaning that data on similar
characteristics are recorded but not necessarily in the same way or with the same elaborateness. The
comparison was done without the claim of completeness and some systems even might record more
information.
a) WHO Handbook of Reporting Results of Cancer Treatment [119], and further application [327]
b) German clinical Tumour Documentation [328]
c) SEER data set [61]
d) UK National Registry: National Cancer Data Set/Radiotherapy database project data set [63,
329]
e) Charged Particle Database Mayo Clinic (under development) [330]
f) RTOG trial protocols Phase II: Anal Cancer [331]
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a) b) c) d) e) f)
I. Patient
Sex Male, female, unknown x x x x x x
Date of birth Date x x x x x x
Ethnicity White, Black, American
Indian, Chinese etc (see
SEER database)
x x x
Country Text Country where the patient lives x x x
Date of death Date x
Cancer-death-relation tumor-related,
treatment-
complications, no, not
possible, unknown
x
Autopsy performed (y/n) If yes, there is the possibility to fill in
the data in the autopsy form
II. Anamnesis
Prior/synchronous cancer
disease
yes/no/unknown x x x x x
Prior/synchronous cancer
disease: Year & diagnosis
Date, ICD-10, free text (Several entries possible: creates new
entry in database)
x x x x
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Prior Chemotherapy yes, no, unknown CHX in connection with a prior
cancer disease.
(Several entries possible)
x x x
Prior RT, dose, location yes/no/unknown, Gy,
ICD-0
RT in connection with a prior disease
(Several entries possible)
x x x
Relevant concomitant diseases Text, ICD code For the outcome and toxicity of RT
and the course of the disease relevant
concomitant diseases (Several entries
possible). e.g. diabetes,
cardiomyopathy, myocardial
infarction
x x x
Relevant concomitant
behaviour
Drop down menu with
most common
behaviours like smoking,
drinking etc. free text
addable
Behaviour that has an influence on
the treatment course (eg. smoking
has an influence on radiosensitivity),
on the general condition etc.
x
Other information Text Information which has an influence
on the course of the disease, the
therapy response and toxicity (e.g.
certain genetic predisposition).
Several entries possible
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III. Diagnosis
Date of diagnosis Date The date when the tumour was first
diagnosed by a doctor
x x x x x x
Reliability of diagnosis Clinical, cytological,
histological, autopsical,
other, unknown
The best method used for diagnosis
confirmation
x x x x
Diagnosis ICD(-10), free text;
(version no of ICD)
Tumour diagnosis x x x x x
Localisation primary tumour ICD-O (code for
localisation), (version of
ICD-O)
Origin of primary tumour. The
default setting is ICD-O-3.
x x x x x x
Side localisation Right, left, both sides,
middle, systemic,
unknown
Specifies for matched organs the side
for single organs it can be used to
define the side
x x x x x
Infiltration of adjacent
tissue/partition of an organ
ICD-O, (version of
ICD-O)
Additional information on tumour
growth into the vicinity. The default
setting is ICD-O-3.
x
Date of histology date x x x
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Histology ICD-O, text description,
(version of ICD-O)
Histology coded and in addition, a
text description should be added as
well.
The default setting is ICD-O-3.
x x x x x
Behaviour Benign, malignant
potential, carcinoma in
situ, malignant
Malignancy of the tumour x x
Grading (if applicable) Select G1-G4; low grade,
high grade; G1-G3; not
assessable.
Chose from a pull-down menu the
type of grading system to use and
specify. (e.g. for sarcoma usually the
use is G1-G3)
x x x x x x
Grade other than WHO: Grade,
name of system (if applicable:
Other Grading system than
WHO)
Grade as number, letter
or other (text), name of
system (text)
This is applicable e.g. for soft tissue
sarcoma: histological grading
(several entries possible)
No. of sentinel lymph nodes
examined
Number Record the number of sentinel lymph
nodes removed and examined
x x x
No. of sentinel lymph nodes
involved
Number Record the number of sentinel lymph
nodes involved
x x x
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No. of lymph nodes examined Number (Only show if sentinel lymph node is
positive)
Record the number of regional lymph
nodes removed and examined
x x x x
No. of lymph nodes involved Number Record the number of regional lymph
nodes involved
x x x x x
Invasion of lymphatics yes/no/not assessable x x
Invasion of venes yes/yes
macroscopic/no/not
assessable
x x x
TNM classification: version drop down menu Has the default setting on the latest
version
Clinical TNM classification at
diagnosis: T; C-factor
(if applicable)
Tis/1-4, a-c;unknown;
C-factor
Classification before treatment based
on examination like clinical exams,
imaging, biopsy, etc.
x x x x x
Clinical TNM classification at
diagnosis: N,;C-factor
(if applicable)
1-3, unknown
Specify if applicable: r,y
C-factor, r,y
x
Clinical TNM classification at
diagnosis: M,;C-factor
(if applicable)
0,1, unknown
C-factor, r,y
x
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Date of cTNM (if applicable) date Day, month, year x x x x
Clinical stage grouping (if
applicable)
I-IV, A,B,C;unknown, tick
box: not AJCC/UICC,
specify: text
From TNM derived stage group. If the
stage grouping is done not according
to AJCC/UICC, specify name by text.
x x x x
Clinical stage grouping (if
applicable): Score, Name
text, text
Pathological TNM (if
applicable)
pT,pN,pM,
C-factor, r, y
Post-operative classification which
complements the cTNM: structure of
data analog to the clinical TNM (see
above)
x x x x x
Date of pTNM (if applicable) date day, month, year x x x x x
Pathological stage grouping (if
applicable)
I-IV, unknown From TNM derived stage group.
If the stage grouping is done not
according to AJCC/UICC, specify
name by text.
x x x
Pathological stage grouping (if
applicable): Score, Name
text, text
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Localisation of distant
metastasis at diagnosis;
Date
TNM code:
PUL - pulmonary
PLE - pleural
OSS - osseous
PER - peritoneal
HEP - hepatic
ADR - adrenal
BRA - brain
SKI - skin
LYM - lymph nodes
OTH - other organs
MAR - bone marrow;
Date
Distant metastasis are described
through an abbreviation (TNM)
x x x
Type of stage at diagnosis (if
applicable)
Other: text, unknown For tumours not staged by TNM x x x
Stage at diagnosis (if
applicable)
Text, letter or number For tumours not staged by TNM x x x
Date of stage (if applicable) Date For tumours not staged by TNM x x x
Performance status,
name of scoring system
Number, system:
ECOG/Karnofsky
Performance status score as number,
select scoring system by pull-down
menu
x x x x
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IV. Laboratory and other Data
Tumour markers
(if applicable):
select, name of TM,
occurrence, value, units
yes/no,
name of tumour marker,
positive/negative;
number, units as
pull-down menu
If applicable:
depending on the type of tumour it
should be indicated if the specific
tumour marker is positive or
negative, the name of the tumour
marker needs to be recorded and its
specific value.
The units can be selected from a
pull-down menu, if “other is
specified, the unit will be given as
free text”.
Several entries possible
x x x
Complete blood count (if
applicable)
? at the moment: as pdf In the future info from lab system x x
Renal and liver function tests
(if applicable)
? at the moment as pdf In the future info from lab system x x
Evaluation of immune status
(if applicable)
? at the moment: as pdf In the future info from lab system x
Other tumour related findings Text Several entries possible
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V. Therapy
1. Radiotherapy
Treatment status Primary, relapse, boost,
neo-adjuvant, adjuvant
other (text: specify)
Indicates if the treatment was part of
the primary treatment, relapse
treatment or boost. Additional
Information on the status of
treatment.
(Several selections possible)
x x
Treatment intent Curative, palliative, no
answer
x x
Tumour operability Operable, non-operable,
no answer
Characteristic for stratification x
Treatment method Teletherapy, particle
therapy, brachytherapy,
radioisotope therapy,
intraoperative RT, other
(text: specify)
The method of radiotherapy used for
treating the patient.
(Several selections possible)
x x x x
Beam type (only applicable for
teletherapy)
Photon, electron,
photon and electron
Describes the beam type of a
prescribed treatment
x
Beam type (only applicable for
particle therapy)
Proton, carbon, other:
text (specify)
Describes the beam type of a
prescribed treatment
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Beam energy (only applicable
for teletherapy)
Number Gives the energy for the used beam
type. unit: MeV. (*)
(Several entries possible)
x x x
Beam classification (only
applicable for teletherapy)
IMRT, 3D conformal
(number of fields), FSRT,
IGRT, tomotherapy,
radiosurgery, other
Gives the characteristica of fields
used.
(Several selections possible) (*)
x x x
Beam shaping (only applicable
for particle therapy)
Passive, active (*)
Number of fields (if applicable) Number (*) x x
Target area: tumour List of different organs
(several selections
possible)
List of organs irradiated. Depending
on the Diagnosis, a default setting
will be presented.
x x x
Target area: organs at risk List of different organs
(several selections
possible)
List of organs irradiated. Depending
on the Diagnosis, a default setting
will be presented. The irradiated
organs at risk will automatically used
for the side effects scoring.
x x
Side (for each target area) Left, right, middle, both
sides
Added to the above fields Target area.
This field will use as default setting
the information from diagnosis. (*)
x
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Begin (for each target area) Date Added to the above fields Target area.
This will enable to calculate the
treatment time.
x x x x
End (for each target area) Date Added to the above fields Target area.
This will enable to calculate the
treatment time.
x x x x
Treatment volumes: prescribed
total dose (per volume),
prescribed dose/fraction (per
volume), given as prescribed?
CTV1, CTV2,CTV3..
PTV1,PTV2,PTV3..
GTV1,GTV2, GTV3...
Volume [ml], total dose
[Gy], single dose [Gy],
tick box: given as
prescribed. if not,
corrected value
Added to the above fields Target area.
The target lesions are numbered
according to the target
volumes.CTV1-> Target lesion no. 1
etc.
It is marked which volume is organ at
risk or tumour. Prescribed info: (*)
x x x
Description safety margin
(only applicable for particle
therapy/teletherapy, non-boost)
Text Description of margin used to
expand the clinical target volume to
the PTV, what uncertainties were
taken into account (needs to be
adjusted for particle therapy)
Given fractions Number x
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Fractionation scheme:
fractions/day, fractions/week
Number, number;
upload file
possibility to upload RT prescription x x
Prescribed/actual duration of
therapy(only applicable for
brachytherapy)
Number, number Unit: Hours. Default setting: both
numbers at the same value
x
Dose rate (only applicable for
brachytherapy)
Low-dose,
medium-dose,
high-dose, pulsed-dose;
number
Specification of dose rate. give dose
rate in Gy/h.
x
Isotope used (only applicable
for radioisotope therapy)
Text The Isotope used fro Brachytherapy x x
Activity (only applicable for
radioisotope therapy)
Number Activity in GBq x
Radiosensitizers, protectors
used
Tick box, text If ticked, specify (several entries
possible)
x x
concomitant Surgery yes/no If yes, the surgery form (see 1.
Surgery) needs to be filled out. It will
automatically linked to this therapy.
Only applicable for intraoperative RT
(if checked above)
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concomitant CHX yes/no If yes, the CHX form (see 3. CHX)
needs to be filled out. It will
automatically be linked to this
therapy.
x x x
Hyperthermia yes/no Check if hyperthermia was used with
RT.
Oxygen yes/no Check if any kind of oxygen method
was used.
Other concomitant systemic
therapy
yes/no, text: substance If yes, give substance in free text x
Other concomitant therapy yes/no text: description If yes, specify in free text
Treatment interruption Days Record the treatment interruption in
days.
x
Treatment ending Termination due to side
effects, regular finish,
patient refuses further
therapy, other reasons
for termination,
unknown
x x x
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Treatment plan Upload: DICOM RT from
treatment plan, (if not
included: DVH from
treatment plan)
The physical dose distribution can be
recovered from the information
saved in the DICOM-RT. information
(*) can be extracted from the TP.
x
Treatment plan system Text Name and version
Date evaluation treatment
response
Date The fields below should only be used
directly after treatment, otherwise
use follow-up form
x x x x x
Version RECIST Drop down menu Actual version as default setting
Target lesion no., local tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
Progression (P),
assessment not possible,
unknown(X),
RECIST: for each target lesion (see RT
form), the tumour response is
recorded
x
Overall assessment tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
Progression (P),
assessment not possible,
unknown(X),
RECIST x x x
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Specification of local
recurrence in the RT field
(y/n), where: infield,
outfield, field border
This field only occurs for positive
description of residual tumour (see
above). It specifies the nature of the
local failure (geometrical, biological).
The field is related to each target
area: tumour.
x
Primary tumour, local
description
No tumour detectable,
residual tumour, relapse,
unclear, unknown;
certainty of
measurement (clinical
exam, X-ray, etc.);
Important to evaluate the real
tumour spread.
x x
Spread of tumour into regional
lymph nodes
No tumour detectable,
residual tumour, local
relapse, remnants and
relapse, unknown;
certainty of
measurement (clinical
exam, X-ray, etc.);
Important to evaluate the real
tumour spread
x x x
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Distant metastasis No distant metastasis,
new distant metastasis,
relapsing distant
metastasis, remnants
and relapse, unknown,
unclear; certainty of
measurement (clinical
exam, X-ray, etc.);
Important to evaluate the real
tumour spread. The information is
taken for each TNM code for
metastases. “Other” needs to be
specified as text. If a metastasis
persists, the box remnants and
relapse needs to be ticked.
x x x x
Biochemical tumour control (if
applicable)
Use (tick box),
failure/control, type of
marker
if used, direct link to the laboratory
data section (drop down menu of
tumour markers)
Acute side effects List of all side effects and
their grade;
name of scoring system
used (version)
Each individual toxicity can be scored
with the soring system of choice
(Several entries possible)
x x x
Additional info Text
2. Surgery
Date Date Date when the surgery was
performed
x x x x
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SX concomitant to RT yes/no This attribute is automatically
recorded from RT form and (if yes)
linked to the specific RT.
x x
Type of surgery OPS code, text x x x x
Treatment intent Curative,
palliative,
diagnostic,
unknown
x x
Complications yes/no/unknown,
text (if yes)
Complications during and after
surgery
x
Residual Classification (if
applicable)
No local tumour (R0),
no local tumour (LR0),
microscopic residual
tumour (R1),
macroscopic residual
tumour (R2),
not assessable (RX)
Description of tumour resection
margins: Absence or existence of
residual tumour after primary
therapy. This classification can be
used even for tumours not staged by
TNM.
x x x
Tumour resection margins for
CNS tumours (if applicable)
Gross total resection,
sub-totally resected,
not assessable
Additional info Text
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3. CHX
CHX concomitant to RT yes/no This attribute is automatically
recorded from RT form and (if yes)
linked to the specific RT.
x x
Type of CHX Substance Several entries are possible x x x x x
Treatment intent Curative, palliative,
unknown
x x
Status Adjuvant, neoadjuvant,
other
x
Begin, end of CHX Dates x x x x
Prescribed No. of cycles Number The number of cycles the CHX was
given
Prescribed doses of CHX:
single dose, dose per cycle,
overall dose
Number, number,
number, units
The units can be selected with a drop
down menu
x
Prescribed treatment schedule
per cycle: single days
Tick box, number of days
separated by commas
Select if treatment schedule can be
recorded by days
Prescribed treatment schedule
cycle: no. of Doses/day, no. of
doses/week
Tick box, number,
number
Select if the doses per cycle can be
recorded per day and week
x x x
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Prescribed treatment schedule:
as pdf
Tick box, upload of
treatment
schedule/CHX
prescription as PDF
Select if PDF is uploaded
CHX discontinuation yes/no/unknown. if yes:
time period
Documentation if CHX was
administered as foreseen
x x x x
CHX overall dose reduction yes/no/unknown. If yes:
final overall dose
(number), unit
Documentation if CHX was
administered as foreseen. units as
drop down menu
x x x
CHX ending Termination due to side
effects, regular finish,
patient refuses further
therapy, other reasons
for termination,
unknown
x x x x
Date of evaluation of tumour
response
Date The tumour response should only be
recorded here directly after treatment
otherwise use follow-up form
x x x x
Version RECIST (only if
non-commitant to RT)
Drop down menu Actual version as default setting
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Target lesion no., local Tumour
response (only if
non-commitant to RT)
Complete remission
(CR),
partial remission (PR),
no change (NC),
Progression (P),
assessment not possible,
unknown(X)
RECIST: for each target lesion (see RT
form) the tumour response is
recorded.
x
Overall assessment Tumour
response (only if
non-commitant to RT)
Complete remission
(CR),
partial remission (PR),
no change (NC),
Progression (P),
assessment not possible,
unknown(X)
RECIST x x x
CHX: acute side effects Scoring of side effects
according to CTCAE:
Name of AE,
Grade CTC,
version of CTCAE
(Several entries possible)
Default setting for CTCAE version is
the actual one.
x x x
Additional info Text
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4. Other
Hormonal therapy:
substance, dose
Tick box, free text,
number,unit.
It should be ticket if a hormonal
therapy is given. If yes, specify which
and give the dose. The unit needs to
specified by a drop down menu (if
other, unit can specified by text).
Several entries possible
Hormonal therapy:
time sequence
Tick box:
concomitant to
RT/SX/CHX, before RT,
after RT
Only one tick box is possible.
SX, CHX stand for
non-RT-concomitant therapies.
Other systemic therapy:
substance, dose
Tick box, free text,
number/unit.
Several entries possible
It should be ticket if an other
systemic therapy is given. If yes,
specify which and give the dose. The
unit needs to specified by a drop
down menu (if other, unit can
specified by text)
Other systemic therapy:
time sequence
Tick box: concomitant to
RT/SX/CHX, before RT,
after RT
Only one tick box is possible.
SX, CHX stand for
non-RT-concomitant therapies.
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Pain therapy: Substance Tick box, substance: free
text.
It should be ticket if pain therapy is
given. If yes, specify which and give
the dose. The unit needs to specified
by a drop down menu (if other, unit
can specified by text).
Several entries possible
Pain therapy: time sequence Tick box: concomitant to
RT/SX/CHX, before RT,
after RT
Only one tick box is possible.
SX, CHX stand for
non-RT-concomitant therapies.
Other treatment Tick box, description of
other treatment
It should be ticket if other treatment
than above is given.
Treatment description as free text.
Several entries possible
Other treatment: time
sequence
Tick box: concomitant to
RT/SX/CHX, before RT,
after RT
Only one tick box is possible.
SX, CHX stand for
non-RT-concomitant therapies.
Additional info Test
VI. Follow-Up
Date of examination Date Date when the examination was
performed.
x x x x
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Last follow-up yes/no If yes, the file will be closed. Please fill
out both rows below
Reason for last follow-up (if
applicable)
Death of patient, patient
lost to follow-up, patient
doesn’t need follow-up
anymore (often 5 after
yrs.), patient is treated
somewhere else-no data
input, follow-up
canceled by the patient,
unknown
x
Final assessment of tumour (if
applicable)
Last follow-up
assessment, autopsy
If follow-up is ticked, the last data
will automatically recorded. If the
final assessment was through
autopsy, the post-mortem form
needs to be filled out
x
Status after primary/relapse
therapy
Primary therapy, relapse
therapy
Should be ticked if the primary
therapy has started or is
finished/after a relapse has
occurred/is treated
x
174
Therapies SX, RT, CHX, Hormonal
therapy,
immunotherapy, pain
therapy, other: specify.
add: actual or planned
Tick boxes for all therapies with
columns actual, planned. To have an
overview of all treatment modalities
because not all are described in
detail. All actual treatments if RT, SX
or CHX will be automatically listed
(with date and exact specification)
x x x x
Date of evaluation of tumour
response
Date x x x x x
Version RECIST Drop down menu Actual version as default setting
Target lesion no., local Tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
progression (P),
assessment not possible,
unknown(X)
RECIST: for each target lesion (see RT
form), the tumour response is
recorded
x
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Overall assessment Tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
progression (P),
assessment not possible,
unknown(X)
RECIST x x x
Primary tumour, local
description
No tumour detectable,
residual tumour, relapse,
unclear, unknown;
certainty of
measurement (clinical
exam, X-ray, etc.)
Important to evaluate the real
tumour spread.
x x x
Specification of local
recurrence in the RT field
yes/no,
if yes, where: infield,
outfield, field border
This field only occurs for positive
description of residual tumour (see
above). This field only occurs for
positive description of residual
tumour (see above). It specifies the
nature of the local failure
(geometrical, biological).
x
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Spread of tumour into regional
lymph nodes
No tumour detectable,
residual tumour, local
relapse, remnants and
relapse,
unknown;
certainty of
measurement (clinical
exam, X-ray, etc.);
date
Important to evaluate the real
tumour spread
x x x x
Distant metastasis No distant metastasis,
new distant metastasis,
relapsing distant
metastasis, remnants
and relapse,
unknown, unclear;
certainty of
measurement (clinical
exam, X-ray, etc.)
Important to evaluate the real
tumour spread. The information is
taken for each TNM code for
metastases. “other” needs to be
specified as text. If a metastasis
persists, the box remnants and
relapse needs to be ticked.
x x x x x
Biochemical tumour control (if
applicable)
Use (tick box),
failure/control, type of
marker
If used, direct link to the laboratory
data section (drop down menu of
tumour markers)
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New histology y/n/unknown, date (if
yes)
Specify in case the tumour is
specified through a new histology.
The old histology is saved.
x
TNM/stage rT,N,M etc. Specifications see diagnosis x
Performance status Grade,
kind (ECOG/Karnofsky)
Both systems can be used.
They need to be specified
x x x
Late side effects Grade,
side effect,
scoring system
(LENT-SOMA, CTCAE
etc.) with version
Each individual toxicity can be scored
with the soring system of choice
(Several entries possible)
x x x x
VII. Vital Status
Date, vital status, tumour
status
Date,
alive/dead/unknown,
with/without
tumour/unknown
Matrix in which it is specified if the
patient lives or not and if the tumour
is present or not
x x x x
Reason of death (if applicable) Tumour-related, related
to treatment (AE), other
reason of death,
unknown, unclear,
specify (text)
Depending on the scoring system
used in case of death and recorded at
the AEs, this is filled out
automatically.
x x x x
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VIII. Post-Mortem
Date of closure date x
Reason Death of patient, patient
lost to follow-up, patient
doesn’t need follow-up
anymore (often 5 after
yrs.), patient is treated
somewhere else-no data
input, follow-up
cancelled by the patient,
unknown
x
Final assessment of tumour Last follow-up
assessment, autopsy
If follow-up is ticked, the last data will
automatically recorded. If the final
assessment was through autopsy, the
autopsy form needs to be filled out
x
Date of biopsy Date Date when the autopsy was
performed
x
aTNM-classification y,r,aT,aN,aM (See diagnosis) x
Overall Stage, if other grouping
than WHO
I-IV, A/B/C Overall stage x
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Stage (non TNM), name Text, text x
Histology date Date x
Histology ICD-O, text description x
Invasion of lymphatics yes/no/not assessable x
Invasion of venes yes/yes
macroscopic/no/not
assessable
x
Target lesion no., local Tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
Progression (P),
assessment not possible,
unknown(X),
RECIST: for each target lesion (see RT
form), the tumour response is
recorded
x
Overall assessment Tumour
response
Complete remission
(CR), partial remission
(PR), no change (NC),
Progression (P),
assessment not possible,
unknown(X),
RECIST x
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Primary tumour, local
description
No tumour detectable,
residual tumour, relapse,
unclear, unknown;
certainty of
measurement (clinical
exam, X-ray, etc.); date
Important to evaluate the real
tumour spread.
x
Specification of local
recurrence in the RT field
(y/n), where: infield,
outfield, field border
This field only occurs for positive
description of residual tumour (see
above).
Spread of tumour into regional
lymph nodes
No tumour detectable,
residual tumour, local
relapse, remnants and
relapse, unknown;
certainty of
measurement (clinical
exam, X-ray, etc.); date
Important to evaluate the real
tumour spread
x
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Distant metastasis No distant metastasis,
new distant metastasis,
relapsing distant
metastasis, remnants
and relapse, unknown,
unclear; certainty of
measurement (clinical
exam, X-ray, etc.); date
Important to evaluate the real
tumour spread. The information is
taken for each TNM code for
metastases. “other” needs to be
specified as text. If a metastasis
persists, the box remnants and
relapse needs to be ticked.
x
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A.2 SQL Files for the Database Model
SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0;
SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0;
SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE=’TRADITIONAL’;
CREATE SCHEMA IF NOT EXISTS ‘default_schema‘ ;
USE ‘default_schema‘ ;
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘PATIENT_ANONYMOUS‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘PATIENT_ANONYMOUS‘(
‘ID_Patient‘ CHAR(20) NOT NULL ,
‘Date_of_Birth‘ DATE NOT NULL ,
‘Gender‘ CHAR(1) NOT NULL ,
‘Ethnicity‘ VARCHAR(40) NULL DEFAULT NULL ,
PRIMARY KEY (‘ID_Patient‘) ,
UNIQUE INDEX ‘ID_Patient‘ (‘ID_Patient‘ ASC) );
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘PATIENT_N‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘PATIENT_N‘ (
‘ID_PatientN‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Surname‘ VARCHAR(40) NULL DEFAULT NULL ,
‘First_Name‘ CHAR(40) NULL DEFAULT NULL ,
‘Postal_Code‘ INT(8) UNSIGNED NULL DEFAULT NULL ,
‘Country‘ VARCHAR(2) NULL DEFAULT NULL ,
‘ID_Patient‘ CHAR(20) NOT NULL ,
PRIMARY KEY (‘ID_PatientN‘) ,
INDEX ‘Relationship2‘ (‘ID_Patient‘ ASC) ,
CONSTRAINT ‘Relationship2‘
FOREIGN KEY (‘ID_Patient‘ )
REFERENCES ‘default_schema‘.‘PATIENT_ANONYMOUS‘ (‘ID_Patient‘)
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘TUMOUR‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘TUMOUR‘ (
‘ID_Tumour‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Tumour_Status‘ CHAR(1) NOT NULL ,
‘Diagnosis‘ VARCHAR(300) NOT NULL ,
‘Diagnosis_Code‘ VARCHAR(4) NULL DEFAULT NULL ,
‘ICD_Version‘ SMALLINT(2) NULL DEFAULT NULL ,
‘Date_Diagnosis‘ DATE NOT NULL ,
‘Side_Localisation‘ CHAR(1) NULL DEFAULT NULL ,
‘Histology_Code‘ SMALLINT(4) NULL DEFAULT NULL ,
‘Tumour_Localisation‘ VARCHAR(4) NULL DEFAULT NULL ,
‘ICD_O_Version‘ SMALLINT(2) NULL DEFAULT NULL ,
‘Description_Histology‘ VARCHAR(300) NULL DEFAULT NULL ,
‘Tumour_Behavior‘ SMALLINT(1) NULL DEFAULT NULL ,
‘Grade‘ CHAR(1) NULL DEFAULT NULL ,
‘Grading_System‘ VARCHAR(20) NULL DEFAULT NULL ,
‘ID_Patient‘ CHAR(20) NOT NULL ,
PRIMARY KEY (‘ID_Tumour‘) ,
INDEX ‘Relationship1‘ (‘ID_Patient‘ ASC) ,
CONSTRAINT ‘Relationship1‘
FOREIGN KEY (‘ID_Patient‘ )
REFERENCES ‘default_schema‘.‘PATIENT_ANONYMOUS‘ (‘ID_Patient‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘STAGING‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘STAGING‘ (
‘ID_Staging‘ BIGINT NOT NULL AUTO_INCREMENT ,
‘T_Stage‘ VARCHAR(2) NOT NULL ,
‘N_Stage‘ CHAR(1) NULL DEFAULT NULL ,
‘M_Stage‘ CHAR(1) NULL DEFAULT NULL ,
‘Staging_Type‘ VARCHAR(2) NULL DEFAULT NULL ,
‘Date_Staging‘ DATE NULL DEFAULT NULL ,
‘TNM_Edition‘ SMALLINT(2) NOT NULL ,
‘Overall_Stage‘ VARCHAR(3) NULL DEFAULT NULL ,
‘ID_Tumour‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Staging‘, ‘ID_Tumour‘) ,
INDEX ‘Relationship3‘ (‘ID_Tumour‘ ASC) ,
CONSTRAINT ‘Relationship3‘
FOREIGN KEY (‘ID_Tumour‘ )
REFERENCES ‘default_schema‘.‘TUMOUR‘ (‘ID_Tumour‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘DOCTOR‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘DOCTOR‘ (
‘ID_Doctor‘ CHAR(20) NOT NULL ,
‘Surname‘ VARCHAR(40) NOT NULL ,
‘First_Name‘ VARCHAR(40) NOT NULL ,
‘Specialization‘ VARCHAR(40) NULL ,
‘Institution‘ VARCHAR(100) NULL ,
PRIMARY KEY (‘ID_Doctor‘) ,
UNIQUE INDEX ‘ID_Doctor_UNIQUE‘ (‘ID_Doctor‘ ASC) );
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘OBSERVER‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘OBSERVER‘ (
‘ID_Observer‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Observer‘ CHAR(1) NOT NULL ,
‘ID_Doctor‘ CHAR(20) NOT NULL ,
PRIMARY KEY (‘ID_Observer‘) ,
INDEX ‘fk_OBSERVER_DOCTOR1‘ (‘ID_Doctor‘ ASC) ,
CONSTRAINT ‘fk_OBSERVER_DOCTOR1‘
FOREIGN KEY (‘ID_Doctor‘ )
REFERENCES ‘default_schema‘.‘DOCTOR‘ (‘ID_Doctor‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘OBSERVATION‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘OBSERVATION‘ (
‘ID_Observation‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Date_Recorded‘ DATE NOT NULL ,
‘ID_Observer‘ BIGINT UNSIGNED NULL ,
‘ID_Patient‘ CHAR(20) NOT NULL ,
PRIMARY KEY (‘ID_Observation‘) ,
INDEX ‘Relationship8‘ (‘ID_Observer‘ ASC) ,
INDEX ‘Relationship19‘ (‘ID_Patient‘ ASC) ,
CONSTRAINT ‘Relationship8‘
FOREIGN KEY (‘ID_Observer‘ )
REFERENCES ‘default_schema‘.‘OBSERVER‘ (‘ID_Observer‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION,
CONSTRAINT ‘Relationship19‘
FOREIGN KEY (‘ID_Patient‘ )
REFERENCES ‘default_schema‘.‘PATIENT_ANONYMOUS‘ (‘ID_Patient‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘ANAMNESIS‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘ANAMNESIS‘ (
‘ID_Anamnesis‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘ID_Observation‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Anamnesis‘) ,
INDEX ‘Relationship9‘ (‘ID_Observation‘ ASC) ,
CONSTRAINT ‘Relationship9‘
FOREIGN KEY (‘ID_Observation‘ )
REFERENCES ‘default_schema‘.‘OBSERVATION‘ (‘ID_Observation‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘CONCOMITANT_BEHAVIOR‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘CONCOMITANT_BEHAVIOR‘(
‘ID_Concomitant_Behavior‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT
,
‘Behavior‘ SMALLINT(1) NULL DEFAULT NULL ,
‘Descriptiom‘ VARCHAR(200) NULL DEFAULT NULL ,
‘Start_Behavior‘ DATE NULL DEFAULT NULL ,
‘End_Behavior‘ DATE NULL DEFAULT NULL ,
‘ID_Anamnesis‘ BIGINT UNSIGNED NULL ,
PRIMARY KEY (‘ID_Concomitant_Behavior‘, ‘ID_Anamnesis‘) ,
INDEX ‘Relationship10‘ (‘ID_Anamnesis‘ ASC) ,
CONSTRAINT ‘Relationship10‘
FOREIGN KEY (‘ID_Anamnesis‘ )
REFERENCES ‘default_schema‘.‘ANAMNESIS‘ (‘ID_Anamnesis‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘CONCOMITANT_DISEASE‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘CONCOMITANT_DISEASE‘(
‘ID_Concomitant_Disease‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT
,
‘Disease‘ VARCHAR(200) NULL DEFAULT NULL ,
‘Disease_Code‘ VARCHAR(4) NULL DEFAULT NULL ,
‘ICD_Version‘ SMALLINT(2) NULL DEFAULT NULL ,
‘Disease_Start‘ DATE NULL DEFAULT NULL ,
‘Disease_End‘ DATE NULL DEFAULT NULL ,
‘Treatment‘ VARCHAR(300) NULL DEFAULT NULL ,
‘ID_Anamnesis‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Concomitant_Disease‘, ‘ID_Anamnesis‘) ,
INDEX ‘Relationship13‘ (‘ID_Anamnesis‘ ASC) ,
CONSTRAINT ‘Relationship13‘
FOREIGN KEY (‘ID_Anamnesis‘ )
REFERENCES ‘default_schema‘.‘ANAMNESIS‘ (‘ID_Anamnesis‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘VITAL_STATUS‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘VITAL_STATUS‘ (
‘ID_Vital_Status‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
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‘Status‘ CHAR(1) NOT NULL ,
‘Date_of_Death‘ DATE NULL DEFAULT NULL ,
‘Cause_of_Death‘ CHAR(1) NULL DEFAULT NULL ,
‘Performance_Status‘ SMALLINT(3) NULL DEFAULT NULL ,
‘Performance_System‘ SMALLINT(1) NULL DEFAULT NULL ,
‘ID_Observation‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Vital_Status‘) ,
INDEX ‘Relationship14‘ (‘ID_Observation‘ ASC) ,
CONSTRAINT ‘Relationship14‘
FOREIGN KEY (‘ID_Observation‘ )
REFERENCES ‘default_schema‘.‘OBSERVATION‘ (‘ID_Observation‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘SIDEEFFECT‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘SIDEEFFECT‘ (
‘ID_Sideeffect‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Sideeffect‘ VARCHAR(40) NOT NULL ,
‘Code‘ INT NULL ,
‘Score‘ SMALLINT(1) NOT NULL ,
‘Scoring_System‘ VARCHAR(20) NOT NULL ,
‘Date_ocurred‘ DATE NULL DEFAULT NULL ,
‘Treatment‘ VARCHAR(200) NULL DEFAULT NULL ,
‘Comments‘ VARCHAR(300) NULL DEFAULT NULL ,
‘ID_Observation‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Sideeffect‘) ,
INDEX ‘Relationship16‘ (‘ID_Observation‘ ASC) ,
CONSTRAINT ‘Relationship16‘
FOREIGN KEY (‘ID_Observation‘ )
REFERENCES ‘default_schema‘.‘OBSERVATION‘ (‘ID_Observation‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘THERAPY‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘THERAPY‘ (
‘ID_Therapy‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Treatment_Intent‘ CHAR(1) NULL DEFAULT NULL ,
‘Treatment_Status‘ CHAR(1) NULL DEFAULT NULL ,
‘ID_Tumour‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Therapy‘) ,
INDEX ‘Relationship17‘ (‘ID_Tumour‘ ASC) ,
CONSTRAINT ‘Relationship17‘
FOREIGN KEY (‘ID_Tumour‘ )
REFERENCES ‘default_schema‘.‘TUMOUR‘ (‘ID_Tumour‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘OTHER_THERAPY‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘OTHER_THERAPY‘ (
‘ID_Other_Therapy‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Concom_Th‘ CHAR(1) NULL DEFAULT NULL ,
‘Treatment‘ VARCHAR(3) NULL DEFAULT NULL ,
‘Description‘ VARCHAR(300) NULL DEFAULT NULL ,
‘Treatment_Start‘ DATE NULL DEFAULT NULL ,
‘Treatment_End‘ DATE NULL DEFAULT NULL ,
‘ID_Therapy‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Other_Therapy‘) ,
INDEX ‘Relationship21‘ (‘ID_Therapy‘ ASC) ,
CONSTRAINT ‘Relationship21‘
FOREIGN KEY (‘ID_Therapy‘ )
REFERENCES ‘default_schema‘.‘THERAPY‘ (‘ID_Therapy‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘CHEMOTHERAPY‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘CHEMOTHERAPY‘ (
‘ID_CHX‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Concom_Th‘ CHAR(1) NULL DEFAULT NULL ,
‘Treatment_Start‘ DATE NULL DEFAULT NULL ,
‘Treatment_End‘ DATE NULL DEFAULT NULL ,
‘ID_Therapy‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_CHX‘) ,
INDEX ‘Relationship22‘ (‘ID_Therapy‘ ASC) ,
CONSTRAINT ‘Relationship22‘
FOREIGN KEY (‘ID_Therapy‘ )
REFERENCES ‘default_schema‘.‘THERAPY‘ (‘ID_Therapy‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘AGENT‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘AGENT‘ (
‘ID_Agent‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Agent‘ VARCHAR(20) NULL DEFAULT NULL ,
‘Cyle_Dose‘ SMALLINT(4) NULL DEFAULT NULL ,
‘Cyle_No‘ SMALLINT(2) NULL DEFAULT NULL ,
‘Cyle_Length‘ SMALLINT(2) NULL DEFAULT NULL ,
‘ID_CHX‘ BIGINT UNSIGNED NULL ,
PRIMARY KEY (‘ID_Agent‘, ‘ID_CHX‘) ,
INDEX ‘Relationship26‘ (‘ID_CHX‘ ASC) ,
CONSTRAINT ‘Relationship26‘
FOREIGN KEY (‘ID_CHX‘ )
REFERENCES ‘default_schema‘.‘CHEMOTHERAPY‘ (‘ID_CHX‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘SURGERY‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘SURGERY‘ (
‘ID_SX‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Concom_Th‘ CHAR(1) NULL DEFAULT NULL ,
‘Surgery‘ VARCHAR(100) NULL DEFAULT NULL ,
‘Surgery_Code‘ VARCHAR(7) NULL DEFAULT NULL ,
‘Code_System‘ VARCHAR(7) NULL DEFAULT NULL ,
‘Location‘ VARCHAR(100) NULL DEFAULT NULL ,
‘R_Classification‘ CHAR(1) NULL DEFAULT NULL ,
‘Treatment_date‘ DATE NULL DEFAULT NULL ,
‘ID_Therapy‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_SX‘) ,
INDEX ‘Relationship23‘ (‘ID_Therapy‘ ASC) ,
CONSTRAINT ‘Relationship23‘
FOREIGN KEY (‘ID_Therapy‘ )
REFERENCES ‘default_schema‘.‘THERAPY‘ (‘ID_Therapy‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘RADIOTHERAPY‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘RADIOTHERAPY‘ (
‘ID_RT‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Institution‘ VARCHAR(100) NOT NULL ,
‘Treatment_Method‘ CHAR(1) NULL DEFAULT NULL ,
‘Boost‘ CHAR(1) NULL DEFAULT NULL ,
‘Mixed_Beam‘ CHAR(1) NULL DEFAULT NULL ,
‘Treatment_Start‘ DATE NULL DEFAULT NULL ,
‘Treatment_End‘ DATE NULL DEFAULT NULL ,
‘Given_Treatment‘ CHAR(1) NULL DEFAULT NULL ,
‘DVH‘ BLOB NULL DEFAULT NULL ,
‘ID_Therapy‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_RT‘) ,
INDEX ‘Relationship27‘ (‘ID_Therapy‘ ASC) ,
CONSTRAINT ‘Relationship27‘
FOREIGN KEY (‘ID_Therapy‘ )
REFERENCES ‘default_schema‘.‘THERAPY‘ (‘ID_Therapy‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘TARGET_VOLUME‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘TARGET_VOLUME‘ (
‘ID_PTV‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Type‘ VARCHAR(3) NOT NULL ,
‘Location‘ VARCHAR(200) NOT NULL ,
‘Volume‘ FLOAT NULL DEFAULT NULL ,
‘Dose‘ SMALLINT(3) NOT NULL ,
‘Dose_per_Fraction‘ SMALLINT(3) NULL DEFAULT NULL ,
‘Fractions‘ SMALLINT(2) NULL DEFAULT NULL ,
‘Name_DVH‘ VARCHAR(40) NULL DEFAULT NULL ,
‘ID_RT‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_PTV‘, ‘ID_RT‘) ,
INDEX ‘Relationship28‘ (‘ID_RT‘ ASC) ,
CONSTRAINT ‘Relationship28‘
FOREIGN KEY (‘ID_RT‘ )
REFERENCES ‘default_schema‘.‘RADIOTHERAPY‘ (‘ID_RT‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
-- -----------------------------------------------------
-- Table ‘default_schema‘.‘BEAM‘
-- -----------------------------------------------------
CREATE TABLE IF NOT EXISTS ‘default_schema‘.‘BEAM‘ (
‘ID_Beam‘ BIGINT UNSIGNED NOT NULL AUTO_INCREMENT ,
‘Beam_Type‘ CHAR(1) NULL DEFAULT NULL ,
‘Beam_Energy‘ FLOAT NULL DEFAULT NULL ,
‘Beam_Class‘ VARCHAR(4) NULL DEFAULT NULL ,
‘ID_RT‘ BIGINT UNSIGNED NOT NULL ,
PRIMARY KEY (‘ID_Beam‘, ‘ID_RT‘) ,
INDEX ‘Relationship29‘ (‘ID_RT‘ ASC) ,
CONSTRAINT ‘Relationship29‘
FOREIGN KEY (‘ID_RT‘ )
REFERENCES ‘default_schema‘.‘RADIOTHERAPY‘ (‘ID_RT‘ )
ON DELETE NO ACTION
ON UPDATE NO ACTION);
SET SQL_MODE=@OLD_SQL_MODE;
SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS;
SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS;
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A.3 A Detailed Description of Database Tables
Data field characterisation for a SQL data base. Tables are listed in alphabetic order
Abbreviations: PK: primary key, M: mandatory, Y: yes, DT Kind: kind of data definiton. Here, all
fields are defined through a domain model (DOM) or conceptual model.
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Table Name AGENT 
 
Description Name and dosage for each chemotherapy agent 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
units Comments 
1 ID_Agent P Y BIGINT DOM Numeric_ID   Auto-increment 
2 Agent   VARCHAR (20) DOM Chemotherapy 
agent 
  Name of the chemotherapy agent 
 
3 Cycle_Dose   SMALLINT (4) DOM Chemotherapy 
Dose 
 mg/m2 Chemotherapy dose given per cycle. The dose of the agent is referenced 
to mg per square meter of body surface. 
4 Cycle_No   SMALLINT (2) DOM Chemotherapy 
Cycle 
  Number of chemotherapy cycles within a course 
5 Cycle_Length   SMALLINT (2) DOM Chemotherapy 
Cycle Length 
 days The lengths of the chemotherapy cycle. If a chemotherapy is given on 
single days the cycle length is 1. 
 
Table Name ANAMNESIS 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Anamnesis P Y BIGINT DOM Numeric_ID  Auto-increment 
 
Table Name BEAM 
 
Description Properties of the radiation beam 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
units Comments 
1 ID_Beam P Y BIGINT DOM Numeric_ID   Auto-increment 
2 Beam_Type  Y CHAR (1) DOM Beam Type   This is only applicable for teletherapy 
3 Beam_Energy   FLOAT (7) DOM Beam Energy  MeV Only applicable for teletherapy. Please note to convert energies given in 
keV 
4 Beam_Class   VARCHAR (4) DOM Beam 
Classification 
  Description of the beams. Only applicable for teletherapy 
 
Constraints 
Column / Constraint 
Name 
Details 
Beam_Type  
Value List 
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Value Description 
C Carbon 
E Electron 
N Neutron 
P Proton 
X Photon 
 
Beam_Class  
Value List 
Value Description 
Conf 3D Conformal radiotherapy 
FSRT Fractionated stereotactic radiotherapy 
IGRT Image guided radiotherapy 
IMRT Intensity modulated radiotherapy 
O Other 
RSX Radiosurgery 
Tomo Tomotherapy 
 
 
Table Name CHEMOTHERAPY 
 
Description Each entry describes one chemotherapy course. 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_CHX P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Concom_Th   CHAR (1) DOM Decision  Describes if the chemotherapy is given concomitant to radiation: yes/no 
3 Treatment_Start   Date DOM Date  Not applicable if concomitant therapy. 
4 Treatment_End   Date DOM Date  Not applicable if concomitant therapy. 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Concom_Th  
Value List 
Value Description 
N No 
U Unknown 
Y Yes 
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Table Name CONCOMITANT_BEHAVIOR 
 
Description Life habits which can have an influence on the effects of RT.  
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Concomitant_Behavior P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Behavior   SMALLINT (1) DOM Behavior 9 Behavior which can have an influence on the effect of RT 
3 Description   VARCHAR (200) DOM Behavior 
Description 
 The behavior can be described more in detail, e.g. frequency etc. 
4 Start_Behavior   Date DOM Date   
5 End_Behavior   Date DOM Date   
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Behavior  
Value List 
Value Description 
0 No relevant concomitant behavior 
1 Alcohol 
2 Other 
3 Smoking 
9 Unknown 
 
 
Table Name CONCOMITANT_DISEASE 
Comments 
Description All relevant concomitant diseases should be recorded. E.g. diabetes (has an influence on sideeffect of RT), heart problems (if irradiation in the heart area), etc. 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Concomitant_Disease P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Disease   VARCHAR(200) DOM Disease Name  Description of the disease in text form  
3 Disease_Code   VARCHAR (4) DOM Disease Code  ICD coded disease. The code is saved without points (C51.1=C511). ICD-9 has 4 
digits. ICD-10 has a letter and 3 number digits. 
4 ICD_Version   SMALLINT (2) DOM ICD Version 10 International  Statistical Classification of Diseases and Related Health Problems 
(WHO):There are different ICD Versions. The current one is ICD-10 
5 Treatment   VARCHAR (300) DOM Procedure  treatment procedure 
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6 Disease_Start   Date DOM Date   
7 Disease_End   Date DOM Date   
Constraints 
Type Column / Constraint 
Name 
Details 
 ICD_Version  
Value List 
Value Description 
10 ICD-10 (published 1992) 
11 ICD-11 (expected in 2011) 
12 ICD-12 
9 ICD-9 (published 1975 ) 
 
 
Table Name DOCTOR     (relevant for follow-up form of sideeffects) 
Comments 
Description In case a doctor has performed the examination his data is saved in this table. Ideally this happens automatically when he signs in with his credentials. 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Doctor P Y CHAR(20) DOM Unique Identifier  Unique Identifier 
3 Surname  Y VARCHAR (40) DOM Surname   
4 First_Name  Y VARCHAR (40) DOM First Name   
5 Specialization   VARCHAR (40) DOM Specialization  What specialization has the doctor 
6 Institution   VARCHAR(100) DOM Institution  Name of treating institution: clinic, etc 
Constraints 
Type Column / Constraint 
Name 
Details 
 Specialization  
Value List 
Value Description 
GP  
Oncologist  
Other  
Radiotherapist  
Surgeon  
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Table Name OBSERVATION       (relevant for follow-up form of sideeffects) 
Comments 
Description The entries in this table are part of the follow-up 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Observation P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Observer  Y CHAR (1) DOM Role  All observations can only be made by a medical doctor. There is one exception 
though. Side effects can be recorded by medical doctors as well as by the patient 
himself. 
3 Date_Recorded  Y Datetime DOM Date of saving  The date when the information was recorded 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Observer  
Value List 
Value Description 
0 Self (patient) 
1 Doctor 
2 Researcher 
 
 
Table Name OTHER_THERAPY 
 
Description Description of the therapies other than CHX, RT and surgery 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Other_Therapy P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Concom_Th   CHAR (1) DOM Decision  Is this treatment given concomitant to radiotherapy: yes/no 
3 Treatment   VARCHAR (3) DOM Treatment Type   
4 Description   VARCHAR(300) DOM Procedure  Treatment procedure 
 
5 Treatment_Start   Date DOM Date  Not applicable if concomitant therapy. 
6 Treatment_End   Date DOM Date  If the treatment is only at one point in time this column is not applicable. Not 
applicable if concomitant therapy. 
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Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Concom_Th  
Value List 
Value Description 
N No 
U Unknown 
Y Yes 
 
 Treatment  
Value List 
Value Description 
HOR Hormonal therapy 
HYP Hyperthermia (only applicable for concomitant radiotherapy) 
OTH Other 
OXY Oxygen (only applicable for concomitant radiotherapy) 
RTS Radiosensitizers used (only applicable for concomitant radiotherapy) 
SYS Other systemic drug 
 
 
Table Name PATIENT_ANONYMOUS 
 
Description Table which includes relevant information of the patient for evaluation 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Patient P Y CHAR(20) DOM Unique Identifier  Unique Identifier 
2 Date_of_Birth  Y Date DOM Date  Date of birth 
3 Gender  Y CHAR (1) DOM Gender  Gender of the patient 
4 Ethnicity   VARCHAR (40) DOM Ethnicity  Can have an effect on sideeffects. 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Gender  
Value List 
Value Description 
F Female 
M Male 
U Unknown 
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X Not assessable 
 
 
 
Table Name PATIENT_N 
 
Description Personal information on the patient 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_PatientN P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Surname   VARCHAR (40) DOM Surname   
3 First_Name   VARCHAR (40) DOM First Name   
4 Postal_Code   Integer (8) DOM Postal Code   
5 Country   VARCHAR (2) DOM Country Code  Country Abbreviation (see number plate of cars) 
 
Table Name RADIOTHERAPY 
Comments 
Description Each entry describes the dose an characteristics of radiation for one radiotherapy course 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_RT P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Institution  Y VARCHAR(100) DOM Institution  Institution where the radiation was performed 
4 Treatment_Method   CHAR (1) DOM Treatment RT 
Method 
 The method used to deliver the dose 
5 Boost   CHAR (1) DOM Decision  Describes if the treatment is foreseen as boost. Only applicable for teletherapy. 
6 Mixed_Beam   CHAR (1) DOM Decision  Gives the description if the beam is mixed (yes) or not (no). Only applicable for 
teletherapy. For mixed beams a common treatment plan is done. therefore there will 
be one DVH for a mix of beams, but each beam quality needs to be specified 
through their beam energy and type (see table beam). 
7 Treatment_Start   Date DOM Date   
8 Treatment_End   Date DOM Date   
9 Given_Treatment   CHAR (1) DOM Decision  Was the therapy given as prescribed? yes/no 
10 DVH   BLOB DOM DVH  Dose-Volume-Histogram of the treatment plan 
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Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Treatment_Method  
Value List 
Value Description 
B Brachytherapy 
I Intraoperative Therapy 
O Other 
R Radioisotope Therapy 
T Teletherapy: includes particles and photons 
 
 Boost  
Value List 
Value Description 
N No 
U Unknown 
Y Yes 
 
 Mixed_Beam  
Value List 
Value Description 
N No 
U Unknown 
Y Yes 
 
 Given_Treatment  
Value List 
Value Description 
N No 
U Unknown 
Y Yes 
 
 
Table Name SIDEEFFECT     (relevant for follow-up form of sideeffects) 
Comments 
Description The entries in this table are part of the follow-up. It is recommended to describe the baseline situation: in an initial form the status for all relevant sideeffects can  
be evaluated (e.g. difficulty swallowing before radiotherapy of a head and neck cancer). 
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Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Sideeffect P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Sideeffect  Y VARCHAR (40) DOM Sideeffect  The sideeffect will be saved in the same term as used in the scoring system used.  
(Although there are some trials by the RTOG and NCI were the MEDRA code is 
saved in addition, but not for all sideffects a MEDRA Code exists and for this cases a 
preliminary one is used. Therefore it seems to be better to just save the term of the 
respective scoring system.) 
3 Code   INT DOM MEDRA Code  MedDRA (the Medical Dictionary for Regulatory Activities) Code for the sideeffect. 
Not applicable in all cases. (The code consists of an 8 digit integer) 
4 Score  Y SMALLINT (1) DOM Sideeffect Grade  The severity of Adverse Event 
5 Scoringsystem  Y VARCHAR (20) DOM Sideeffect Scoring 
System 
 There exit a big variety which can be used to record Adverse Events. Listed are the 
most common ones (not specific to a certain body site) 
6 Date_ocurred   Date DOM Date   
7 Treatment   VARCHAR (200) DOM Procedure  Treatment procedure of sideeffects if not saved in the score. 
 
8 Comments   VARCHAR (300) DOM Comments  Possibility to record additional information and comments 
 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Score  
Value List 
Value Description 
0 No Adverse Event 
1 Mild Adverse Event 
2 Moderate Adverse Event 
3 Severe Adverse Event 
4 Life-threatening or disabling Adverse Event 
5 Death related to Adverse Event 
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 Scoring system  
Value List 
Value Description 
CTC1 CTC version 1 (CHX effects) 
CTC2 CTC version 2 (mostly CHX effects, but also other. does not incorporate enough effects from RT) 
CTCAE3 CTCAE version 3 (effects of all therapies, covers late and early) 
CTCAE4 CTCAE version 4 (effects of all therapies, covers late and early) 
LENTSOMA LENT-SOMA (specialized on RT late effects) 
RTOGearly Scoring system By RTOG for acute effects, mainly RT 
RTOGlate System by RTOG/EORTC to score RT late effects 
WHO For acute and sub-acute effects (CHX effects)  
 
 
 
Table Name STAGING 
 
Comments 
Description A tumour can be restaged over time (happens rarely) or can be staged clinically and pathologically - therefore one tumour can have more than one entry on its 
stage. 
 
 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Staging P Y BIGINT DOM Numeric_ID  Auto-increment 
2 T_Stage  Y VARCHAR (2) DOM Stage: T  Describes the size or direct extent of tumour 
Some tumours are not only described with T1,2,3 or 4 but subgroups a, b and c are 
also possible. 
3 N_Stage   CHAR (1) DOM Stage: N  Staging: description of the spread into regional lymphnodes 
4 M_Stage   CHAR (1) DOM Stage: M  Staging of solid tumours: Do distant metastasis exist? 
5 Staging_Type   VARCHAR (2) DOM Staging Type c Prefix modifiers for the TNM classification: How and when (during therapy) the 
staging was performed 
6 Date_Staging   Date DOM Date  The date when the staging was performed 
7 TNM_Edition  Y Smallint (2) DOM Stage: TNM-
Classification 
Edition 
7 The TNM Classification is updated constantly over time: Due to better diagnostics 
more features to stage tumours are added or certain characteristics are regrouped in 
other stages.  
 Therefore is necessary to record the edition number. 
8 Overall_Stage   VARCHAR (3) DOM Stage Overall  UICC overall stage based on TNM 
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Constraints 
Type Column / Constraint 
Name 
Details 
Column Level T_Stage  
Value List 
Value Description 
0 T0: no primary tumour 
1 T1: specified size of tumour (depends on tumour) 
1a T1 sub-category 
1b T1 sub-category 
1c T1 sub-category 
2 T2: specified size of tumour (depends on tumour), larger than T1 
2a T2 sub-category 
2b T2 sub-category 
2c T2 sub-category 
3 T3: specified size of tumour (depends on tumour). Larger than T2 
3a T3 sub-category 
3b T3 sub-category 
3c T3 sub-category 
4 T4: specified size of tumour (depends on tumour). Larger than T3 
4a T4 sub-category 
4b T4 sub-category 
N Not applicable 
X Not assessed 
a Tis/Ta: tumour has not infiltrated the basal membrane yet 
 
 N_Stage  
Value List 
Value Description 
0 NO: No spread 
1 N1: regional lymphnode metastasis are present 
2 N2: Spread between N1 and N3 
3 N3: Spread to distant lymphnodes or various regional lymphnodes 
X NX: Not assessed 
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 M_Stage  
Value List 
Value Description 
0 No distant metastasis 
1 distant metastasis 
X Not assessed 
 
 Staging_Type  
Value List 
Value Description 
c staging based on clinical examination 
p staging based on histo-pathological examination of extracted tumour tissue 
rc clinical staging of relapsed tumour 
rp Histo-pathological staging of relapsed tumour 
yc clinical staging, after neo-adjuvant therapy 
yp Histo-pathological staging , after neo-adjuvant therapy 
 
 TNM_Edition  
Value List 
Value Description 
1 1st edition (published 1968) 
2 2nd edition (published 1974) 
3 3rd edition (published 1982) 
4 4th edition (published 1987) 
5 5th edition (published 1997) 
6 6th edition (published 2002) 
7 7th edition (published 2009) 
8 8th edition 
9 9th edition 
N not applicable 
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 Overall_Stage  
Value List 
Value Description 
0  
I  
II  
III  
IV  
N not applicable 
X unknown 
 
 
Table Name SURGERY 
 
Description Information on the surgery performed 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_SX P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Concom_Th   CHAR (1) DOM Decision  Describes if surgery is performed concomitant to radiation 
3 Surgery   VARCHAR (100) DOM Procedure  Description of treatment procedure 
 
4 Surgery_Code   VARCHAR (7) DOM Procedure Code  Code of the procedure 
5 Code_System   VARCHAR (7) DOM Procedure Code 
System 
 There are various systems which can be used to encode medical procedures. The 
current version (at the time of surgery) needs to be used. 
6 Location   VARCHAR (100) DOM Surgery location  Anatomical localization where the surgery was performed.  
7 R_Classification   CHAR (1) DOM R-Classification  Result of Resection 
8 Treatment_Date   Date DOM Date  Not applicable if concomitant therapy. 
 
Constraints 
Type Column / Constraint 
Name 
Details 
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Column Level Code_System  
Value List 
Value Description 
ICHI International Classification of Health Interventions (WHO): new system, released now in beta version 
ICPC International Classification of Primary Care 
ICPM International Classification of procedures in Medicine (1978). There are many national systems based on 
ICPM 
OPCS National System (UK) 
OPS National System (GER) 
SNOWMED National system (US): use P-Axis 
 
 R_Classification  
Value List 
Value Description 
0 R0: No residual tumour 
1 R1: Microscopic residual tumour 
2 R2: Macroscopic residual tumour 
X RX: Not assessable 
 
 
Table Name TARGET_VOLUMES 
Comments 
Description All irradiated volumes can be listed, tumour volumes and organs at risk. 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
unit Comments 
1 ID_PTV P Y BIGINT DOM Numeric_ID   Auto-increment 
2 Type  Y VARCHAR (3) DOM Treatment Volume 
Type 
  Distinction between organs at risk and tumour. 
3 Location  Y VARCHAR (200) DOM Treatment location   Anatomical localization of the Target Volume 
4 Volume   FLOAT (5) DOM Volume  ml treatment volume 
5 Dose  Y SMALLINT (3) DOM Dose  Gy Total radiation dose: dose which is planned to be delivered. 
6 Dose_per_Fraction   SMALLINT (3) DOM Dose  Gy Only relevant for fractionated radiotherapy (teletherapy, particle therapy, 
not boost) 
7 Fractions   SMALLINT (2) DOM Fractions   Only relevant for fractionated radiotherapy (teletherapy and particle 
therapy). 
8 Name_DVH   VARCHAR (40) DOM Name DVH   Corresponding name given in the DVH. This is necessary to map information 
of (part of) organs to dose distribution.  
Only applicable if the DVH is saved. 
Constraints 
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Type Column / Constraint 
Name 
Details 
Column Level Type  
Value List 
Value Description 
OAR Organ at risk 
T Tumour 
 
 
Table Name THERAPY 
Comments 
Description One entry combines the information on treatment at the same time.  
Example: 
- radiation therapy with concommitant chemotherapy and hormonal therapy as primary treatment (#1).   
- surgery as primary treatment (#1), radiotherapy with boost and with concommitant chemotherapy as adjuvant treatment (#2), treatment of relapse with 
chemotherapy (#3) 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Therapy P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Treatment_Intent   CHAR (1) DOM Treatment Intent  Does the Treatment aim to cure the patient or treat the symptoms? This determines  
3 Treatment Status   CHAR (1) DOM Treatment Status  Description of the status of the treatment. 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Treatment_Intent  
Value List 
Value Description 
C Curative 
P Palliative 
U Unknown 
 
 Treatment Status  
Value List 
Value Description 
a adjuvant 
n Neo-adjuvant 
o other 
p primary 
r relapse 
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Table Name TUMOUR 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Tumour P Y BIGINT DOM Numeric_ID  Auto-increment 
2 Tumour_Status   CHAR (1) DOM Tumour_Status  Status of the tumour at the time of diagnosis. 
3 Diagnosis  Y VARCHAR (300) DOM Disease Name  Description of the disease in text form.  
For the sideeffects it is necessary to record the prior RT and if possible the site of 
irradiation 
4 Diagnosis_Code   VARCHAR (4) DOM Disease Code  ICD coded disease. The code is saved without points (C51.1=C511). ICD-9 has 4 
digits. ICD-10 has a letter and 3 number digits. Tumour are ranging  from C00-D48. 
In case of recording the history of a patient: If a prior tumour is recorded (and 
unknown), one can fill in 9999. This will still enable the possibility to record prior RT 
which has an impact on the sideeffects (depending on body site). 
Explanation ICD: ICD can be used to code any disease, also to tumours. In contrary 
to ICD-O coding tumours are not coded in a consistent way. In most cases, the 
location of the tumour and the behavior is described. But only very few histological 
types are identified in ICD. For example, there is no way in ICD to distinguish 
between an adenocarcinoma of the lung and a squamous cell carcinoma of the lung. 
From a clinical point of view it makes sense though to give information about the 
location and the behavior - and, most clinicians are used to code in ICD (at least in 
Germany). 
5 ICD_Version   SMALLINT (2) DOM ICD Version 10 International  Statistical Classification of Diseases and Related Health Problems 
(WHO):There are different ICD Versions. The current one is ICD-10 
6 Date_Diagnosis  Y Date DOM Date   
7 Side_Localisation   VARCHAR (1) DOM Side localization  Affected side of paired organs 
8 Histology_Code   SMALLINT (4) DOM Histology Code  Histology is recorded with ICD-O code, use the morphological axis (do no record the 
letter "M"). 4 Digits (Without behavioral code).  
Explanation ICD-O: 
ICD-O contains two axes.- A topographic code which consists of a lead character 
followed by two numeric digits (site), a decimal point and one additional digit (sub-
site). - The morphology axis has five-digit codes ranging from M-8000/0 to M-
9989/3. The first four digits indicate the specific histological term. The fifth digit, 
after the slash (/), is a behavior code, which indicates whether a tumor is malignant, 
benign, in situ, or uncertain whether malignant or benign. 
9 Tumour_Localisation   VARCHAR (4) DOM Tumour 
Topography 
 Localization of the tumour coded with the topographic axis of ICD-O. It consists of a 
leading Character, two digits then a decimal point and another digit. The decimal 
point will not be entered when recording the code: e.g. C51.0=C510 
10 ICD_O_Version   SMALLINT (2) DOM ICD-O Version 3 There are different versions of ICD-O codes 
11 Description_Histology   VARCHAR (300) DOM Histology 
(description) 
 Description of the histology in text form. Some characteristics cannot be coded with 
ICD-O 
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12 Tumour_Behavior   SMALLINT (1) DOM Tumour Behavior  From ICD-O: Specifies the biological behavior (malignancy) of the tumour: this is 
part of the ICD-O code (last digit) 
13 Grade   CHAR (1) DOM Grade  Score of Grade 
14 Grading_System   VARCHAR (20) DOM Grading system WHO Grading system used 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Tumour_Status  
Value List 
Value Description 
A loco-regional relapse and distant metastasis 
G general progression of the disease 
L lymphnode relapse 
M distant metastasis 
P primary tumour relapse 
R loco-regional relapse 
T primary tumour 
 
 ICD_Version  
Value List 
Value Description 
10 ICD-10 (published 1992) 
11 ICD-11 (expected in 2011) 
12 ICD-12 
9 ICD-9 (published 1975 ) 
 
 Side_Localisation  
Value List 
Value Description 
9 unknown 
B both sides 
L left 
M middle 
R right 
S systemic 
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 ICD_O_Version  
Value List 
Value Description 
0 ICD-field trials (published 1988) 
1 ICD-O-1 (published 1976) 
2 ICD-O-2 (published 1990) 
3 ICD-O-3 (published 2000) 
4 ICD-O-4 
5 ICD-O-5 
6  
 
 Tumour_Behavior  
Value List 
Value Description 
0 benign 
1 uncertain whether benign or malignant 
2 carcinoma in situ 
3 malignant 
6 Malignant neoplasm, stated or presumed to be secondary 
 
 Grade  
Value List 
Value Description 
0 Not relevant/unknown 
1 G1, Grade I 
2 G2, Grade II 
3 G3, Grade III 
4 G4, Grade IV 
X Not assessable 
 
 
 
Table Name VITAL_STATUS     (relevant for follow-up form of sideeffects) 
Comments 
Description The entries in this table are part of the follow-up.The performance status should also be part of the information recorded at baseline 
Columns 
No Column Name PK M Data Type DT 
Kind 
Domain Name Default 
Value 
Comments 
1 ID_Vital_Status P Y BIGINT DOM Numeric_ID  Auto-increment 
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2 Status  Y CHAR (1) DOM Vital Status A Vital status of the patient 
3 Date_of_Death   Date DOM Date   
4 Cause_of_Death   CHAR (1) DOM Cause of death 9 What caused death? The Therapy, the tumour, other or not assessable? 
5 Performance_Status   SMALLINT (3) DOM Performance 
Status Score 
 Performance status of the patient: recorded is the number (do not report % for 
Karnofsky scoring).  
6 Perfomance_System   SMALLINT (1) DOM Performance 
Status Scoring 
System 
 The system in which the performance status of the patient is described in 
Constraints 
Type Column / Constraint 
Name 
Details 
Column Level Status  
Value List 
Value Description 
A Alive 
D Dead 
U Unknown 
 
 Cause_of_Death  
Value List 
Value Description 
1 Tumour 
2 Treatment 
3 Other, non tumour related 
9 Unknown 
X Not assessable 
 
 Performance_Status  
Value List 
Value Description 
0 Karnofsky 0%: death, Zubrod/ECOG 0: Asymptomatic (Fully active, able to carry on all pre-disease activities 
without restriction) 
1 Zubrod/ECOG 1: symptomatic but completely ambulatory (restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature) 
10 Karnofsky 10%: moribund, rapidly progressive fatal disease processes 
100 Karnofsky: 100%: normal, no complaints, no signs of disease 
2 Zubrod/ECOG 2: symptomatic, <50% in bed during the day (ambulatory and capable of a self  care but 
unable to carry out any work activities. Up and about more than 50% of waking hours) 
20 Karnofsky 20%: very ill, urgently requiring admission, requires supportive measures or treatment 
3 Zubrod/ECOG 3: symptomatic, >50% in bed, but not bed-bound (capable of only limited self-care, confine to 
bed or chair 50% or more of wakening hours) 
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bed or chair 50% or more of wakening hours) 
30 Karnofsky 30%: severely disabled, hospital admission indicated but no risk of death 
4 Zubrod/ECOG 4: bed-bound (completely disable. Cannot carry on any self-care. Totally confined to bed or 
chair) 
40 Karnofsky 40%: disabled, requires special care and help 
5 Zubrod/ECOG: 5: death 
50 Karnofsky 50%: requires help often, requires frequent medial care 
60 Karnofsky: 60%: requiring some help, can take care of most personal requirements  
70 Karnofsky 70%: caring for self, not capable of normal activity or work 
80 Karnofsky 80%: normal activity, with some difficulty, some symptoms or signs 
90 Karnofsky 90%: capable of normal activity, few symptoms or signs of disease 
 
 Perfomance_System  
Value List 
Value Description 
1 Karnofsky Index 
2 ECOG/Zubrod score 
 
 
Often used Domains  
 
Domain Name Date 
Data Type Date 
Comments For unknown day/month fill in 99, for completely unknown date fill in 99999999. Example Dec 1st 1975: 01121975 
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A.4 Query for Data from HISP
The following queries with in the prototype HISP define the generic states (see section 5.2.2):
Determine severe acute side effects:
SELECT DISTINCT SIDEEFFECT.Sideeffect FROM default_schema.OBSERVATION, default_schema.RADIOTHERAPY, default_schema.SIDEEFFECT
WHERE default_schema.OBSERVATION.ID_Patient = default_schema.RADIOTHERAPY.ID_Patient AND default_schema.OBSERVATION.ID_Observation
= default_schema.SIDEEFFECT.ID_Observation AND default_schema.OBSERVATION.Date_Recorded < default_schema.RADIOTHERAPY.Treatment_End
AND default_schema.SIDEEFFECT.Score > 2 AND default_schema.SIDEEFFECT.Score < 5
Determine severe chronic side effects:
SELECT DISTINCT SIDEEFFECT.Sideeffect FROM default_schema.OBSERVATION, default_schema.RADIOTHERAPY, default_schema.SIDEEFFECT
WHERE default_schema.OBSERVATION.ID_Patient = default_schema.RADIOTHERAPY.ID_Patient AND default_schema.OBSERVATION.ID_Observation
= default_schema.SIDEEFFECT.ID_Observation AND default_schema.OBSERVATION.Date_Recorded > default_schema.RADIOTHERAPY.Treatment_End
AND default_schema.SIDEEFFECT.Score > 2 AND default_schema.SIDEEFFECT.Score < 5
Check for existence of death (returns patients ID)
SELECT ID_Patient FROM default_schema.PATIENT WHERE default_schema.PATIENT.Death_Type
= ’0’ SELECT ID_Patient FROM default_schema.PATIENT
WHERE default_schema.PATIENT.Death_Type=’t’
State without AE or mild AE always exists.
For the transition probabilities similar queries are used. If a transition does not exist in the data, the probability will be zero.
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